



(11)

EP 3 656 396 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
27.05.2020 Bulletin 2020/22

(51) Int Cl.:
A61K 39/155 (2006.01)

(21) Application number: **19211547.5**

(22) Date of filing: **15.03.2013**

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**
Designated Extension States:
BA ME

(72) Inventors:
• **Steigerwald, Robin**
80469 Munich (DE)
• **Cheminay, Cédric**
80992 Munich (DE)
• **Chaplin, Paul**
2820 Gentofte (DK)

(30) Priority: **01.08.2012 US 201261678367 P**
01.08.2012 EP 12005594

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
13717721.8 / 2 879 702

(71) Applicant: **Bavarian Nordic A/S**
3490 Kvistgaard (DK)

(74) Representative: **Preuß, Ilka Susanne**
c/o Bavarian Nordic GmbH
Fraunhoferstraße 13
82152 Martinsried (DE)

Remarks:


This application was filed on 26-11-2019 as a
divisional application to the application mentioned
under INID code 62.

(54) **RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) RESPIRATORY SYNCYTIAL
VIRUS (RSV) VACCINE**

(57) Provided herein are recombinant modified vac-
cinia virus Ankara (MVA) strains as improved vaccines
against infection with Respiratory Syncytial Virus (RSV
virus) and to related products, methods and uses. Spe-
cifically, provided herein are genetically engineered re-
combinant MVA vectors comprising at least one nucle-
otide sequence encoding an antigenic determinant of an

RSV membrane glycoprotein and at least one nucleotide
sequence encoding an antigenic determinant of an RSV
nucleocapsid protein. Also provided herein are products,
methods and uses thereof, e.g., suitable to affect an im-
mune response in a subject, or suitable to diagnose an
RSV infection, as well as to determine whether a subject
is at risk of recurrent RSV infection.

FIGURE 1



Description**FIELD**

[0001] The present invention relates to a recombinant modified vaccinia virus Ankara (MVA virus) as an improved vaccine against an infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, the present invention relates to a genetically engineered recombinant MVA vector comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. The invention also relates to products, methods and uses thereof, *e.g.*, suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.

BACKGROUND

[0002] RSV is a significant respiratory pathogen. Acute lower respiratory tract (LRT) infection causes significant morbidity and mortality in infants and children under the age of five years worldwide [A.M. Aliyu et al. (2010), *Bayero J. PureAppl. Sci.* 3(1):147-155]. Respiratory syncytial virus (RSV) is the most clinically important cause of LRT infection; primary infection with RSV generally occurs by age 2 [W.P. Glezen (1987), *Ped. Virol.* 2:1-4; Y. Murata (2009), *Clin. Lab. Med.* 29(4):725-739]. Because primary RSV infection does not induce complete immunity to RSV, frequent re-infections occur throughout life, with the most severe infections developing in the very young, the very old, and in immune-compromised patients of any age [Y. Murata (2009)].

[0003] As many of 40% of those infected with RSV eventually develop serious LRT disease requiring hospitalization, with the severity and intensity of the disease depending on the magnitude and intensity of infection and the host response [Aliyu et al. (2010)]. RSV can also cause serious LRT disease in patients of any age having compromised immune, respiratory, or cardiac systems, and may also predispose children to later development of asthma. In the United States alone, RSV causes an estimated 126,000 hospitalizations and 300 infant deaths a year [Y. Murata (2009)].

[0004] Furthermore, RSV accounts for more than 80,000 hospitalizations and more than 13,000 deaths each winter among elderly patients, and those with underlying cardiopulmonary or immunosuppressive conditions [Y. Murata (2009)]. Despite the importance of RSV as a respiratory pathogen, however, there is currently no safe and effective RSV vaccine on the market.

[0005] RSV is an enveloped RNA virus of the family *Paramyxoviridae*, subfamily *Pneumovirinae* [Aliyu et al. (2010)]. Each RSV virion contains a non-segmented, negative-sense, single-stranded RNA molecule of approximately 15,191 nucleotides containing ten genes encoding eleven separate proteins (M2 contains two open reading frames), including eight structural (G, F, SH, M1, N, P, M2.1, and L) and three non-structural proteins (NS1, NS2, and M2.2) [Y. Murata (2009)]. The genome is transcribed sequentially from NS1 to L, in the following order: 3'-NS1-NS2-N-P-M1-SH-G-F-M2.1-M2.2-L-5'.

[0006] The viral envelope contains three transmembrane glycoproteins (attachment glycoprotein (G), fusion glycoprotein (F), and small hydrophobic protein (SH)), as well as the matrix (M1) protein [Y. Murata (2009)]. During RSV replication, the virus first attaches to the target cell in a process mediated by the heavily glycosylated G protein. The virus then fuses with the host cell in a process mediated by the F protein, thereby penetrating the cell membrane and entering the host cell; the F protein is also required for the formation of the syncytia characteristic of RSV-infected cells. The attachment and fusion processes are augmented by SH protein. The M1 protein regulates the assembly of mature RSV by interacting with the envelope proteins F and G and with the nucleocapsid proteins N, P, and M2.1 (see below). Within the envelope, viral RNA is encapsidated by a transcriptase complex consisting of the nucleocapsid protein (N), phosphoprotein (P), transcription elongation factor (M2.1) and RNA polymerase (L) proteins [Y. Murata (2009)]. N associates with the genomic RNA, while P is a cofactor for L, the viral RNA polymerase. M2.1 is an elongation factor necessary for viral transcription, and M2.2 regulates transcription of the viral genome. Finally, NS1 and NS2 inhibit type I interferon activity.

[0007] Clinical RSV isolates are classified according to antigenic group (A or B) and further subdivided into multiple genotypes (*e.g.*, A2 or A_{Long} for the A group; and B1, CH-18537, or 8/60 for the B group) based on the genetic variability within the viral genome of each antigenic group [Y. Murata (2009)]. Classification is based on the reactivity of the viruses with monoclonal antibodies directed against the attachment glycoprotein (G protein) and by various genetic analyses. [M. Sato et al., *J. Clin. Microbiol.* 43(1):36-40 (2005)]. Among viral isolates, some RSV-encoded proteins are highly conserved at the level of amino acid sequence (*e.g.*, F), while others vary extensively (*e.g.*, G) between and within the two major antigenic groups [Y. Murata (2009)]. The F proteins from the A and B antigenic groups share considerable homology. In contrast, the G protein differs considerably between the two antigenic groups.

[0008] The G protein is the most variable RSV protein, with its hypervariable C-terminal region accounting for most of the strain-specific epitopes. The molecular epidemiology and evolutionary patterns of G protein have provided important information about the clinical and epidemiological features of RSV. Typically several different genotypes circulate at

once, and the one that predominates in a community every year may change. However, the importance of strain diversity to the clinical and epidemiological features of RSV remains poorly understood. Recombinant RSV proteins are therefore accompanied by a strain designation to indicate the original RSV strain from which the gene or protein was cloned. For example, a cloned G protein from RSV strain A_{Long} is designated G(A_{Long}), RSV A_{Long} G, or RSV A_{Long} G protein.

[0009] RSV stimulates a variety of immune responses in infected hosts, including the secretion of chemokines and cytokines, production of neutralizing humoral and mucosal antibodies, and production of CD4⁺ (e.g., T_H1 and T_H2) and CD8⁺ (e.g., CTL) T-cells. Such host immune responses are largely responsible for the clinical manifestations of RSV infection, since the virus causes limited cell cytopathology *in vivo* [Y. Murata (2009)]. The phenotypic manifestations and severity of RSV-induced disease are apparently mediated by the balance and interactions among the range of immune responses stimulated by RSV infection [Y. Murata (2009)].

[0010] Many previous studies suggest that the cellular and humoral immune responses play different roles in the induction of immunity to RSV and the resolution of RSV infection, as well as in disease progression [Y. Murata (2009) and references therein]. For example, studies with a humanized anti-F antibody showed that while anti-RSV antibodies are sufficient to prevent or limit the severity of infection, they are not required for clearing viral infection [Y. Murata (2009); A.F.G. Antonis et al. (2007), Vaccine 25:4818-4827]. In contrast, T-cell responses are necessary for clearing established RSV infections [Y. Murata (2009)]. The RSV-induced T-cell response also plays a key role in pulmonary pathology during infection. For example, interferon- γ (IFN γ)-secreting T_H1 cells-with or without an associated CD8⁺ CTL response-clear RSV with minimal lung pathology, while interleukin 4 (IL-4)-secreting T_H2 cells also clear RSV, but frequently accompanied by significant pulmonary changes, including eosinophilic infiltration, a hallmark of the enhanced disease observed during previous vaccine trials (see below).

[0011] Despite the abundance of information available regarding the immunology, virology, and physiology of RSV infection, however, it remains far from clear precisely what sort of immune response is likely to be most effective at inducing lasting immunity while also not producing enhanced disease on post-vaccination exposure to RSV, as discussed in more detail in the following sections.

Prior Vaccine Development

[0012] Vaccines typically use one of several strategies to induce protective immunity against a target infectious agent or pathogen (e.g., a virus, bacterium, or parasite), including: (1) inactivated pathogen preparations; (2) live attenuated pathogen preparations, including genetically attenuated pathogen strains; (3) purified protein subunit vaccine preparations; (4) viral vector-based vaccines encoding pathogen antigens and/or adjuvants; and (5) DNA-based vaccines encoding pathogen antigens.

[0013] Initial RSV vaccine development efforts focused on an inactivated virus preparation, until a clinical trial testing efficacy of a formalin-inactivated RSV (FI-RSV) vaccine was conducted in the United States during the 1960s with disastrous results [M.R. Olson & S.M. Varga (2007), J. Immunol. 179:5415-5424]. A significant number of vaccinated patients developed enhanced pulmonary disease characterized by eosinophil and neutrophil infiltrations and a substantial inflammatory response after subsequent natural infection with RSV [Olson & Varga (2007), [Blanco JC et al. (2010) Hum Vaccin. 6:482-92]. Many of those patients required hospitalization and a few critically ill patients died. Consequently, investigators began searching for viral and/or host factors contributing to the development of enhanced disease after subsequent challenge in an effort to develop a safer RSV vaccine. That search has yielded much new information about RSV biology and the broad spectrum of immune responses it can induce, but a safe and effective RSV vaccine remains elusive.

[0014] Post-FI-RSV vaccine development efforts have focused in large part on single antigen vaccines using G, F, and, to a lesser extent, N or M2, with the viral antigens delivered either by viral or plasmid DNA vectors expressing the viral genes or as purified proteins. [See, e.g., W. Olszewska et al. (2004), Vaccine 23:215-221; G. Taylor et al. (1997), J. Gen. Virol. 78:3195-3206; and L.S. Wyatt et al. (2000), Vaccine 18:392-397]. Vaccination with a combination of F+G has also been tested in calves, cotton rats and BALB/c mice with varying results [Antonis et al. (2007) (calves); B. Moss, US Patent Application No. 06/849,299 ('the '299 application'), filed April 8, 1986 (cotton rats); and L.S. Wyatt et al. (2000) (BALB/c mice)]. Both F and G are immunogenic in calves, mice, cotton rats, humans, and to at least some degree in infant macaques [A.F.G. Antonis et al. (2007) (calves); B. Moss, the '299 application (cotton rats); L. de Waal et al. (2004), Vaccine 22:923-926 (infant macaques); L.S. Wyatt et al. (2000) (BALB/c mice); Y. Murata (2009) (humans)].

[0015] Significantly, however, the nature and type of immune response induced by RSV vaccine candidates varies—often quite considerably—depending on the type of vaccine used, the antigens selected, the route of administration, and even the model organism used. For example, immunization with live RSV or with replicating vectors encoding RSV F protein induces a dominant T_H1 response accompanied by production of neutralizing anti-F antibodies and CD8⁺ CTLs, both associated with minimal pulmonary pathology upon post-vaccination virus challenge [Y. Murata (2009) and references cited therein]. In contrast, immunization with an FI-inactivated RSV preparation induces a dominant T_H2 response completely lacking a CD8⁺ CTL response, which produces increased pathological changes in the lungs [Y. Murata

(2009) and references cited therein]. Interestingly, the administration of RSV G protein as a purified subunit vaccine or in a replicating vector induces a dominant T_H2 response eventually producing eosinophilic pulmonary infiltrates and airway hyper-reactivity following post-vaccination virus challenge, a response very similar to the enhanced disease observed with FI-RSV [Y. Murata (2009) and references cited therein]. In addition, while vaccination with modified vaccinia virus Ankara (MVA) encoding RSV F protein induced anti-F antibodies and F-specific CD8⁺ T-cells in calves, vaccination with MVA-F+MVA-G induced anti-F and anti-G antibodies but no F- or G-specific CD8⁺ T-cells [A.F.G. Antonis et al. (2007)].

[0016] Vaccination of mice with vaccinia virus (VV) expressing F protein (VV-F) induced a strong CD8⁺ T-cell response which lead to clearance of replicating RSV from lung accompanied by a similar or greater weight loss than mice immunized with FI-RSV [W. Olszewska et al. (2004)]. However it was not related to the enhanced disease induced by FI-RSV or VV expressing G protein (VV-G) (combined T_H2 response lung eosinophilia and weight loss) resulting from enhanced secretion of T_H2 cytokines such as IL-4 and IL-5. Some in the field suggested that an RSV vaccine capable of inducing a relatively balanced immune response including both a cellular and a humoral component would be less likely to display enhanced immunopathology on post-vaccination challenge [W. Olszewska et al. (2004)].

[0017] However, while vaccination of BALB/c mice with modified vaccinia virus Ankara (MVA) encoding F, G, or F+G induced just such a balanced immune response, including both a humoral response (*i.e.*, a balanced IgG1 and IgG2a response) and a T_H1 response (*i.e.*, increased levels of IFN γ /interleukin-12 (IL-12) and decreased levels of interleukin-4 (IL-4)/interleukin-5 (IL-5)), vaccinated animals nevertheless still displayed some weight loss [W. Olszewska et al. (2004)].

[0018] Despite expending considerable effort to characterize the nature and extent of the immune responses induced by various vaccine candidates in several different model systems, it remains unclear precisely what sort of immune response is required to convey lasting and complete immunity to RSV without predisposing vaccine recipients to enhanced disease. Because of the marked imbalance between the clinical burden of RSV and the available therapeutic and prophylactic options, development of an RSV vaccine remains an unmet medical need.

DESCRIPTION

[0019] While prior unsuccessful efforts to develop an RSV vaccine focused primarily on vaccination with either RSV-F or RSV-G membrane glycoprotein or both, the present inventors have discovered that vaccination with a recombinant vaccinia virus Ankara (MVA) expressing at least one antigenic determinant of an RSV membrane glycoprotein and at least one antigenic determinant of an RSV nucleocapsid protein induces better protection. In addition, such constructs induce almost complete sterile immunity when applied by the intranasal route compared to subcutaneous application, or even when compared to the intramuscular route of administration used by Wyatt and colleagues [L.S. Wyatt et al. (2000)]. Enhanced protection can be obtained by administering candidate RSV vaccines intranasally in comparison to intramuscular administration.

[0020] With recombinant MVAs expressing either RSV F or RSV G membrane glycoprotein (or both) (*e.g.*, MVA-mBN199B) or with recombinant MVAs expressing at least one antigenic determinant of an RSV membrane glycoprotein and at least one antigenic determinant of an RSV nucleocapsid protein (*e.g.*, MVA-mBN201B), the present inventors observed no replicating RSV in the lung 4 days post-challenge, although RSV genomes were still detectable by RT-qPCR. Recombinant MVAs expressing at least one antigenic determinant of an RSV membrane glycoprotein and at least one antigenic determinant an RSV nucleocapsid protein (*e.g.*, MVA-mBN201B) induced better protection and a larger decrease in the RSV viral load detectable by RT-qPCR because they induced a stronger CD8⁺ T cell response against the antigenic determinant of an RSV nucleocapsid protein. Administration of such recombinant viruses by the intranasal route furthermore induced almost complete sterile immunity (almost no RSV viral load detectable by RT-qPCR) because they induced the mucosal immune response and IgA antibody secretion, responses which were absent when such constructs were administered subcutaneously.

[0021] In contrast to FI-RSV, such constructs induce a balanced T_H1 -immune response generating good antibody responses, as well as strong, specific cellular immune responses to the RSV antigens. With intranasal administration of the vaccine producing IgG antibody levels even higher than those resulting from conventional subcutaneous administration in addition to the induction of a good IgA antibody response, protection is improved and body weight loss reduced. The magnitude of the cellular immune response was independent of the route of administration, however. Interestingly, the inventors observed a pattern of T-cell response induced by recombinant MVAs expressing at least one heterologous nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one heterologous nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein (*e.g.*, MVA-mBN201 B, expressing RSV F, G, N, and M2 proteins) that was similar to the T-cell response induced by RSV administrations, albeit much higher.

[0022] Thus, in a first aspect, the present invention provides a recombinant modified vaccinia virus Ankara (MVA) comprising at least one nucleotide sequence encoding an antigenic determinant of a respiratory syncytial virus (RSV)

membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein.

Modified Vaccinia Virus Ankara (MVA)

[0023] MVA has been generated by more than 570 serial passages on chicken embryo fibroblasts of the dermal vaccinia strain Ankara [Chorioallantois vaccinia virus Ankara virus, CVA; for review see Mayr et al. (1975), *Infection* 3, 6-14] that was maintained in the Vaccination Institute, Ankara, Turkey for many years and used as the basis for vaccination of humans. However, due to the often severe post-vaccinal complications associated with vaccinia viruses, there were several attempts to generate a more attenuated, safer smallpox vaccine.

[0024] During the period of 1960 to 1974, Prof. Anton Mayr succeeded in attenuating CVA by over 570 continuous passages in CEF cells [Mayr et al. (1975)]. It was shown in a variety of animal models that the resulting MVA was avirulent [Mayr, A. & Danner, K. (1978), *Dev. Biol. Stand.* 41: 225-234]. As part of the early development of MVA as a pre-smallpox vaccine, there were clinical trials using MVA-517 in combination with Lister Elstree [Stickl (1974), *Prev. Med.* 3: 97-101; Stickl and Hochstein-Mintzel (1971), *Munich Med. Wochenschr.* 113: 1149-1153] in subjects at risk for adverse reactions from vaccinia. In 1976, MVA derived from MVA-571 seed stock (corresponding to the 571st passage) was registered in Germany as the primer vaccine in a two-stage parenteral smallpox vaccination program. Subsequently, MVA-572 was used in approximately 120,000 Caucasian individuals, the majority children between 1 and 3 years of age, with no reported severe side effects, even though many of the subjects were among the population with high risk of complications associated with vaccinia (Mayr et al. (1978), *Zentralbl. Bacteriol. (B)* 167:375-390). MVA-572 was deposited at the European Collection of Animal Cell Cultures as ECACC V94012707.

[0025] As a result of the passaging used to attenuate MVA, there are a number of different strains or isolates, depending on the passage number in CEF cells. For example, MVA-572 was used in Germany during the smallpox eradication program, and MVA-575 was extensively used as a veterinary vaccine. MVA-575 was deposited on Dec. 7, 2000, at the European Collection of Animal Cell Cultures (ECACC) with the deposition number V00120707. The attenuated CVA-virus MVA (Modified Vaccinia Virus Ankara) was obtained by serial propagation (more than 570 passages) of the CVA on primary chicken embryo fibroblasts.

[0026] Even though Mayr et al. demonstrated during the 1970s that MVA is highly attenuated and avirulent in humans and mammals, certain investigators have reported that MVA is not fully attenuated in mammalian and human cell lines since residual replication might occur in these cells [Blanchard et al. (1998), *J Gen Virol* 79:1159-1167; Carroll & Moss (1997), *Virology* 238:198-211; U.S. Pat. No. 5,185,146; Ambrosini et al. (1999), *J Neurosci Res* 55: 569]. It is assumed that the results reported in these publications have been obtained with various known strains of MVA, since the viruses used essentially differ in their properties, particularly in their growth behaviour in various cell lines. Such residual replication is undesirable for various reasons, including safety concerns in connection with use in humans.

[0027] Strains of MVA having enhanced safety profiles for the development of safer products, such as vaccines or pharmaceuticals, have been developed by Bavarian Nordic: MVA was further passaged by Bavarian Nordic and is designated MVA-BN. MVA as well as MVA-BN lacks approximately 15% (31 kb from six regions) of the genome compared with ancestral CVA virus. The deletions affect a number of virulence and host range genes, as well as the gene for Type A inclusion bodies. A sample of MVA-BN corresponding to passage 583 was deposited on Aug. 30, 2000 at the European Collection of Cell Cultures (ECACC) under number V00083008.

[0028] MVA-BN can attach to and enter human cells where virally-encoded genes are expressed very efficiently. However, assembly and release of progeny virus does not occur. MVA-BN is strongly adapted to primary chicken embryo fibroblast (CEF) cells and does not replicate in human cells. In human cells, viral genes are expressed, and no infectious virus is produced. MVA-BN is classified as Biosafety Level 1 organism according to the Centers for Disease Control and Prevention in the United States. Preparations of MVA-BN and derivatives have been administered to many types of animals, and to more than 2000 human subjects, including immune-deficient individuals. All vaccinations have proven to be generally safe and well tolerated. Despite its high attenuation and reduced virulence, in preclinical studies MVA-BN has been shown to elicit both humoral and cellular immune responses to vaccinia and to heterologous gene products encoded by genes cloned into the MVA genome [E. Harrer et al. (2005), *Antivir. Ther.* 10(2):285-300; A. Cosma et al. (2003), *Vaccine* 22(1):21-9; M. Di Nicola et al. (2003), *Hum. Gene Ther.* 14(14):1347-1360; M. Di Nicola et al. (2004), *Clin. Cancer Res.*, 10(16):5381-5390].

[0029] "Derivatives" or "variants" of MVA refer to viruses exhibiting essentially the same replication characteristics as MVA as described herein, but exhibiting differences in one or more parts of their genomes. MVA-BN as well as a derivative or variant of MVA-BN fails to reproductively replicate in vivo in humans and mice, even in severely immune suppressed mice. More specifically, MVA-BN or a derivative or variant of MVA-BN has preferably also the capability of reproductive replication in chicken embryo fibroblasts (CEF), but no capability of reproductive replication in the human keratinocyte cell line HaCat [Boukamp et al (1988), *J Cell Biol* 106: 761-771], the human bone osteosarcoma cell line 143B (ECACC No. 91112502), the human embryo kidney cell line 293 (ECACC No. 85120602), and the human cervix adenocarcinoma

cell line HeLa (ATCC No. CCL-2). Additionally, a derivative or variant of MVA-BN has a virus amplification ratio at least two fold less, more preferably three-fold less than MVA-575 in HeLa cells and HaCaT cell lines. Tests and assay for these properties of MVA variants are described in WO 02/42480 (US 2003/0206926) and WO 03/048184 (US 2006/0159699), both incorporated herein by reference.

[0030] The amplification or replication of a virus is normally expressed as the ratio of virus produced from an infected cell (output) to the amount originally used to infect the cell in the first place (input) referred to as the "amplification ratio". An amplification ratio of "1" defines an amplification status where the amount of virus produced from the infected cells is the same as the amount initially used to infect the cells, meaning that the infected cells are permissive for virus infection and reproduction. In contrast, an amplification ratio of less than 1, *i.e.*, a decrease in output compared to the input level, indicates a lack of reproductive replication and therefore attenuation of the virus.

[0031] The advantages of MVA-based vaccine include their safety profile as well as availability for large scale vaccine production. Preclinical tests have revealed that MVA-BN demonstrates superior attenuation and efficacy compared to other MVA strains (WO02/42480). An additional property of MVA-BN strains is the ability to induce substantially the same level of immunity in vaccinia virus prime/vaccinia virus boost regimes when compared to DNA-prime/vaccinia virus boost regimes.

[0032] The recombinant MVA-BN viruses, the most preferred embodiment herein, are considered to be safe because of their distinct replication deficiency in mammalian cells and their well-established avirulence. Furthermore, in addition to its efficacy, the feasibility of industrial scale manufacturing can be beneficial. Additionally, MVA-based vaccines can deliver multiple heterologous antigens and allow for simultaneous induction of humoral and cellular immunity.

[0033] In another aspect, an MVA viral strain suitable for generating the recombinant virus may be strain MVA-572, MVA-575 or any similarly attenuated MVA strain. Also suitable may be a mutant MVA, such as the deleted *chorioallantois vaccinia virus Ankara* (dCVA). A dCVA comprises del I, del II, del III, del IV, del V, and del VI deletion sites of the MVA genome. The sites are particularly useful for the insertion of multiple heterologous sequences. The dCVA can reproducibly replicate (with an amplification ratio of greater than 10) in a human cell line (such as human 293, 143B, and MRC-5 cell lines), which then enable the optimization by further mutation useful for a virus-based vaccination strategy (see WO 2011/092029).

Definitions

[0034] The term "antigenic determinant" refers to any molecule that stimulates a host's immune system to make an antigen-specific immune response, whether a cellular response and/or a humoral antibody response. Antigenic determinants may include proteins, polypeptides, antigenic protein fragments, antigens, and epitopes which still elicit an immune response in a host and form part of an antigen, homologue or variant of proteins, polypeptides, and antigenic protein fragments, antigens and epitopes including, for example, glycosylated proteins, polypeptides, antigenic protein fragments, antigens and epitopes, and nucleotide sequences encoding such molecules. Thus, proteins, polypeptides, antigenic protein fragments, antigens and epitopes are not limited to particular native nucleotide or amino acid sequences but encompass sequences identical to the native sequence as well as modifications to the native sequence, such as deletions, additions, insertions and substitutions.

[0035] Preferably, such homologues or variants have at least about 50%, at least about 60% or 65%, at least about 70% or 75%, at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically, at least about 90%, 91%, 92%, 93%, or 94% and even more typically at least about 95%, 96%, 97%, 98% or 99%, most typically, at least about 99% identity with the referenced protein, polypeptide, antigenic protein fragment, antigen and epitope at the level of nucleotide or amino acid sequence. The term homologue or variant also encompasses truncated, deleted or otherwise modified nucleotide or protein sequences such as, for example, (1) RSV-F or RSV-G nucleotide sequences encoding soluble forms of the corresponding RSV-F or RSV-G proteins lacking the signal peptide as well as the transmembrane and/or cytoplasmic domains of the full-length RSV-F or RSV-G proteins, (2) RSV-M2 or RSV-N nucleotide sequences encoding deleted, truncated or otherwise mutated versions of the full-length RSV-M2 or RSV-N proteins, (3) soluble forms of the RSV-F or RSV-G proteins lacking the signal peptide as well as the transmembrane and/or cytoplasmic domains of the full-length RSV-F or RSV-G proteins, or (4) deleted, truncated or otherwise mutated versions of the full-length RSV-M2 or RSV-N proteins.

[0036] Techniques for determining sequence identity between nucleic acids and amino acids are known in the art. Two or more sequences can be compared by determining their "percent identity." The percent identity of two sequences, whether nucleic acid or amino acid sequences, is the number of exact matches between two aligned sequences divided by the length of the shorter sequences and multiplied by 100.

[0037] "Percent (%) amino acid sequence identity" with respect to proteins, polypeptides, antigenic protein fragments, antigens and epitopes described herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference sequence (*i.e.*, the protein, polypeptide, antigenic protein fragment, antigen or epitope from which it is derived), after aligning the sequences and introducing gaps, if necessary,

to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for example, using publically available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximum alignment over the full length of the sequences being compared.

[0038] The same applies to "percent (%) nucleotide sequence identity", *mutatis mutandis*.

[0039] For example, an appropriate alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman, (1981), *Advances in Applied Mathematics* 2:482-489. This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff, *Atlas of Protein Sequences and Structure*, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA, and normalized by Gribskov (1986), *Nucl. Acids Res.* 14(6):6745-6763. An exemplary implementation of this algorithm to determine percent identity of a sequence is provided by the Genetics Computer Group (Madison, Wis.) in the "BestFit" utility application. The default parameters for this method are described in the Wisconsin Sequence Analysis Package Program Manual, Version 8 (1995) (available from Genetics Computer Group, Madison, Wis.). A preferred method of establishing percent identity in the context of the present invention is to use the MPSRCH package of programs copyrighted by the University of Edinburgh, developed by John F. Collins and Shane S. Sturrok, and distributed by IntelliGenetics, Inc. (Mountain View, Calif). From this suite of packages the Smith-Waterman algorithm can be employed where default parameters are used for the scoring table (for example, gap open penalty of 12, gap extension penalty of one, and a gap of six). From the data generated the "Match" value reflects "sequence identity." Other suitable programs for calculating the percent identity or similarity between sequences are generally known in the art, for example, another alignment program is BLAST, used with default parameters. For example, BLASTN and BLASTP can be used using the following default parameters: genetic code=standard; filter=none; strand=both; cutoff=60; expect=10; Matrix=BLOSUM62; Descriptions=50 sequences; sort by=HIGH SCORE; Databases=non-redundant, GenBank+EMBL+DDBJ+PDB+ GenBank CDS translations+Swiss protein+Spupdate+PIR. Details of these programs can be found at the following internet address: <http://blast.ncbi.nlm.nih.gov/>.

[0040] As used herein, a "heterologous" gene, nucleic acid, antigen, or protein is understood to be a nucleic acid or amino acid sequence which is not present in the wild-type poxviral genome (e.g., MVA). The skilled person understands that a "heterologous gene", when present in a poxvirus such as MVA, is to be incorporated into the poxviral genome in such a way that, following administration of the recombinant poxvirus to a host cell, it is expressed as the corresponding heterologous gene product, i.e., as the "heterologous antigen" and/or "heterologous protein." Expression is normally achieved by operatively linking the heterologous gene to regulatory elements that allow expression in the poxvirus-infected cell. Preferably, the regulatory elements include a natural or synthetic poxviral promoter.

[0041] "Sterile immunity" as used herein means protective immunity in the absence of detectable RSV genome when sensitive detection methods, such as RT-qPCR, are applied.

[0042] It must be noted that, as used herein, the singular forms "a", "an", and "the", include plural references unless the context clearly indicates otherwise. Thus, for example, reference to "an epitope" includes one or more of epitopes and reference to "the method" includes reference to equivalent steps and methods known to those of ordinary skill in the art that could be modified or substituted for the methods described herein.

[0043] Unless otherwise indicated, the term "at least" preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the present invention.

[0044] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step. When used herein the term "comprising" can be substituted with the term "containing" or "including" or sometimes when used herein with the term "having". Any of the aforementioned terms (comprising, containing, including, having), though less preferred, whenever used herein in the context of an aspect or embodiment of the present invention can be substituted with the term "consisting of".

[0045] When used herein "consisting of" excludes any element, step, or ingredient not specified in the claim element. When used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim.

[0046] As used herein, the conjunctive term "and/or" between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by "and/or", a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term "and/or" as used

herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term "and/or."

RSV Nucleotide Sequences and Proteins

[0047] The RSV genes as mentioned herein refer to the genes, or to a homologue or variant of the genes, encoding the corresponding protein in any RSV strain or isolate, even though the exact sequence and/or genomic location of the gene may differ between strains or isolates.

[0048] Likewise, the RSV proteins mentioned herein refer to proteins, or to a homologue or variant of the proteins, encoded and expressed by the corresponding protein gene as defined above.

[0049] By way of example, as used interchangeably herein, the terms "F protein gene", "F glycoprotein gene", "RSV F protein gene", "RSV F glycoprotein gene" or "F gene" refer to the gene, or to a homologue or variant of the gene, encoding the transmembrane fusion glycoprotein in any RSV strain or isolate, even though the exact sequence and/or genomic location of the F protein gene may differ between strains or isolates. For example, in the A2 strain of RSV, the F(A2) protein gene comprises nucleotides 5601-7499 (endpoints included) as numbered in GenBank Accession Number M11486. The F(A2) protein gene further comprises a protein coding open reading frame (ORF) spanning nucleotides 5614-7338 (endpoints included) as numbered in GenBank Accession No. M11486. The nucleotide sequence of the F protein gene from RSV A2 is set forth in SEQ ID NO:28.

[0050] Also interchangeably used herein are the terms "F protein", "F glycoprotein", "RSV F protein", "RSV F glycoprotein", or "F" which refer to the heavily glycosylated transmembrane fusion glycoprotein, or to a homologue or variant of the protein, encoded and expressed by an RSV F protein gene as defined above. The amino acid sequence of the F protein from RSV A2 is set forth in SEQ ID NO:29. The RSV(A2) F protein comprises a signal peptide, an extracellular domain, a transmembrane domain, and a cytoplasmic domain (see, e.g., UniProtKB/Swiss-Prot Accession No. P03420). The signal peptide of RSV A2 F protein consists of amino acids 1-21 of SEQ ID NO:29; the extracellular domain of RSV A2 F protein consists of amino acids 1-529 of SEQ ID NO:29 or amino acids 22-529 of SEQ ID NO:29; the transmembrane domain of RSV A2 F protein consists of amino acids 530-550 of SEQ ID NO:29; and the cytoplasmic domain of RSV A2 F protein consists of amino acids 551-574 of SEQ ID NO:29.

[0051] Likewise, also the terms "G protein gene", "G glycoprotein gene", "RSV G protein gene", "RSV G glycoprotein gene" or "G gene" are used interchangeably herein. For example, in the A2 strain of RSV, the G(A2) protein gene comprises nucleotides 4626-5543 (endpoints included) as numbered in GenBank Accession Number M11486. The G(A2) protein gene further comprises a protein coding open reading frame (ORF) spanning nucleotides 4641-5537 (endpoints included) as numbered in GenBank Accession No. M11486. The nucleotide sequence of the G protein gene from RSV A2 is set forth in SEQ ID NO:30.

[0052] The terms "G protein", "G glycoprotein", "RSV G protein", "RSV G glycoprotein", or "G" refer to the heavily glycosylated transmembrane attachment glycoprotein, or to a homologue or variant of the protein. The amino acid sequence of the G protein from RSV A2 is set forth in SEQ ID NO:31. RSV A2 G protein comprises an extracellular domain, a transmembrane domain, and a cytoplasmic domain (see, e.g., UniProtKB/Swiss-Prot Accession No. P03423). The extracellular domain of RSV A2 G protein consists of amino acids 67-298 of SEQ ID NO:31; the transmembrane domain of RSV A2 G protein consists of amino acids 38-66 of SEQ ID NO:31; and the cytoplasmic domain of RSV A2 G protein consists of amino acids 1-37 of SEQ ID NO:31.

[0053] Interchangeably used herein are also the terms "M2 protein gene", "M2 nucleocapsid protein gene", "RSV M2 protein gene", "RSV M2 matrix protein gene", "RSV M2 nucleocapsid protein gene" or "M2 gene". For example, in the A2 strain of RSV, the M2(A2) protein gene comprises nucleotides 7550-8506 (endpoints included) as numbered in GenBank Accession Number M11486. The M2(A2) protein gene further comprises a protein coding open reading frame (ORF) spanning nucleotides 7559-8143 (endpoints included) as numbered in GenBank Accession No. M11486. The nucleotide sequence of the M2 protein gene from RSV A2 is set forth in SEQ ID NO:32.

[0054] Used interchangeably herein are the terms "M2 protein", "M2 nucleocapsid protein", "RSV M2 protein", "RSV M2 nucleocapsid protein", "RSV M2 matrix protein", or "M2". The amino acid sequence of the M2 protein from RSV A2 is set forth in SEQ ID NO:33 (see, e.g., UniProtKB/Swiss-Prot Accession No. P04545).

[0055] Also, the terms "N protein gene", "N nucleocapsid protein gene", "RSV N protein gene", "RSV N nucleocapsid protein gene" or "N gene" may be used interchangeably herein. For example, in the A2 strain of RSV, the N(A2) protein gene comprises nucleotides 1081-2277 (endpoints included) as numbered in GenBank Accession Number M11486. The N(A2) protein gene further comprises a protein coding open reading frame (ORF) spanning nucleotides 1096-2271 (endpoints included) as numbered in GenBank Accession No. M11486. The nucleotide sequence of the N protein gene from RSV A2 is set forth in SEQ ID NO:34.

[0056] The amino acid sequence of the "N protein", "N nucleocapsid protein", "RSV N protein", "RSV N nucleocapsid protein", or "N", terms which are interchangeably used herein, from RSV A2 is set forth in SEQ ID NO:35 (see, e.g., UniProtKB/Swiss-Prot Accession No. P03418).

[0062] In certain embodiments, the recombinant MVA comprises three heterologous nucleotide sequences, each encoding an antigenic determinant of an RSV membrane glycoprotein and two heterologous nucleotide sequences, each encoding an antigenic determinant of an RSV nucleocapsid protein. In certain embodiments, the first antigenic determinant of an RSV membrane glycoprotein is an RSV F antigenic determinant and the second antigenic determinant of an RSV membrane glycoprotein is an RSV G antigenic determinant, the first antigenic determinant of an RSV nucleocapsid protein is an RSV M2 antigenic determinant, and the second antigenic determinant of an RSV nucleocapsid

protein is an RSV N antigenic determinant. In certain embodiments, both the first antigenic determinant of an RSV membrane glycoprotein and the second antigenic determinant of an RSV membrane glycoprotein are derived from RSV strain A2. In certain embodiments, the third antigenic determinant of an RSV membrane glycoprotein is an RSV F antigenic determinant.

[0063] In certain embodiments, the recombinant MVA comprises four heterologous nucleotide sequences, each encoding an antigenic determinant of an RSV membrane glycoprotein and two heterologous nucleotide sequences, each encoding an antigenic determinant of an RSV nucleocapsid protein. In certain embodiments, the first antigenic determinant of an RSV membrane glycoprotein is an RSV F antigenic determinant and the second antigenic determinant of an RSV membrane glycoprotein is an RSV G antigenic determinant, the first antigenic determinant of an RSV nucleocapsid protein is an RSV M2 antigenic determinant, and the second antigenic determinant of an RSV nucleocapsid protein is an RSV N antigenic determinant. In certain embodiments, both the first antigenic determinant of an RSV membrane glycoprotein and the second antigenic determinant of an RSV membrane glycoprotein are derived from RSV strain A2. In certain embodiments, the third antigenic determinant of an RSV membrane glycoprotein is an RSV F antigenic determinant. In certain embodiments, the fourth antigenic determinant of an RSV membrane glycoprotein is an RSV G antigenic determinant.

[0064] In certain embodiments, the at least one heterologous nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein encodes an RSV F antigenic determinant. In certain embodiments, the RSV F antigenic determinant is full-length. In certain embodiments, the RSV F antigenic determinant is truncated. In certain embodiments, the RSV F antigenic determinant is a variant RSV F antigenic determinant. In certain embodiments, the full-length, truncated or variant RSV F antigenic determinant is derived from RSV strain A2. In certain embodiments, the full-length RSV(A2) F antigenic determinant comprises the nucleotide sequence of SEQ ID NO:28 encoding the amino acid sequence of SEQ ID NO:29. In certain embodiments, the variant RSV(A2) F antigenic determinant comprises the nucleotide sequence of SEQ ID NO:3 encoding the amino acid sequence of SEQ ID NO:4. In certain embodiments, the truncated RSV(A2) F antigenic determinant lacks the cytoplasmic and transmembrane domains of the full-length RSV(A2) F antigenic determinant. In certain embodiments, the truncated RSV(A2) F antigenic determinant comprises the nucleotide sequence of SEQ ID NO:15 encoding the amino acid sequence of SEQ ID NO:16. In certain embodiments, the full-length, truncated or variant RSV F antigenic determinant is derived from RSV strain ALong. In certain embodiments, the variant RSV(ALong) F antigenic determinant comprises the nucleotide sequence of SEQ ID NO:5 encoding the amino acid sequence of SEQ ID NO:6. In certain embodiments, the truncated RSV(ALong) F antigenic determinant lacks the cytoplasmic and transmembrane domains of the full-length RSV(ALong) F antigenic determinant.

[0065] In certain embodiments, the at least one heterologous nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein encodes an RSV G antigenic determinant. In certain embodiments, the RSV G antigenic determinant is full-length. In certain embodiments, the RSV G antigenic determinant is truncated. In certain embodiments, the RSV G antigenic determinant is a variant RSV G antigenic determinant. In certain embodiments, the full-length, truncated or variant RSV G antigenic determinant is derived from RSV strain A2. In certain embodiments, the full-length RSV(A2) G antigenic determinant comprises the nucleotide sequence of SEQ ID NO:1 encoding the amino acid sequence of SEQ ID NO:2. In certain embodiments, the truncated RSV(A2) G antigenic determinant lacks the cytoplasmic and transmembrane domains of the full-length RSV(A2) G antigenic determinant. In certain embodiments, the full-length, truncated or variant RSV G antigenic determinant is derived from RSV strain B. In certain embodiments, the truncated RSV(B) G antigenic determinant lacks the cytoplasmic and transmembrane domains of the full-length RSV(B) G antigenic determinant. In certain embodiments, the truncated RSV(B) G antigenic determinant comprises the nucleotide sequence of SEQ ID NO:7 encoding the amino acid sequence of SEQ ID NO:8.

[0066] In certain embodiments, the at least one heterologous nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein encodes an RSV M2 antigenic determinant. In certain embodiments, the RSV M2 antigenic determinant is full-length. In certain embodiments, the RSV M2 antigenic determinant is truncated. In certain embodiments, the RSV M2 antigenic determinant is a variant RSV M2 antigenic determinant. In certain embodiments, the full-length, truncated or variant RSV M2 antigenic determinant is derived from RSV strain A2. In certain embodiments, the RSV(A2) M2 antigenic determinant comprises the nucleotide sequence of SEQ ID NO:32, encoding the amino acid sequence of SEQ ID NO:33.

[0067] In certain embodiments, the at least one heterologous nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein encodes an RSV N antigenic determinant. In certain embodiments, the RSV N antigenic determinant is full-length. In certain embodiments, the RSV N antigenic determinant is truncated. In certain embodiments, the RSV N antigenic determinant is a variant RSV N antigenic determinant. In certain embodiments, the full-length, truncated or variant RSV N antigenic determinant is derived from RSV strain A2. In certain embodiments, the RSV(A2) N antigenic determinant comprises the nucleotide sequence of SEQ ID NO:34, encoding the amino acid sequence of SEQ ID NO:35.

[0068] In certain embodiments, both the RSV N antigenic determinant and the RSV M2 antigenic determinant are encoded by a single open reading frame and separated by a self-cleaving protease domain. In certain embodiments,

the RSV M2 antigenic determinant is full-length. In certain embodiments, the RSV M2 antigenic determinant is truncated. In certain embodiments, the RSV M2 antigenic determinant is a variant RSV M2 antigenic determinant. In certain embodiments, the full-length, truncated or variant RSV M2 antigenic determinant is derived from RSV strain A2. In certain embodiments, the RSV N antigenic determinant is full-length. In certain embodiments, the RSV N antigenic determinant is truncated. In certain embodiments, the RSV N antigenic determinant is a variant RSV N antigenic determinant. In certain embodiments, the full-length, truncated or variant RSV N antigenic determinant is derived from RSV strain A2. In certain embodiments, the self-cleaving protease domain is derived from Foot and Mouth Disease Virus. In certain embodiments, the self-cleaving protease domain is the protease 2A fragment from Foot and Mouth Disease Virus, comprising the nucleotide sequence of SEQ ID NO:11, encoding the amino acid sequence of SEQ ID NO:12. In certain embodiments, the at least one heterologous nucleotide sequence encoding an RSV N antigenic determinant and an RSV M2 antigenic determinant comprises the nucleotide sequence of SEQ ID NO:17, encoding the amino acid sequence of SEQ ID NO:18.

Integration sites into MVA

[0069] In certain embodiments, the heterologous nucleotide sequences encoding one or more antigenic determinants of RSV membrane glycoproteins and one or more antigenic determinants of RSV nucleocapsid proteins are incorporated in a variety of insertion sites in the MVA genome, or in the MVA-BN genome. The heterologous nucleotide sequences encoding one or more antigenic determinants RSV proteins can be inserted into the recombinant MVA as separate transcriptional units or as fusion genes, as depicted in Figure 1.

[0070] In certain embodiments, the heterologous RSV nucleotide sequences are inserted into one or more intergenic regions (IGR) of the MVA. The IGR may be selected from IGR07/08, IGR 44/45, IGR 64/65, IGR 88/89, IGR 136/137, and IGR 148/149, preferably from IGR64/65, IGR88/89, and/or IGR 148/149. The heterologous RSV nucleotide sequences may be, additionally or alternatively, inserted into one or more of the naturally occurring deletion sites I, II, III, IV, V, or VI of the MVA. In certain embodiments, less than 5, 4, 3, or 2 of the integration sites comprise heterologous RSV nucleotide sequences.

[0071] The number of insertion sites of MVA comprising heterologous RSV nucleotide sequences can be 1, 2, 3, 4, 5, 6, 7, or more. The recombinant MVA can comprise heterologous RSV nucleotide sequences inserted into 4, 3, 2, or fewer insertion sites, but preferably two insertion sites are used. In certain embodiments, three insertion sites are used. Preferably, the recombinant MVA comprises at least 4, 5, 6, or 7 nucleotide sequences inserted into 2 or 3 insertion sites.

[0072] The recombinant MVA viruses provided herein can be generated by routine methods known in the art. Methods to obtain recombinant poxviruses or to insert heterologous nucleotide sequences into a poxviral genome are well known to the person skilled in the art. For example, methods for standard molecular biology techniques such as cloning of DNA, DNA and RNA isolation, Western blot analysis, RT-PCR and PCR amplification techniques are described in Molecular Cloning, A laboratory Manual (2nd Ed.) [J. Sambrook et al., Cold Spring Harbor Laboratory Press (1989)], and techniques for the handling and manipulation of viruses are described in Virology Methods Manual [B.W.J. Mahy et al. (eds.), Academic Press (1996)]. Similarly, techniques and know-how for the handling, manipulation and genetic engineering of MVA are described in Molecular Virology: A Practical Approach [A.J. Davison & R.M. Elliott (Eds.), The Practical Approach Series, IRL Press at Oxford University Press, Oxford, UK (1993)(see, e.g., Chapter 9: Expression of genes by Vaccinia virus vectors)] and Current Protocols in Molecular Biology [John Wiley & Son, Inc. (1998)(see, e.g., Chapter 16, Section IV: Expression of proteins in mammalian cells using vaccinia viral vector)].

[0073] For the generation of the various recombinant MVAs disclosed herein, different methods may be applicable. The nucleotide sequences to be inserted into the virus can be placed into an *E. coli* plasmid construct into which DNA homologous to a section of DNA of the MVA has been inserted. Separately, the DNA sequence to be inserted can be ligated to a promoter. The promoter-gene linkage can be positioned in the plasmid construct so that the promoter-gene linkage is flanked on both ends by DNA homologous to a DNA sequence flanking a region of MVA DNA containing a non-essential locus. The resulting plasmid construct can be amplified by propagation within *E. coli* bacteria and isolated. The isolated plasmid containing the DNA gene sequence to be inserted can be transfected into a cell culture, e.g., of chicken embryo fibroblasts (CEFs), at the same time the culture is infected with MVA. Recombination between homologous MVA DNA in the plasmid and the viral genome, respectively, can generate an MVA modified by the presence of foreign DNA sequences.

[0074] According to a preferred embodiment, a cell of a suitable cell culture as, e.g., CEF cells, can be infected with a poxvirus. The infected cell can be, subsequently, transfected with a first plasmid vector comprising a foreign gene or genes, preferably under the transcriptional control of a poxvirus expression control element. As explained above, the plasmid vector also comprises sequences capable of directing the insertion of the exogenous sequence into a selected part of the poxviral genome. Optionally, the plasmid vector also contains a cassette comprising a marker and/or selection gene operably linked to a poxviral promoter. Suitable marker or selection genes are, e.g., the genes encoding the green fluorescent protein, β -galactosidase, neomycin-phosphoribosyltransferase or other markers. The use of selection or

marker cassettes simplifies the identification and isolation of the generated recombinant poxvirus. However, a recombinant poxvirus can also be identified by PCR technology. Subsequently, a further cell can be infected with the recombinant poxvirus obtained as described above and transfected with a second vector comprising a second foreign gene or genes. In case, this gene can be introduced into a different insertion site of the poxviral genome, the second vector also differs in the poxvirus-homologous sequences directing the integration of the second foreign gene or genes into the genome of the poxvirus. After homologous recombination has occurred, the recombinant virus comprising two or more foreign genes can be isolated. For introducing additional foreign genes into the recombinant virus, the steps of infection and transfection can be repeated by using the recombinant virus isolated in previous steps for infection and by using a further vector comprising a further foreign gene or genes for transfection.

[0075] Alternatively, the steps of infection and transfection as described above are interchangeable, i.e., a suitable cell can at first be transfected by the plasmid vector comprising the foreign gene and, then, infected with the poxvirus. As a further alternative, it is also possible to introduce each foreign gene into different viruses, coinfect a cell with all the obtained recombinant viruses and screen for a recombinant including all foreign genes. A third alternative is ligation of DNA genome and foreign sequences in vitro and reconstitution of the recombined vaccinia virus DNA genome using a helper virus. A fourth alternative is homologous recombination in *E. coli* or another bacterial species between a vaccinia virus genome cloned as a bacterial artificial chromosome (BAC) and a linear foreign sequence flanked with DNA sequences homologous to sequences flanking the desired site of integration in the vaccinia virus genome.

Expression of RSV genes

[0076] In one embodiment, expression of one, more, or all of the heterologous RSV nucleotide sequences is under the control of one or more poxvirus promoters. In certain embodiments, the poxvirus promoter is a Pr7.5 promoter, a hybrid early/late promoter, a PrS promoter, a synthetic or natural early or late promoter, or a cowpox virus ATI promoter. In certain embodiments, the poxvirus promoter is selected from the group consisting of the PrS promoter (SEQ ID NO:39), the Pr7.5 promoter (SEQ ID NO:40), the PrSynIIIm promoter (SEQ ID NO:41), the PrLE1 promoter (SEQ ID NO:42), and the PrH5m promoter (SEQ ID NO:43 [L.S. Wyatt et al. (1996), Vaccine 14(15):1451-1458]). In certain embodiments, the poxvirus promoter is the PrS promoter (SEQ ID NO:39). In certain embodiments, the poxvirus promoter is the Pr7.5 promoter (SEQ ID NO:40). In certain embodiments, the poxvirus promoter is the PrSynIIIm promoter (SEQ ID NO:41). In certain embodiments, the poxvirus promoter is the PrLE1 promoter (SEQ ID NO:42). In certain embodiments, the poxvirus promoter is the PrH5m promoter (SEQ ID NO:43).

[0077] A heterologous RSV nucleotide sequence or sequences can be expressed as a single transcriptional unit. For example, a heterologous RSV nucleotide sequence can be operably linked to a vaccinia virus promoter and/or linked to a vaccinia virus transcriptional terminator. In certain embodiments, one or more heterologous RSV nucleotide sequences are expressed as a fusion protein. The fusion protein can further comprise a recognition site for a peptidase or a heterologous self-cleaving peptide sequence. The heterologous self-cleaving peptide sequence may be the 2A peptidase from Foot and Mouth Disease Virus.

[0078] In certain embodiments, the "transcriptional unit" is inserted by itself into an insertion site in the MVA genome, but may also be inserted with other transcriptional unit(s) into an insertion site in the MVA genome. The "transcriptional unit" is not naturally occurring (i.e., it is heterologous, exogenous or foreign) in the MVA genome and is capable of transcription in infected cells.

[0079] Preferably, the recombinant MVA comprises 1, 2, 3, 4, 5, or more transcriptional units inserted into the MVA genome. In certain embodiments, the recombinant MVA stably expresses RSV proteins encoded by 1, 2, 3, 4, 5, or more transcriptional units. In certain embodiments, the recombinant MVA comprises 2, 3, 4, 5, or more transcriptional units inserted into the MVA genome at 1, 2, 3, or more insertion sites in the MVA genome.

RSV Vaccines and Pharmaceutical Compositions

[0080] Since the recombinant MVA viruses, including MVA-BN, described herein are highly replication restricted and, thus, highly attenuated, they are ideal candidates for the treatment of a wide range of mammals including humans and even immune-compromised humans. Hence, provided herein are the recombinant MVAs according to the present invention for use as active pharmaceutical substances as well as pharmaceutical compositions and vaccines, all intended for inducing an immune response in a living animal body, including a human.

[0081] For this, the recombinant MVA, vaccine or pharmaceutical composition can be formulated in solution in a concentration range of 10^4 to 10^9 TCID₅₀/ml, 10^5 to 5×10^8 TCID₅₀/ml, 10^6 to 10^8 TCID₅₀/ml, or 10^7 to 10^8 TCID₅₀/ml. A preferred dose for humans comprises between 10^6 to 10^9 TCID₅₀, including a dose of 10^6 TCID₅₀, 10^7 TCID₅₀, 10^8 TCID₅₀ or 5×10^8 TCID₅₀.

[0082] The pharmaceutical compositions provided herein may generally include one or more pharmaceutically acceptable and/or approved carriers, additives, antibiotics, preservatives, adjuvants, diluents and/or stabilizers. Such aux-

iliary substances can be water, saline, glycerol, ethanol, wetting or emulsifying agents, pH buffering substances, or the like. Suitable carriers are typically large, slowly metabolized molecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates, or the like.

[0083] For the preparation of vaccines, the recombinant MVA viruses provided herein can be converted into a physiologically acceptable form. This can be done based on experience in the preparation of poxvirus vaccines used for vaccination against smallpox as described by H. Stickl et al., Dtsch. med. Wschr. 99:2386-2392 (1974).

[0084] For example, purified viruses can be stored at -80°C with a titer of 5×10^8 TCID₅₀/ml formulated in about 10 mM Tris, 140 mM NaCl pH 7.7. For the preparation of vaccine shots, e.g., 10^2 - 10^8 or 10^2 - 10^9 particles of the virus can be lyophilized in 100 ml of phosphate-buffered saline (PBS) in the presence of 2% peptone and 1% human albumin in an ampoule, preferably a glass ampoule. Alternatively, the vaccine shots can be produced by stepwise freeze-drying of the virus in a formulation. This formulation can contain additional additives such as mannitol, dextran, sugar, glycine, lactose or polyvinylpyrrolidone or other aids such as antioxidants or inert gas, stabilizers or recombinant proteins (e.g., human serum albumin) suitable for in vivo administration. The glass ampoule is then sealed and can be stored between 4°C and room temperature for several months. However, as long as no need exists, the ampoule is stored preferably at temperatures below -20°C .

[0085] For vaccination or therapy, the lyophilisate can be dissolved in an aqueous solution, preferably physiological saline or Tris buffer, and administered either systemically or locally, i.e., parenteral, subcutaneous, intravenous, intramuscular, intranasal, or any other path of administration known to the skilled practitioner. The mode of administration, the dose and the number of administrations can be optimized by those skilled in the art in a known manner. However, most commonly a patient is vaccinated with a second shot about one month to six weeks after the first vaccination shot.

Kits Comprising Recombinant MVA Viruses

[0086] Also provided herein are kits comprising any one or more of the recombinant MVAs described herein. The kit can comprise one or multiple containers or vials of the recombinant MVA, together with instructions for the administration of the recombinant MVA to a subject at risk of RSV infection. In certain embodiments, the subject is a human. The instructions may indicate that the recombinant MVA is administered to the subject in a single dose, or in multiple (i.e., 2, 3, 4, etc.) doses. In certain embodiments, the instructions indicate that the recombinant MVA virus is administered in a first (priming) and second (boosting) administration to naïve or non-naïve subjects.

[0087] Further provided is a kit comprising the recombinant MVA virus in a first vial or container for a first administration (priming) and in a second vial or container for a second administration (boosting). The kit may also comprise the recombinant MVA in a third, fourth or further vial or container for a third, fourth or further administration (boosting).

Methods and Uses of Recombinant MVA Viruses

[0088] Also provided herein are methods of immunizing a subject animal, as well as recombinant MVAs for use in methods of immunizing a subject animal and use of the recombinant MVAs provided herein in the preparation of a medicament or vaccine for immunizing a subject animal. In certain embodiments, the animal is a mammal. In certain embodiments, the mammal is a rat, rabbit, pig, mouse, or human, and the methods comprise administering a dose of any one or more of the recombinant MVAs provided herein to the subject.

[0089] The subject is preferably a human and may be an adult, wherein the adult may be immune-compromised. In certain embodiments, the adult is over the age of 50, 55, 60, 65, 70, 75, 80, or 85 years. In other embodiments, the subject's age is less than 5 years, less than 3 years, less than 2 years, less than 15 months, less than 12 months, less than 9 months, less than 6, or less than 3 months. The subject's age may also range from 0-3 months, 3-6 months, 6-9 months, 9-12 months, 1-2 years, or 2-5 years.

[0090] In certain embodiments, any of the recombinant MVAs provided herein are administered to the subject at a dose of 10^6 to 10^9 TCID₅₀, at a dose of 10^6 to 5×10^8 TCID₅₀, or 10^7 to 10^8 TCID₅₀. The recombinant MVAs provided herein may also be administered to the subject at a dose of 10^6 , 10^7 TCID₅₀, 10^8 , or 5×10^8 TCID₅₀. In certain embodiments, any of the recombinant MVAs provided herein are administered to a human subject at a dose of 10^7 TCID₅₀, 10^8 , or 5×10^8 TCID₅₀.

[0091] The recombinant MVAs provided herein are administered to the subject in a single dose, or in multiple (i.e., 2, 3, 4, etc.) doses. In certain embodiments, the recombinant MVAs are administered in a first (priming) and second (boosting) administration. In certain embodiments, the first dose comprises 10^7 to 10^8 TCID₅₀ of recombinant MVA virus and the second dose comprises 10^7 to 10^8 TCID₅₀ of recombinant MVA virus.

[0092] The recombinant MVAs can be administered systemically or locally, parenterally, subcutaneously, intravenously, intramuscularly, or intranasally, preferably subcutaneously or intranasally. The recombinant MVAs can also be administered by any other path of administration known to the skilled practitioner.

[0093] In another aspect, provided herein are methods of diagnosing RSV infection and methods of determining

whether a subject is at risk of recurrent RSV infection, which may be a severe threat, particularly for newborn infants, children between 1 and 6 years old, and/or the elderly.

[0094] The present inventors have found that current methods of diagnosing an RSV infection may provide incorrect results. For example, an immunoassay detecting antibodies against RSV or a viral plaque assay may not necessarily accurately identify individuals at risk of a recurrent infection. Indeed, the present inventors observed that even though a sample taken from an individual may return a negative result in a viral plaque assay [see, e.g., W. Olszewska et al., 2004.], such results can sometimes be false negatives, since more sensitive methods sometimes demonstrate that infectious RSV particles are still present. In fact, methods such as quantitative real time-polymerase chain reaction (qRT-PCR) are required to confirm whether a subject may actually be infected with RSV, is at risk of recurrent infection, or indeed, whether a vaccinated subject has acquired sterile immunity to RSV. This determination may be critical, because reinfection following vaccination sometimes causes enhanced disease, occasionally resulting in death.

[0095] Accordingly, in certain embodiments, provided herein are methods of determining whether a subject is at risk of recurrent RSV infection, comprising quantitatively determining whether a sample obtained from the subject contains RSV genomes, wherein the presence of RSV genomes indicates the likelihood of a recurrent infection with RSV. In certain embodiments, the quantitative determination of whether a sample obtained from a subject contains RSV genomes is performed by qRT-PCR.

[0096] As used herein, the term "sample" refers to any biological sample obtained from an individual, cell line, tissue culture, or other source containing polynucleotides and polypeptides or portions thereof. Biological samples include body fluids (such as, for example, blood, serum, plasma, urine, synovial fluid, spinal fluid, bronchoalveolar lavage (BAL)) and body tissues found and/or suspected to contain RSV, including clinical samples obtained, for example, from subjects participating in a clinical trial or other experimental study. Methods for obtaining tissue biopsies and body fluids from mammals are well-known in the art. In certain embodiments, the biological sample includes RSV nucleic acids.

[0097] As used interchangeably herein, the terms "RT-qPCR" or "qRT-PCR" refer to a method known as "quantitative real time polymerase chain reaction" In some cases, this method may also be referred to as kinetic polymerase chain reaction (KPCR).

[0098] In certain embodiments, provided herein are methods of determining whether a subject has acquired sterile immunity against RSV, comprising quantitatively determining whether a sample obtained from the subject contains RSV genomes, wherein the presence of RSV genomes indicates that the subject has not acquired sterile immunity against RSV. Also provided herein are methods of immunizing a subject that has not acquired sterile immunity against RSV, comprising intranasally administering any one of the recombinant MVAs described herein to the subject. Additionally or alternatively, any one of the recombinant MVAs described herein is provided for use in methods of immunizing a subject that has not acquired sterile immunity against RSV, the method comprising intranasally administering any one of the recombinant MVAs described herein to the subject. Provided herein is also the use of any of the recombinant MVAs described herein in the preparation of a medicament and/or vaccine for immunizing a subject that has not acquired sterile immunity against RSV, wherein the medicament or vaccine is administered intranasally.

[0099] In certain embodiments, provided herein are methods of inducing sterile immunity against RSV in a subject that has not acquired sterile immunity against RSV, comprising intranasally administering any of the recombinant MVAs described herein to the subject. Also provided herein is any one of the recombinant MVAs described herein for use in methods of inducing sterile immunity against RSV in a subject that has not acquired sterile immunity against RSV, the methods comprising intranasally administering any one of the recombinant MVAs described herein to the subject. Additionally or alternatively, provided herein is the use of any of the recombinant MVAs described herein in the preparation of a medicament and/or vaccine for inducing sterile immunity against RSV in a subject that has not acquired sterile immunity against RSV, wherein the medicament or vaccine is administered intranasally.

[0100] Certain embodiments of the present invention also include the following items:

1. A recombinant modified vaccinia virus Ankara (MVA) comprising a nucleotide sequence encoding an antigenic determinant of at least one respiratory syncytial virus (RSV) membrane glycoprotein for treating or preventing an RSV infection by intranasal administration, wherein an intramuscular administration is excluded.
2. Use of a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleotide sequence encoding an antigenic determinant of at least one respiratory syncytial virus (RSV) membrane glycoprotein for the preparation of a pharmaceutical composition and/or vaccine, wherein the pharmaceutical composition and/or vaccine is administered intranasally and wherein an intramuscular administration is excluded.
3. A method of immunizing a subject, including a human, against RSV infection, comprising intranasally administering a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleotide sequence encoding at least one antigenic determinant of a respiratory syncytial virus (RSV) membrane glycoprotein to the subject, including the human, wherein an intramuscular administration is excluded.

4. The recombinant MVA of item 1, the use of item 2 and/or the method of item 3 comprising solely intranasal administration.

5. The recombinant MVA of item 1, the use of item 2 and/or the method of item 3 comprising subcutaneous administration.

6. The recombinant MVA of any one of items 1 or 4 to 5, the use of any one of items 2, 4 or 5 and/or the method of any one of items 3 to 5, wherein the recombinant MVA further comprises a nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein.

7. A recombinant modified vaccinia virus Ankara (MVA) comprising at least one nucleotide sequence encoding an antigenic determinant of a respiratory syncytial virus (RSV) membrane glycoprotein and at least one nucleotide sequence encoding an RSV nucleocapsid antigenic determinant.

8. The recombinant MVA, the use and/or method of any one of items 1 to 7, wherein the nucleotide sequence encoding an antigenic determinant of the RSV membrane glycoprotein encodes an RSV F antigenic determinant.

9. The recombinant MVA, the use and/or method of any one of items 1 to 8 further comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV F membrane glycoprotein.

10. The recombinant MVA, the use and/or method of any one of items 1 to 9, wherein the nucleotide sequence encoding an antigenic determinant of the RSV membrane glycoprotein encodes a full length RSV F membrane glycoprotein.

11. The recombinant MVA, the use and/or method of any one of items 8 to 10, wherein the nucleotide sequence encoding an antigenic determinant of the RSV F membrane glycoprotein is derived from RSV strain A, preferably from A₂ and/or A_{long}.

12. The recombinant MVA, the use and/or method of any one of items 8 to 11, wherein the nucleotide sequence encoding an antigenic determinant of the RSV F membrane glycoprotein comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:4.

13. The recombinant MVA, the use and/or method of any one of items 8 to 12, wherein the nucleotide sequence encoding an antigenic determinant of an RSV F membrane glycoprotein comprises the nucleotide sequence SEQ ID NO:3.

14. The recombinant MVA, the use and/or method of any one of items 1 to 13, wherein the nucleotide sequence encoding an antigenic determinant of the RSV membrane glycoprotein encodes a truncated RSV F membrane glycoprotein.

15. The recombinant MVA, the use and/or method of item 14, wherein the nucleotide sequence encoding the truncated RSV F membrane glycoprotein is derived from RSV strain A, preferably from A_{long}.

16. The recombinant MVA, the use and/or method of item 14 or 15, wherein the truncated RSV F membrane glycoprotein lacks the transmembrane domain.

17. The recombinant MVA, the use and/or method of any one of items 14 to 16, wherein the truncated RSV F membrane glycoprotein lacks the cytoplasmic domain.

18. The recombinant MVA, the use and/or method of any one of items 8 to 17, wherein the nucleotide sequence encoding an antigenic determinant of the RSV F membrane glycoprotein comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:6.

19. The recombinant MVA, the use and/or method of any one of items 8 to 18, wherein the nucleotide sequence encoding an antigenic determinant of the RSV F membrane glycoprotein comprises the nucleotide sequence of SEQ ID NO:5.

20. The recombinant MVA, the use and/or method of any of the preceding items, wherein the nucleotide sequence

encoding an antigenic determinant of the RSV membrane glycoprotein encodes an antigenic determinant of the RSV G membrane glycoprotein.

21. The recombinant MVA, the use and/or method of any one of items 1 to 20 further comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV G membrane glycoprotein.

22. The recombinant MVA, the use and/or method of any one of item 1 to 21, wherein the nucleotide sequence encoding an antigenic determinant of the RSV membrane glycoprotein encodes a full length RSV G membrane glycoprotein.

23. The recombinant MVA, the use and/or method of any one of items 20 to 22, wherein the nucleotide sequence encoding an antigenic determinant of the RSV G membrane glycoprotein is derived from RSV strain A, preferably from strain A2, and/or B.

24. The recombinant MVA, the use and/or method of any one of items 20 to 23, wherein the nucleotide sequence encoding an antigenic determinant of the RSV G membrane glycoprotein comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:2.

25. The recombinant MVA, the use and/or method of any one of items 20 to 24, wherein the nucleotide sequence encoding an antigenic determinant of the RSV G membrane glycoprotein comprises the nucleotide sequence SEQ ID NO:1.

26. The recombinant MVA, the use and/or method of any one of items 1 to 25 wherein the nucleotide sequence encoding an antigenic determinant of the RSV membrane glycoprotein encodes a truncated RSV G membrane glycoprotein.

27. The recombinant MVA, the use and/or method of item 26, wherein the nucleotide sequence encoding an antigenic determinant of a truncated RSV G membrane glycoprotein is derived from RSV strain B.

28. The recombinant MVA, the use and/or method of item 26 or 27, wherein the truncated RSV G membrane glycoprotein lacks the transmembrane domain.

29. The recombinant MVA, the use and/or method of any one of items 26 to 28, wherein the truncated RSV G membrane glycoprotein lacks the cytoplasmic domain.

30. The recombinant MVA, the use and/or method of any one of items 20 to 29, wherein the nucleotide sequence encoding an antigenic determinant of the RSV G membrane glycoprotein comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:8.

31. The recombinant MVA, the use and/or method of any one of items 20 to 30, wherein the nucleotide sequence encoding an antigenic determinant of the RSV G membrane glycoprotein comprises the nucleotide sequence of SEQ ID NO:7.

32. The recombinant MVA, the use and/or method of any one of items 6 to 31, wherein the nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein encodes an antigenic determinant of the RSV N nucleocapsid protein.

33. The recombinant MVA, the use and/or method of any of one of items 6 to 32, wherein the nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein encodes an antigenic determinant of an RSV M2 matrix protein.

34. The recombinant MVA, the use and/or method of any one of items 6 to 33, wherein the nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein encodes a full length protein.

35. The recombinant MVA, the use and/or method of any one of items 32 to 34, wherein the nucleotide sequence encoding an antigenic determinant of the RSV N nucleocapsid protein is derived from RSV strain A, preferably strain A2.

EP 3 656 396 A1

36. The recombinant MVA, the use and/or method of any one of items 32 to 35, wherein the nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein encodes antigenic determinants of both the RSV N nucleocapsid and RSV M2 matrix proteins.

37. The recombinant MVA, the use and/or method of item 36, wherein both the antigenic determinants of the RSV N nucleocapsid and of the RSV M2 matrix proteins are encoded by a single open reading frame.

38. The recombinant MVA, the use and/or method of item 36 or 37, wherein the antigenic determinants of the RSV N nucleocapsid and of the RSV M2 matrix proteins are separated by a self-cleaving protease domain.

39. The recombinant MVA, the use and/or method of item 38, wherein the self-cleaving protease domain sequence is derived from Foot and Mouth Disease Virus.

40. The recombinant MVA, the use and/or method of item 38 or 39, wherein the self-cleaving protease domain sequence is the protease 2A fragment sequence.

41. The recombinant MVA, the use and/or method of any one items 38 to 40, wherein the self-cleaving protease domain sequence comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:12.

42. The recombinant MVA, the use and/or method of any one of items 38 to 41, wherein the self-cleaving protease domain comprises the nucleotide sequence of SEQ ID NO:11.

43. The recombinant MVA, the use and/or method of any one of items 37 to 42, wherein the single open reading frame comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:18.

44. The recombinant MVA, the use and/or method of any one of items 37 to 43, wherein the single open reading frame comprises the nucleotide sequence of SEQ ID NO:17.

45. The recombinant MVA, the use and/or method of any of the preceding items comprising one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein.

46. The recombinant MVA, the use and/or method of item 45 comprising antigenic determinants of the RSV F membrane glycoprotein and of the RSV N nucleocapsid protein.

47. The recombinant MVA, the use and/or method of item 45 comprising antigenic determinants of the RSV F membrane glycoprotein and of the RSV M2 matrix protein.

48. The recombinant MVA, the use and/or method of item 45 comprising antigenic determinants of the RSV G membrane glycoprotein and of the RSV N nucleocapsid protein.

49. The recombinant MVA, the use and/or method of item 45 comprising antigenic determinants of the RSV G membrane glycoprotein and of the RSV M2 matrix protein.

50. The recombinant MVA, the use and/or method of any one of items 1 to 44 comprising two nucleotide sequences encoding an antigenic determinant of an RSV membrane glycoprotein and one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein.

51. The recombinant MVA, the use and/or method of item 50 comprising antigenic determinants of the RSV F and/or of the G membrane glycoproteins and of the RSV N nucleocapsid protein.

52. The recombinant MVA, the use and/or method of item 50 comprising antigenic determinants of the RSV F and/or of the G membrane glycoproteins and of the RSV M2 matrix protein.

53. The recombinant MVA, the use and/or method of any one of items 1 to 44 comprising two nucleotide sequences encoding antigenic determinants of an RSV membrane glycoprotein and two nucleotide sequences encoding antigenic determinants of an RSV nucleocapsid protein.

54. The recombinant MVA, the use and/or method of item 53 comprising nucleotide sequences encoding antigenic determinants of an RSV F and/or of a G membrane glycoprotein and antigenic determinants of an RSV N nucleocapsid and/or of an M2 matrix protein.

55. The recombinant MVA, the use and/or method of any one of items 1 to 44 comprising three nucleotide sequences encoding an antigenic determinant of an RSV membrane glycoprotein and two nucleotide sequences encoding antigenic determinants of an RSV nucleocapsid protein.

56. The recombinant MVA, the use and/or method of item 55 comprising antigenic determinants of two RSV F membrane glycoproteins and/or of one RSV G membrane glycoprotein and an antigenic determinant of the RSV N nucleocapsid protein and/or of the RSV M2 matrix protein.

57. The recombinant MVA, the use and/or method of item 55 comprising antigenic determinants of two RSV G membrane glycoproteins and/or of one RSV F membrane glycoprotein and an antigenic determinant of the RSV N nucleocapsid protein and/or of the RSV M2 matrix protein.

58. The recombinant MVA, the use and/or method of any one of items 1 to 44 comprising four nucleotide sequences encoding antigenic determinants of RSV membrane glycoproteins and one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein.

59. The recombinant MVA, the use and/or method of item 58 comprising antigenic determinants of two RSV F membrane glycoproteins and/or two RSV G membrane glycoproteins and an antigenic determinant of the RSV N nucleocapsid protein or of the RSV M2 matrix protein.

60. The recombinant MVA, the use and/or method of any one of items 1 to 44 comprising four nucleotide sequences encoding antigenic determinants of RSV membrane glycoproteins and two nucleotide sequences encoding antigenic determinants of RSV nucleocapsid proteins.

61. The recombinant MVA, the use and/or method of item 60 comprising antigenic determinants of two RSV F membrane glycoproteins and/or of two RSV G membrane glycoproteins and antigenic determinants of the RSV N nucleocapsid protein and/or of the RSV M2 matrix proteins.

62. The recombinant MVA, the use and/or method of any one of items 1 to 61, wherein the MVA used for generating the recombinant MVA is MVA-BN or a derivative thereof.

63. The recombinant MVA of any one of items 1 or 4 to 62 for use as an active pharmaceutical substance.

64. A pharmaceutical composition and/or vaccine comprising the recombinant MVA of any one of items 1 or 4 to 63 and, optionally, a pharmaceutically acceptable carrier and/or diluent.

65. Use of the recombinant MVA of any one of items 1 or 4 to 63 for the preparation of a pharmaceutical composition and/or vaccine.

66. The recombinant MVA of any one of items 6 to 63, the pharmaceutical composition and/or vaccine of item 64 and/or the use of any one of items 2, 4 to 6, 8 to 62 or 65 for treating or preventing an RSV infection.

67. A method of immunizing a subject, including a human, against RSV infection, comprising administering the recombinant MVA of any one of items 1, 4 to 63 or 66 and/or the pharmaceutical composition and/or vaccine according to item 64 or 66 to the subject, including the human.

68. The recombinant MVA of any one of items 1, 4 to 63 or 66, the pharmaceutical composition and/or vaccine of item 64 or 66, the use of any one of items 2, 4 to 6, 8 to 62, 65 or 66 and/or the method of any one of items 3 to 6, 8 to 62 or 67, wherein the recombinant MVA is or is to be administered in a dose of between 10^7 - 10^9 TCID₅₀.

69. The recombinant MVA, the pharmaceutical composition and/or vaccine, the use and/or the method of any one of items 5 to 68, wherein the recombinant MVA is or is to be administered intranasally and/or subcutaneously.

70. The recombinant MVA, the pharmaceutical composition and/or vaccine, the use and/or the method of any one

of items 1 to 69, wherein the recombinant MVA is or is to be administered in a single or multiple doses to an immunologically naïve or an immunologically experienced subject, including a human.

71. The recombinant MVA, the pharmaceutical composition and/or vaccine, the use and/or the method of any one of items 1 to 70 for administering to a subject, including the human, with more than 2 years of age.

72. The recombinant MVA, the pharmaceutical composition and/or vaccine, the use and/or the method of any one of items 1 to 70 for administering to a subject, including the human, with less than 2 years of age.

73. A kit comprising one or multiple vials of the recombinant MVA of any one of items 1, 4 to 63, 66 or 68 to 72 and instructions for the administration of the virus to a subject at risk of RSV infection.

74. A kit comprising the recombinant MVA according to any one of items 1, 4 to 63, 66 or 68 to 72 and/or the kit according to item 73, comprising the recombinant MVA in a first vial or container for a first administration (priming) and in a second vial or container for a second administration (boosting).

75. The kit according to item 73 or 74, comprising the recombinant MVA in a third, fourth or further vial or container for a third, fourth or further administration (boosting).

76. A cell comprising the recombinant MVA according to any one of items 1, 4 to 63 or 66.

77. A method of generating a recombinant MVA according to any one of items 1, 4 to 63, 66 or 68 to 72, comprising the steps of:

(a) infecting a host cell with an MVA virus,

(b) transfecting the infected cell with a recombinant vector comprising a nucleotide sequence encoding an RSV antigenic determinant, said nucleotide sequence further comprising a genomic MVA virus sequence capable of directing the integration of the nucleotide sequence into the MVA virus genome,

(c) identifying, isolating and, optionally, purifying the generated recombinant MVA virus.

78. A recombinant MVA generated according to the method of item 77.

79. A method for producing a recombinant MVA according to any one items 1, 4 to 63, 66 or 68 to 72 and/or for producing an antigenic determinant expressed from the genome of said recombinant MVA comprising the steps of:

(a) infecting a host cell with the recombinant MVA of any one of items 1, 4 to 63, 66 or of items 68 to 72, or transfecting the cell with the recombinant DNA of the recombinant MVA,

(b) cultivating the infected or transfected cell,

(c) isolating the MVA and/or antigenic determinant from said cell.

80. A recombinant MVA and/or antigenic determinant obtainable by the method of item 79.

81. A method for determining whether a subject is at risk of recurrent RSV infection, comprising determining by means of RT-qPCR whether in a sample obtained from the subject RSV is present, whereby the presence of RSV indicates the presence of a recurrent RSV infection.

82. A method for determining whether a subject has acquired sterile immunity against RSV, comprising determining by means of RT-qPCR whether in a sample obtained from the subject RSV is present, whereby the presence of RSV indicates that the subject has not acquired sterile immunity against RSV.

83. A method of immunizing a subject diagnosed by the method of item 82 to not have acquired sterile immunity against RSV, comprising intranasally administering the recombinant MVA of any one of items 1, 4 to 63, 66, 68 to 72, 78 or 80 and/or the pharmaceutical composition and/or vaccine of any one of items 64, 66 or 68 to 72 to the subject.

84. The recombinant MVA of any one of items 1, 4 to 63, 66, 68 to 72, 78 or 80 and/or the pharmaceutical composition and/or vaccine of any one of items 64, 66 or 68 to 72 for use in a method of immunizing a subject diagnosed by the method of item 82 to not have acquired sterile immunity against RSV, said method comprising intranasally administering said recombinant MVA to the subject.

85. Use of the recombinant MVA of any one of items 1, 4 to 63, 66, 68 to 72, 78 or 80 for the preparation of a pharmaceutical composition and/or vaccine for immunizing a subject diagnosed by the method of item 82 to not have acquired sterile immunity against RSV, wherein the pharmaceutical composition and/or vaccine is for intranasal administration.

86. A method of inducing sterile immunity in a subject diagnosed by the method of item 82 to not have acquired sterile immunity against RSV, comprising intranasally administering the recombinant MVA of any one of items 1, 4 to 63, 66, 68 to 72, 78 or 80 and/or the pharmaceutical composition and/or vaccine of any one of items 64, 66 or 68 to 72 to the subject.

87. The recombinant MVA of any one of items 1, 4 to 63, 66, 68 to 72, 78 or 80 and/or the pharmaceutical composition and/or vaccine of any one of items 64, 66 or 68 to 72 for use in a method of inducing sterile immunity in a subject diagnosed by the method of item 82 to not have acquired sterile immunity against RSV, said method comprising intranasally administering said recombinant MVA to the subject.

88. Use of the recombinant MVA of any one of items 1, 4 to 63, 66, 68 to 72, 78 or 80 for the preparation of a pharmaceutical composition and/or vaccine for inducing sterile immunity in a subject diagnosed by the method of item 82 to not have acquired sterile immunity against RSV, wherein the pharmaceutical composition or vaccine is for intranasal administration.

[0101] It is to be understood that both the foregoing general and detailed description are exemplary and explanatory only and do not restrict or limit the invention as claimed. The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate various embodiments of the invention and together with the description, serve to explain the principles of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0102]

Figure 1 shows the heterologous RSV genes used in the tested recombinant MVA-constructs, MVA-mBN199B, MVA-mBN201B, MVA-mBN201BΔM2, MVA-mBN294B, MVA-mBN295B and MVA-mBN330B.

Figure 2 shows serum RSV-specific IgG responses measured by IBL Hamburg-based ELISA. Mice were immunized (s.c. or i.n.) two or three times with TBS or 1×10^8 TCID₅₀ of either MVA-mBN199B, MVA-mBN201B or MVA-mBN201BΔM2. Control mice were immunized twice i.n. with 10^6 pfu RSV. Sera were diluted 1/100 and analyzed using an RSV-specific IgG ELISA based on the IBL Hamburg kit using plates coated with RSV F and G proteins.

Figure 3 shows serum RSV-specific IgG responses measured by IBL Hamburg-based ELISA after serial dilution. Mice were immunized two or three times (s.c. or i.n.) with TBS or 1×10^8 TCID₅₀ of MVA-mBN199B, MVA-mBN201B or MVA-mBN201BΔM2. Control mice were immunized twice i.n. with 10^6 pfu RSV. Sera were diluted (1/100, 1/200 and 1/400) and analyzed using an RSV-specific IgG ELISA based on the IBL Hamburg kit using plates coated with RSV F and G proteins.

Figure 4 shows serum RSV-specific IgG responses measured by IBL Hamburg-based ELISA using plates coated only with the F protein. Mice were immunized s.c. two or three times with TBS or 1×10^8 TCID₅₀ of MVA-mBN199B, MVA-mBN201B or MVA-mBN201BΔM2. Control mice were immunized twice i.n. with 10^6 pfu RSV. Sera were diluted 1/100 and analyzed using an RSV-specific IgG ELISA based on the IBL Hamburg kit using plates coated with RSV F protein only.

Figure 5 shows serum RSV-specific IgG responses measured by Serion-based ELISA. Mice were immunized two or three times (s.c. or i.n.) with TBS or 1×10^8 TCID₅₀ of either MVA-mBN199B, MVA-mBN201B or MVA-mBN201BΔM2. Control mice were immunized twice i.n. with 10^6 pfu RSV. Sera were diluted (1/100) and analyzed using an RSV-specific IgG ELISA based on the Serion kit using plates coated with an RSV lysate.

Figure 6 shows RSV-specific IgA versus IgG responses measured by IBL Hamburg-based ELISA in bronchoalveolar lavage (BAL) fluid and sera. Mice were immunized two or three times (s.c. or i.n.) with TBS or 1×10^8 TCID₅₀ of MVA-mBN199B, MVA-mBN201B or MVA-mBN201BΔM2. Control mice were immunized twice i.n. with 10^6 pfu RSV. Sera and BAL fluid were diluted (1/100) and analyzed using an RSV-specific IgG or IgA ELISA based on the IBL Hamburg kit using plates coated with RSV F and G proteins.

Figure 7 shows RSV F-, RSV G- and RSV M2-specific T-cell responses measured by ELISPOT. Mice were immunized two or three times (s.c. or i.n.) with TBS or 1×10^8 TCID₅₀ of either MVA-mBN199B, MVA-mBN201B or MVA-mBN201BΔM2. Control mice were immunized twice i.n. with 10^6 pfu RSV. Spleens were isolated on Day 48 and splenocytes were restimulated with three different RSV F-specific peptides (RSV-1 (SEQ ID NO:19), RSV-2 (SEQ ID NO:20) and RSV-3 (SEQ ID NO:21), one RSV G-specific peptide (RSV-4 (SEQ ID NO:22)), one RSV M2-specific peptide (RSV-9 (SEQ ID NO:27)) or MVA-BN. IFN γ -secreting cells were detected by ELISPOT. The stimulation index was calculated as explained in the Examples.

Figure 8 shows relative body weight loss after challenged with RSV(A2). Mice were immunized two or three times (s.c. or i.n.) with TBS or 1×10^8 TCID₅₀ of MVA-mBN199B, MVA-mBN201B or MVA-mBN201BΔM2. Control mice were immunized twice i.n. with 10^6 pfu RSV. Mice were then challenged with 10^6 pfu RSV(A2) on Day 49. Weight was measured daily from the day of challenge. The weight on the day of challenge was used as baseline to calculate percentage of relative body weight change.

Figure 9 shows RSV load in lungs measured by plaque assay. Mice were immunized two or three times (s.c. or i.n.) with TBS or 1×10^8 TCID₅₀ of MVA-mBN199B, MVA-mBN201B or MVA-mBN201BΔM2. Control mice were immunized twice i.n. with 10^6 pfu RSV. Mice were then challenged with 10^6 pfu RSV(A2) on Day 49. Lungs were isolated 4 days later and the RSV load (pfu per lung) was determined by plaque assay.

Figure 10 shows RSV load in lung measured by RT-qPCR. Mice were immunized two or three times (s.c. or i.n.) with TBS or 1×10^8 TCID₅₀ of MVA-mBN199B, MVA-mBN201B or MVA-mBN201BΔM2. Control mice were immunized twice i.n. with 10^6 pfu RSV. Mice were then challenged with 10^6 pfu RSV A2 on Day 49. Lungs were isolated 4 days later and the RSV load (estimated based on the number of L gene copies observed) was determined by RT-qPCR.

Figure 11 shows IL4 level in bronchoalveolar lavage (BAL) 4 days post RSV(A2) challenge measured by ELISA. Mice were immunized two times (s.c. or i.n.) with TBS or 1×10^8 TCID₅₀ of MVA-mBN199B or MVA-mBN201B. Control mice were immunized twice i.n. with 10^6 pfu RSV. Mice were then challenged with 10^6 pfu RSV A2. Lungs were washed with 1ml PBS 4 days later and the IL4 level in BAL was determined by ELISA. (n.d. = not detectable)

Figure 12 shows IL5 level in bronchoalveolar lavage (BAL) 4 days post RSV(A2) challenge measured by ELISA. Mice were immunized two times (s.c. or i.n.) with TBS or 1×10^8 TCID₅₀ of MVA-mBN199B or MVA-mBN201B. Control mice were immunized twice i.n. with 10^6 pfu RSV. Mice were then challenged with 10^6 pfu RSV A2. Lungs were washed with 1ml PBS 4 days later and the IL5 level in BAL was determined by ELISA. (n.d. = not detectable)

Figure 13 shows serum RSV-specific IgG responses measured by Serion-based ELISA. Mice were immunized s.c. twice 3 weeks apart with TBS or 1×10^8 TCID₅₀ of either MVA-mBN199B, MVA-mBN201B or MVA-mBN294A. Control mice were immunized twice i.n. with 10^6 pfu RSV. Sera of 5 mice per group obtained 2 weeks after the last immunization were diluted and analyzed using an RSV-specific IgG ELISA based on the Serion kit using plates coated with an RSV lysate.

Figure 14 shows serum RSV-specific neutralizing antibody responses measured by PRNT. Mice were immunized s.c. twice 3 weeks apart with TBS or 1×10^8 TCID₅₀ of either MVA-mBN199B, MVA-mBN201B or MVA-mBN294A. Control mice were immunized twice i.n. with 10^6 pfu RSV. Sera of 5 mice per group obtained 2 weeks after the last immunization analyzed by PRNT.

Figure 15 shows RSV F- and RSV M2-specific T-cell responses measured by ELISPOT. Mice were immunized s.c. twice 3 weeks apart with TBS or 1×10^8 TCID₅₀ of either MVA-mBN199B, MVA-mBN201B or MVA-mBN294A. Control mice were immunized twice i.n. with 10^6 pfu RSV. Spleens were isolated on Day 34 and splenocytes were restimulated with one RSV F-specific peptides (RSV-2 (SEQ ID NO:20), one RSV M2-specific peptide (RSV-9 (SEQ ID NO:27)) or MVA-BN. IFN γ -secreting cells were detected by ELISPOT. The stimulation index was calculated as explained in the Examples.

Figure 16 shows RSV load in lungs measured by plaque assay. Mice were immunized s.c. twice 3 weeks apart with TBS or 1×10^8 TCID₅₀ of either MVA-mBN199B, MVA-mBN201B or MVA-mBN294A. Control mice were immunized twice i.n. with 10^6 pfu RSV or i.m. with 50 μ l FI-RSV. Mice were then challenged with 10^6 pfu RSV(A2) on Day 49. Lungs were isolated 4 days later and the RSV load (pfu per lung) was determined by plaque assay.

Figure 17 shows RSV load in lung measured by RT-qPCR. Mice were immunized s.c. twice 3 weeks apart with TBS or 1×10^8 TCID₅₀ of either MVA-mBN199B, MVA-mBN201B or MVA-mBN294A. Control mice were immunized twice i.n. with 10^6 pfu RSV or i.m. with 50 μ l FI-RSV. Mice were then challenged with 10^6 pfu RSV A2 on Day 49. Lungs were isolated 4 days later and the RSV load (estimated based on the number of L gene copies observed) was determined by RT-qPCR.

Figure 18 shows eosinophil and neutrophil infiltrations in bronchoalveolar lavage (BAL) fluids 4 days post RSV(A2) challenge. Mice were immunized s.c. twice 3 weeks apart with TBS or 1×10^8 TCID₅₀ of either MVA-mBN199B, MVA-mBN201B or MVA-mBN294A. Control mice were immunized twice i.n. with 10^6 pfu RSV or i.m. with 50 μ l FI-RSV. Mice were then challenged with 10^6 pfu RSV A2. Lungs were washed with 1ml PBS 4 days later and the percentage of eosinophil and neutrophil in BAL fluid was determined.

BRIEF DESCRIPTION OF THE SEQUENCES

[0103]

SEQ ID NO:1 is a DNA sequence encoding full-length G protein from human RSV (hRSV) strain A2 (GenBank Accession No. M11486).

SEQ ID NO:2 is the amino acid sequence of full-length G protein from hRSV strain A2 (GenBank Accession No. M11486).

SEQ ID NO:3 is a DNA sequence encoding full-length F protein (BN variant) from hRSV strain A2.

SEQ ID NO:4 is the amino acid sequence of full-length F protein (BN variant) from hRSV strain A2.

SEQ ID NO:5 is a DNA sequence encoding full-length F protein (BN variant) from hRSV strain ALong.

SEQ ID NO:6 is the amino acid sequence encoding full-length F protein (BN variant) from hRSV strain ALong.

SEQ ID NO:7 is a DNA sequence encoding truncated G protein lacking the transmembrane and cytoplasmic domains from hRSV strain B (GenBank Accession No. P20896).

SEQ ID NO:8 is the amino acid sequence of truncated G protein lacking the transmembrane and cytoplasmic domains from hRSV strain B (GenBank Accession No. P20896).

SEQ ID NO:9 is a DNA sequence encoding N protein lacking a stop codon from hRSV strain A2 (Genbank Accession No. M11486).

SEQ ID NO:10 is the amino acid sequence of N protein lacking a stop codon from hRSV strain A2 (Genbank Accession No. M11486).

SEQ ID NO:11 is a DNA sequence encoding a fragment of protease 2A from Foot and Mouth Disease Virus lacking both start and stop codons.

SEQ ID NO:12 is the amino acid sequence of a fragment of protease 2A from Foot and Mouth Disease Virus lacking both start and stop codons.

SEQ ID NO:13 is a DNA sequence encoding full-length M2 protein lacking a start codon from hRSV strain A2 (GenBank Accession No. M11486).

SEQ ID NO:14 is the amino acid sequence encoding full-length M2 protein lacking a start codon from hRSV strain A2 (GenBank Accession No. M11486).

SEQ ID NO:15 is a DNA sequence encoding truncated F protein lacking the transmembrane and cytoplasmic domains (BN variant) from hRSV strain A2 (GenBank Accession No. M11486).

SEQ ID NO:16 is the amino acid sequence of truncated F protein lacking the transmembrane and cytoplasmic domains (BN variant) from hRSV strain A2 (GenBank Accession No. M11486).

SEQ ID NO:17 is a DNA sequence encoding N protein lacking a stop codon hRSV strain A2 (Genbank Accession No. M11486) + a DNA sequence encoding protease 2A fragment from Foot and Mouth Disease Virus, lacking both a start codon and a stop codon + a DNA sequence encoding full-length M2 protein lacking a start codon from hRSV strain A2 (GenBank Accession No. M11486).

SEQ ID NO:18 is the amino acid sequence of N protein from hRSV strain A2 (Genbank Accession No. M11486) + the amino acid sequence of protease 2A fragment from Foot and Mouth Disease Virus, lacking a start codon + the amino acid sequence of full-length M2 protein lacking a start codon from hRSV strain A2 (GenBank Accession No. M11486).

SEQ ID NO:19 is the amino acid sequence of RSV-1 peptide derived from RSV F protein.

SEQ ID NO:20 is the amino acid sequence of RSV-2 peptide derived from RSV F protein.
 SEQ ID NO:21 is the amino acid sequence of RSV-3 peptide derived from RSV F protein.
 SEQ ID NO:22 is the amino acid sequence of RSV-4 peptide derived from RSV G protein.
 SEQ ID NO:23 is the amino acid sequence of RSV-5 peptide derived from RSV G protein.
 SEQ ID NO:24 is the amino acid sequence of RSV-6 peptide derived from RSV G protein.
 SEQ ID NO:25 is the amino acid sequence of RSV-7 peptide derived from RSV G protein.
 SEQ ID NO:26 is the amino acid sequence of RSV-8 peptide derived from RSV G protein.
 SEQ ID NO:27 is the amino acid sequence of RSV-9 peptide derived from RSV M2 protein.
 SEQ ID NO:28 is a DNA sequence encoding full-length F protein from hRSV strain A2.
 SEQ ID NO:29 is the amino acid sequence of full-length F protein from hRSV strain A2.
 SEQ ID NO:30 is a DNA sequence encoding full-length G protein from hRSV strain A2.
 SEQ ID NO:31 is the amino acid sequence of full-length G protein from hRSV strain A2.
 SEQ ID NO:32 is a DNA sequence encoding full-length M2 protein from hRSV strain A2.
 SEQ ID NO:33 is the amino acid sequence of full-length M2 protein from hRSV strain A2.
 SEQ ID NO:34 is a DNA sequence encoding full-length N protein from hRSV strain A2.
 SEQ ID NO:35 is the amino acid sequence of full-length N protein from hRSV strain A2.
 SEQ ID NO:36 is Primer 1 used in RT-qPCR.
 SEQ ID NO:37 is Primer 2 used in RT-qPCR.
 SEQ ID NO:38 is Probe 6 used in RT-qPCR.
 SEQ ID NO:39 is the nucleotide sequence of the PrS promoter.
 SEQ ID NO:40 is the nucleotide sequence of the Pr7.5 promoter.
 SEQ ID NO:41 is the nucleotide sequence of the PrSynllm promoter.
 SEQ ID NO:42 is the nucleotide sequence of the PrLE1 promoter.
 SEQ ID NO:43 is the nucleotide sequence of the PrH5m promoter.

EXAMPLES

Example 1: Construction of Recombinant MVAs.

[0104] Generation of recombinant MVA was done by insertion of the RSV coding sequences together with the indicated promoters (Figure 1) into the MVA genome via homologous recombination in CEF cells using a selection marker to select for recombinant MVA. The use of intergenic regions (IGRs) as insertion sites is described in WO 03/097845. In order to delete the selection marker, a second step of homologous recombination was employed.

[0105] MVA-BN® virus was used as starting material for the generation of the recombinant MVA-mBN199B containing the genes for RSV-A2-G and RSV-F-A2_BN in IGR88/89. The PreMaster material of MVA-mBN199 was used as starting material for the generation of MVA-mBN201B described below.

Insertions into IGR88/89 (MVA-mBN199B):

[0106] The coding sequence for RSV-A2-G is based on the naturally occurring sequence of the RSV-A2-strain glycoprotein G. The coding sequence of the fusion protein RSV-F-A2 BN is also based on the RSV-A2 strain but was modified by Bavarian Nordic. Both inserted genes were synthesized by Geneart with human adapted codon usage and used for cloning of a recombination plasmid. The protein sequence of RSV-A2-G shows 100% identity to GenBank sequence P03423.1. The protein sequence of RSV-F-A2 BN shows only 99% identity to GenBank sequence P03420.1 due to one single amino acid exchange (P to A) on position 103.

Insertions into IGR148/149 (MVA-mBN201B):

[0107] The coding sequences for RSV-N-A2 and RSV-M2-A2 are based on the naturally occurring sequences of the respective RSV-A2-strain glycoproteins. Both genes are connected by a 2A self-cleaving peptide sequence [M.D. Ryan et al. (1991), J. Gen. Virol. 72(Pt 11):2727-2732] that allows the expression of two separate native proteins under the control of a single promoter. The coding sequences for RSV-G(B) and RSV-F A long BN were truncated to remove the transmembrane domains so that the expressed proteins can be secreted. All inserted genes were synthesized by Geneart with optimized codon usage and used for cloning of the recombination plasmid. The protein sequences of RSV-N-A2 and RSV-M2-A2 show 100% identity to GenBank sequence P03418.1 and P04545.1, respectively. The protein sequence of RSV-G(B) truncated shows 100% identity to GenBank sequence P20896.1. The coding sequence of RSV-F A long BN truncated was designed to contain the first 526 amino acids of the RSV-F protein as described by R.P. Du et al. (1994) Biotechnology (N Y) 12(8):813-818.

Deletion mutant in M2(A2) of MVA-mBN210B Δ M2:

[0108] MVA-mBN210B Δ M2 includes a deletion mutation in the 12th codon of the M2(A2) gene not allowing a functional M2 to be expressed. This deletion causes the addition of the two amino acids threonine and alanine to the first 11 amino acids of M2 (A2) followed by a transcriptional stop (UGA stop codon).

Example 2: Immunogenicity and Efficacy of Recombinant MVA Vaccines Expressing RSV F Protein, RSV G Protein, RSV N Protein, and RSV M2 Protein.

[0109] Vaccine candidate MVA-mBN199B encodes the glycoprotein (G) and the fusion (F) protein of RSV, while MVA-mBN201B Δ M2 and MVA-mBN201B express truncated versions of F and G in addition to full-length F and G proteins, the nucleocapsid protein (N) and in case of MVA-mBN201B also the matrix protein (M2) of RSV (see Figure 1). The objective of these experiments was to analyze the immunogenicity and protective efficacy of MVA-mBN201B Δ M2 and MVA-mBN201B compared to MVA-mBN199B after two or three immunizations via the subcutaneous (s.c.) or intranasal (i.n.) routes of administration.

[0110] The efficacy of these constructs was tested using an RSV(A2) challenge model in BALB/c mice. Two immunizations with MVA-mBN199B or MVA-mBN201B offered partial protection as judged by real time quantitative polymerase chain reaction (RT-qPCR) when applied subcutaneously and an almost complete protection when applied by the intranasal route. The protection offered by MVA-mBN201B was better than that offered by MVA-mBN199B. There was no difference in the humoral immune responses induced by the two constructs, although major differences were observed in the T-cell responses. MVA-mBN199B induced a good RSV F-specific cellular response, whereas a strong M2-specific T-cell response with MVA-mBN201B was observed, as well as a more pronounced G-specific response compared to MVA-mBN199B. As the IgG and T-cell responses induced after subcutaneous and intranasal immunization were similar, the almost complete sterile immunity obtained by intranasal immunizations likely correlates with the induction and secretion of RSV-specific IgA at the mucosal infection site. For MVA-mBN201B Δ M2, the lack of M2-specific T-cells responses correlated with a reduced protection compared to MVA-mBN201B and resulted in a similar protection than MVA-mBN199B.

Study Design

[0111] Mice were treated subcutaneously (s.c.) or intranasally (i.n.) with 1×10^8 TCID₅₀ MVA-mBN199B (Groups 3, 4 and 5), 1×10^8 TCID₅₀ MVA-mBN201B (Groups 6, 7 and 8), or 1×10^8 TCID₅₀ MVA-mBN201B Δ M2 (Group 9). Mice were treated either two times (Groups 3, 4, 6, 7 and 9) or three times (Groups 5 and 8) according to Table 1. The two control groups were treated (s.c.) twice with TBS (Group 1) or i.n. with RSV (Group 2) according to Table 7. Blood was collected on the day before immunization or challenge as well as on the day of sacrifice. RSV-specific IgG titres were determined by Enzyme-Linked Immunosorbent Assay (ELISA). On Day 48, half of the mice were sacrificed. Their spleens were removed and prepared for the analysis of RSV-specific T-cell responses by Enzyme-Linked Immunosorbent Spot (ELISPOT). On Day 49, the remaining mice were challenged (i.n.) with 10^6 pfu RSV A2. Appearance and body weight were monitored daily starting on the day of challenge. Four days post challenge, mice were sacrificed by injection of an elevated dose of Ketamine-Xylazine and end-bled. After lung lavage, the lungs were removed and RSV load was analyzed by plaque assay and by RT-qPCR.

Table 1: Experimental Design

Group	Group Size	Cage	Administration of Test or Reference Items				Bleed and ELISPOT (Day)%	Challenge (Day)%, #
			Injections	Schedule (Day)%	Route	Dose per Injection		
1	5	A	TBS	14 and 35	s.c.	n.a.	13, 34, 48 & 53	49
	5	B					13, 34 and 48&	-
2	5	C	RSV	14 and 35	i.n.	10^6 pfu	13, 34, 48 and 53	49
	5	D					13, 34 and 48&	-
3	5	E	MVA-mBN199B	14 and 35	s.c.	1×10^8 TCID ₅₀	13, 34, 48 and 53	49
	5	F					13, 34 and 48&	-

EP 3 656 396 A1

(continued)

Group	Group Size	Cage	Administration of Test or Reference Items				Bleed and ELISPOT (Day)%	Challenge (Day)%, #
			Injections	Schedule (Day)%	Route	Dose per Injection		
4	5	G	MVA-mBN199B	14 and 35	i.n.	1×10^8 TCID ₅₀	13, 34, 48 and 53	49
	5	H					13, 34 and 48&	-
5	5	J	MVA-mBN199B	0, 21 and 35	s.c.	1×10^8 TCID ₅₀	-1, 20 34, 48 and 53	49
	5	K					-1, 20 34 and 48&	-
6	5	L	MVA-mBN201 B	14 and 35	s.c.	1×10^8 TCID ₅₀	13, 34, 48 and 53	49
	5	M					13, 34 and 48&	-
7	5	N	MVA-mBN201 B	14 and 35	i.n.	1×10^8 TCID ₅₀	13, 34, 48 and 53	49
	5	P					13, 34 and 48&	-
8	5	Q	MVA-mBN201 B	0, 21 and 35	s.c.	1×10^8 TCID ₅₀	-1, 20 34, 48 and 53	49
	5	R					20 34 and 48&	-
9	5	W	MVA-mBN201 BΔM2	14 and 35	s.c.	1×10^8 TCID ₅₀	13, 34, 48 and 53	49
% Relative to the first immunization. # Mice were challenged by the intranasal route with 10 ⁶ pfu of RSV A2. Four days after challenge, mice were bled and sacrificed under anesthesia. BAL fluid and lungs were sampled. & On Day 48, these mice were sacrificed and spleens were analyzed by ELISPOT.								

[0112] Study Schedule. The schedule of the in-life phase is summarized in Table 2.

Table 2: Study schedule of the In-life Phase

Day**	Procedures
-16	Arrival and import in animal facility of 85 BALB/c mice, cage card allocation and allocation of 5 mice per cage
-1	Ear clipping, inclusion/exclusion examination of all mice
-1	Pre-bleed of mice from cages J, K, Q and R (facial vein puncture right side)
0	1st administration of mice from cages J, K, Q and R
13	pre-bleed of all mice except mice from cages J, K, Q and R (facial vein puncture right side)
14	1st administration of all mice except mice from cages J, K, Q and R
20	Bleed of mice from cages J, K, Q and R (facial vein puncture left side)
21	2nd administration of mice from cages J, K, Q and R
34	Bleed of all mice (retro-bulbar vein puncture left eye)
35	2nd administration of all mice except mice from cages J, K, Q and R 3rd administration of mice from cages J, K, Q and R

(continued)

Day**	Procedures
48	Bleed of all mice (retro-bulbar vein puncture right eye) Final bleed for cages B, D, F, H, K, M, P and R
48	Spleens of mice from cages B, D, F, H, K, M, P and R will be removed for analysis by ELISPOT
49	Challenge of all remaining mice
49 to 53	Appearance and body weight measurement daily
53	Final bleed, sacrifice & sampling of BAL & lung of remaining mice
** Relative to the day of the 1 st immunization.	

Material and Methods

[0113] Experimental Animals. Eighty-five female BALB/cJ Rj (H-2d) mice at the age of seven weeks were obtained from Janvier (Route des Chênes Secs, F-53940 Le Genest-Saint-Isle, France). All mice were specific pathogen free.

[0114] Housing. The study was performed in room 117 of the animal facility at Bavarian Nordic-Martinsreid. This unit was provided with filtered air at a temperature of 20-24°C and a relative humidity between 40% and 70%. The room was artificially illuminated on a cycle of 14 hours of light and 10 hours of darkness. The study acclimatization period was 15 days.. The animals were housed in transparent SealSafe™-cages (H Temp [polysulfon] cage Type II L - Euro standard), with a floor area of 530 cm². The cages were covered with an H-Temp SealSafe™ lid. The cages were placed in a TECNIPLAST-IVC SealSafe™ system with a SLIMLine™ circulation unit providing every single cage separately with HEPA-filtered air. Animal bedding was changed once a week.

[0115] Diet and water. Mice were provided with free access to irradiated maintenance diet (SSNIFF R/M-H, irradiated, V1534-727) and water (autoclaved at 121°C for 20 minutes).

[0116] Pre-Treatment Procedures: Identification of Animals. To individually mark animals within each cage, ear punching was done according to standard procedures.

[0117] Inclusion/Exclusion Examination. Inclusion/exclusion examination was done according to standard procedures.

[0118] Blood Sampling for Pre-bleed. Blood samples of approximately 150 µl were obtained by facial vein puncture according to standard procedures. Blood samples were transferred to the laboratory for further processing according to standard procedures.

[0119] Treatment Procedures: Preparation and administration of Test Items 1 to 3 and Reference Item. Preparation and administration of test and reference items was performed in a class II microbiological safety cabinet (HERAsafe®/class II type H, Kendro) according to standard procedures. Briefly, for s.c. administration, recombinant MVAs were diluted in TBS to obtain a working solution with a concentration of 2×10^8 TCID₅₀/ml. 1×10^8 TCID₅₀ in 500µl was injected s.c. according to standard procedures. For i.n. administration, recombinant MVAs were diluted in TBS to obtain a working solution with a concentration of 2×10^9 TCID₅₀/ml. 50 µl of the diluted viruses was administered in one nostril of anesthetized (Xylazine/Ketamine) mice according to standard procedures. 500µl TBS was administered s.c. according to standard procedures.

[0120] Preparation and Administration of Test Item 4 / Challenge Virus. The RSV stock vial was thawed and used as quickly as possible due to virus instability (maximal 15 minutes on ice). Virus was kept on ice at all times and used immediately to challenge anaesthetized (Xylazine/Ketamine) mice with 100 µl of the neat virus solution by the intranasal route according to standard procedures.

Post-Treatment Procedures:

[0121] Body Weight. Body weights were monitored on a daily basis from the day of challenge until sacrifice according to standard procedures.

[0122] Blood Sampling. Blood samples (approximately 150 µl) were obtained by retro-bulbar or facial venous puncture (for details see Table 1 and Table 2) according to standard procedures. Blood samples were transferred to the laboratory for further processing according to standard procedures.

[0123] Euthanasia. Euthanasia of half of the mice was performed on Day 48 by cervical dislocation. On Day 53, the remaining mice received a double dose of Ketamine-Xylazine by intra-peritoneal injection and euthanasia was done by cutting the aorta within the peritoneal cavity.

[0124] Spleen Removal. Spleens were removed aseptically. They were placed into tubes filled with medium according to standard procedures. These tubes had been imported into the animal facility and were then exported according to

standard procedures.

[0125] Lung Lavage and Lung Removal. Bronchoalveolar lavage (BAL) fluid was collected by flushing the lungs 4 times with 1 ml of PBS. The lungs were then removed and snap-frozen in two halves in liquid nitrogen for subsequent plaque assay and RNA extraction.

[0126] Analysis: Blood Sample Processing and Storage of Sera. Following transfer to the laboratory, the blood samples were processed to serum according to standard procedures. After preparation the sera were stored at -20°C ($\pm$ 5°C) until required for analysis.

[0127] Analysis of RSV-Specific Antibody Titres from Serum Samples. The total RSV-specific IgG ELISA titres were determined from all serum samples using a modified ELISA kit (Serion ELISA classic, Catalog No. ESR113G): Instead of the Alkaline Phosphatase-conjugated anti-human IgG antibody supplied with the kit, an Alkaline Phosphatase-conjugated goat anti-mouse IgG (Serotec cat: 103004) was used as the secondary antibody.

[0128] The RSV-F/G-specific IgG ELISA titers were determined from all serum samples and BAL fluid using a modified ELISA kit (IBL-Hamburg Ref. RE56881). Instead of the POD-conjugated anti-human IgG antibody supplied with the kit, an HRP-conjugated sheep anti-mouse IgG (ref. BN-687-95/96, Serotec cat: AAC10P) was used as the secondary antibody.

[0129] Except for groups 4 and 7, The RSV-F-specific IgG ELISA titers were determined from serum samples of Day 48 using a modified ELISA kit (IBL-Hamburg Ref. RE56881 reagents and RSV (F-protein) IgG microtiter strips Ref. RE56692). Instead of the POD-conjugated anti-human IgG antibody supplied within the kit, an HRP-conjugated sheep anti-mouse IgG (ref. BN-687-95/96 Serotec cat: AAC10P) was used as the secondary antibody.

[0130] The RSV-specific IgA ELISA titers in sera and BAL fluid were determined from Day 48 and Day 53 samples, respectively, using a modified ELISA kit (IBL-Hamburg Ref. RE56881): Instead of the POD-conjugated anti-human IgG antibody supplied within the kit, an HRP-conjugated sheep anti-mouse IgA (ref. BN-687-95/96 Serotec cat: STAR137P) was used as the secondary antibody.

[0131] Analysis of RSV-Specific Cellular Immune Responses from Splenocytes. The RSV F-, RSV G- and RSV M2-specific cellular responses were determined two weeks after the last administration by re-stimulation of splenocytes with specific peptides as described elsewhere (see, e.g., S.M. Varga et al. (2000); S. Johnstone et al. (2004); S. Jiang et al., (2002); and A.B. Kulkarni et al., J. Virol. 67(7):4086-4092 (1993)) and detection of IFN γ release from the splenocytes by ELISPOT assay.

[0132] ELISPOT Assay Method. The Mouse IFN-Gamma-Kit (BD Biosciences, Catalog No. 551083) was used for the ELISPOT assay. The assay was performed according to the manufacturer's instructions. Briefly, plates were coated with the capture antibody the day prior to splenocyte isolation. After isolation, cells were transferred to the ELISPOT plates and stimulated with different peptides (see Table 3) for 20 hours at 37°C. IFN γ production was detected using the detection antibody. Plates were developed using the BD™ ELISPOT AEC Substrate Set (BD Biosciences, Catalog No. 551951) according to the manufacturer's instructions.

[0133] ELISPOT Stimulation Plan. All conditions were tested in duplicate. RSV-1, RSV-2, RSV-3, RSV-4, and RSV-5 peptides (see Table 3) were used at a final concentration of 5 μ g/ml (1 μ g/well) to stimulate 5×10^5 and 2.5×10^5 splenocytes per well. MVA (immunization control) was used at a Multiplicity of Infection (MOI) of 10 to stimulate 5×10^5 and 2.5×10^5 splenocytes per well and Concanavalin A (ConA [positive control]) was used at a final concentration of 0.5 μ g/ml to stimulate 2.5×10^5 splenocytes. As a negative control, 5×10^5 splenocytes were cultured in medium only (RPMI-1640 supplemented with Glutamax, penicillin, streptomycin, 10% Fetal Calf Serum and 10^5 M β -mercaptoethanol).

Table 3: RSV-Specific Stimulation

Peptide Name	Specificity	Peptide Sequence
RSV-1	F	TYMLTNSELL (SEQ ID NO:19)
RSV-2	F	KYKNAVTEL (SEQ ID NO:20)
RSV-3	F	ELQLLMQSTPAANNR (SEQ ID NO:21)
RSV-4	G	WAICKRIPNKKPG (SEQ ID NO:22)
RSV-5	M2	SYIGSINNI (SEQ ID NO:27)

[0134] Analysis of BAL Fluid and Lungs. Cellular characterization of the BAL was not possible, due to staining issues. The RSV load in the lung samples was determined by RSV plaque assay and by RT-qPCR.

[0135] RSV plaque assay. One half each of the snap-frozen lungs was homogenized in 1 ml cold medium using a French Press (Dulbecco's Modified Eagle Medium supplemented with 7% Fetal Calf Serum). After a brief centrifugation, two tubes of each supernatant were titrated in two-fold serial dilutions onto Vero cell monolayers grown in 48-well flat-

bottomed plates. Six days later, the monolayers were washed and fixed with 1% Formaldehyde. After 24 hours, the monolayers were stained with 0.04% Neutral Red and plaques were counted.

[0136] RSV RT-qPCR. 100 μ l of the homogenized lung tissue was removed immediately and RNA was isolated using the RNeasy® Mini Kit from Qiagen (Catalog No. 74104). The reverse transcription reaction was performed using the High Capacity RNA-to-cDNA Kit from Applied Biosystems (Catalog No. 4387406). PCR specific for the RSV L gene was performed with the following parameters in a thermal cycler: (1) 50°C for 2 minutes; (2) 95°C for 10 minutes; (3) 45 cycles of (15 seconds at 95°C, 1 minute at 60°C) using the Universal PCR Master Mix from Applied Biosystems (Catalog No. 4352042) and a mixture of three primers: (1) primer 1 (5'-GAA CTC AGT GTA GGT AGA ATG TTT GCA-3'; SEQ ID NO:36); (2) primer 2 (5'-TTC AGC TAT CAT TTT CTC TGC CAA T-3'; SEQ ID NO:37); and (3) probe 6 (5'-TTT GAA CCT GTC TGA ACA TTC CCG GTT-3'; (SEQ ID NO:38). Copy number was determined from a standard curve of pMISC202 plasmid vector containing a fragment of the RSV L gene. Similar reactions for murine beta-actin were used as internal controls for input cDNA using a VIC/MGB-labeled probe from Applied Biosystems (Catalog No. 4351315).

[0137] Study Documentation. An in-life phase flow chart was prepared to collect all information during the individual steps of the in-life phase. In addition, mouse- or cage-specific information was recorded on the corresponding cage card. Cage cards are not considered as study raw data but a requirement from the Government of Upper Bavaria.

[0138] An analysis phase flow chart was prepared to collect all information during the individual steps of the analysis phase. Assays were documented in assay-specific test records or Laboratory Note Books; cross-references were documented in the analysis phase flow chart. All assay documentation including raw data was reviewed according to standard procedures. In addition, sample tracking sheets for serum samples were prepared according to standard procedures.

[0139] Data Processing. The raw data were transferred into the corresponding Excel files for further analysis according to standard procedures.

[0140] ELISA. Mean values of the OD and standard errors of the mean were calculated using Excel.

[0141] ELISPOT. ELISPOT plates were read with a CTL reader according to the manufacturer's instructions. The number of spot forming cells (SFC) was determined for each well and transferred into an Excel file for further evaluation. From the incubation with 5×10^5 and 2.5×10^5 cells per well, the number of spots per 1×10^6 splenocytes was calculated for each well. The mean for the negative control was calculated and was subtracted from each individual value prior to the calculation of the mean value per mouse to obtain the Stimulation Index (SI) value (peptide-specific frequency of IFN- γ releasing splenocytes) per mouse.

[0142] For the peptide stimulations, SI was obtained from the wells with 5×10^5 and 2.5×10^5 cells, except when the spots were too numerous to count or for the RSV immunized animals. In those cases only the concentration 2.5×10^5 was used. For MVA-BN stimulation, SI was obtained from the wells with 5×10^5 , except when the spots were too numerous to count. In that case the concentration 2.5×10^5 was used. Following determination of the SI for individual animals, the mean of SI (SFC per 1×10^6 splenocytes) and standard error of the mean (SEM) was calculated per group.

[0143] Body weight changes. Individual body weight values (in grams) prior to RSV challenge were taken as baseline values. With these baseline values, individual animal body weight changes (in %), as well as mean body weight changes of the groups were calculated for each monitored time point post challenge using Microsoft Excel.

[0144] RSV plaque assay. The numbers of plaques were counted in the well with the three highest countable dilutions of virus. The average number of plaques adjusted by the dilution factor was then multiplied by 10 to obtain the titer of the solution in pfu/ml and finally multiplied by 2 to obtain the titer per lung.

[0145] RSV RT-qPCR. PCR amplifications were measured in real time using the ABI 7500 from Applied Biosystems (Catalog No. 4351107) and analyzed using the System Software supplied by Applied Biosystems. All values were compared to the L gene standard and were normalized to the murine beta-actin determination for each sample.

Results

[0146] Analysis of the Humoral Immune Response: Analysis of RSV-Specific IgG Antibody Response from Serum Samples. Sera were first analyzed with an ELISA based on the IBL-Hamburg kit using plates coated only with recombinant RSV F and G proteins (Figure 2 and Figure 3). As shown in Figure 2, similar RSV-specific IgG responses (ODs ranging between 0.870 and 1.347) were observed with all three constructs (MVA-mBN199B, MVA-mBN201B Δ M2 and MVA-mBN201B) after a single immunization and independent of the route used for immunization (s.c. or i.n.). While the second immunization resulted in a 2.0- to nearly 3.5-fold increase in the antibody response (ODs ranging between 2.627 to 3.407), the third s.c. injection had only a minor effect on the B-cell response, producing an increase of approximately 0.500 OD units compared to ODs after the second immunization. Similar results were obtained with an ELISA based on the IBL Hamburg kit using plates coated only with recombinant RSV F protein (Figure 4).

[0147] After serial dilution of sera (1/100, 1/200 and 1/400) RSV F- and RSV G-specific ELISA results showed that MVA-mBN199B, MVA-mBN201B Δ M2 and MVA-mBN201B induced similar RSV F- and RSV G-specific IgG responses despite the additional expression of a truncated RSV F protein and a truncated RSV G protein by MVA-mBN201B Δ M2 and MVA-mBN201B (Figure 3). After two s.c. immunizations with the constructs, the B-cell response was still lower

compared to the immunization with RSV alone (positive control). To reach the level of antibody response induced by two i.n. applications of RSV required a third s.c. immunization with the MVA-mBN constructs. In contrast, 2 i.n. immunizations with MVA-mBN199B and MVA-mBN201B induced similar B-cell responses as two immunizations with RSV alone or 3 s.c. immunizations with MVA-mBN199B, MVA-mBN201B Δ M2 and MVA-mBN201B, when analyzed with

ELISA based on the IBL Hamburg kit (Figure 3).
[0148] When sera were analyzed again by ELISA based on the Serion kit using plates coated with an RSV lysate, again no differences between MVA-mBN199B, MVA-mBN201B Δ M2 and MVA-mBN201B were found. No differences between 2 and 3 immunizations, or between the s.c. and i.n. routes of administration were observed either. In addition, the responses were all lower than the antibody response induced by 2 i.n. applications of RSV (Figure 5).

[0149] Analysis of RSV-Specific IgA Antibody Responses. RSV F- and RSV G-specific IgA (based on the IBL Hamburg kit) was measured in BAL fluid 4 days post-challenge (Day 53). In addition, also BAL and sera for RSV F- and RSV G-specific IgG by ELISA were analyzed. Results were compared to the results obtained in sera just before challenge (Day 48) and are shown in Figure 6.

[0150] As expected, IgA responses were detected only after i.n. application with RSV, MVA-mBN199B and MVA-mBN201B. Although IgG could also be detected in the BAL, IgA was detected at a higher level after i.n. application. Serum levels of IgA were much lower than IgG levels independent of the route of application.

[0151] Analysis of RSV-Specific Cellular Immune Responses. T-cell responses were analyzed in the spleen by ELISPOT two weeks after the last immunization (Figure 7). MVA-mBN199B administered by the i.n. or s.c. route induced a strong RSV-F specific T-cell response. This immune response was mainly directed against the RSV-F-specific peptide RSV-2, which is immunodominant in the absence of RSV-M2. The response was around 2000 spots per 10^6 splenocytes after the 2nd s.c. immunization, and around 4000 after the 3rd s.c. injection or 2nd intranasal application. Similar to the response to RSV intranasal applications, a low G-specific response to peptide RSV-4 was detected after immunization with MVA-mBN199B (approximately 500 spots per 10^6 splenocytes) and as expected, MVA-mBN199B did not induce M2-specific T-cells. The M2 peptide is the immuno-dominant peptide of RSV in mice. Consequently, RSV intranasal immunizations induced a good M2-specific T-cell response above 1000 spots per 10^6 splenocytes and almost no F-specific T-cell response.

[0152] Like MVA-mBN199B, MVA-mBN201B induced a strong T-cell response, but it was dominated by M2 (above 4000 spots per 10^6 splenocytes independent of the number of doses administered or the route of administration). Even the G-specific response induced by MVA-mBN201B was at least 3-fold higher than the G-specific response induced by MVA-mBN199B or RSV. In contrast to MVA-mBN199B, the F-specific response induced by MVA-mBN201B was much lower, with less than 600 spots per 10^6 splenocytes for the RSV-2 peptide.

[0153] RSV Challenge with RSV A2 Strain. Mice were challenged intranasally with 10^6 pfu of RSV(A2) two weeks after the last immunization. Body weight was monitored daily. Four days post challenge, mice were sacrificed. After lung lavage with 1 ml PBS, lungs were removed and the RSV load in lung was determined by plaque assay and RT-qPCR conducted as described above.

[0154] Body weight changes. All mice lost weight one day post-challenge, most probably due to anesthesia or the i.n. challenge itself (Figure 8). TBS-treated mice started to significantly lose weight 4 days post-RSV challenge. In contrast, mice that received RSV intranasally for the third time did not show body weight loss. All mice immunized s.c. with MVA-mBN199B, MVA-mBN201 B or MVA-mBN201B Δ M2 lost about 20% weight 4 days post challenge. Such weight loss was described earlier by Olszewska et al. (Vaccine 23:215 (2004)). However our RT-qPCR results (Figure 10) show that it correlates to a better protection and earlier elimination of RSV from lung via the vaccine-primed CTL response compared to the normal clearance of primary RSV infection. When applied i.n., MVA-mBN201 B immunized mice had a similar weight loss than s.c. immunized mice 2 days post-challenge, but had recovered 4 days post-challenge due to the low RSV load in lungs compared to the s.c. route (Figure 10). Like the RSV-immunized group, mice immunized i.n. with MVA-mBN199B showed no weight loss.

[0155] RSV Load Measured by Plaque Assay. Four days post challenge an average of 57671 pfu per lung for the non-immunized mice was detected (Figure 9). As in the RSV-immunized control group, no RSV A2 plaques were detected in the lungs of animals immunized with MVA-mBN199B, MVA-mBN201B or MVA-mBN201B Δ M2 after 2 s.c. or i.n. applications.

[0156] RSV Load Measured by Quantitative Real-Time PCR. The RSV load in lung was also analyzed by RT-qPCR (Figure 10). While RSV was not detected by plaque assay in any of the vaccinated mice, RSV genomes were still detectable in mice immunized three times with MVA-mBN199B. After 3 immunizations with MVA-mBN199B, the RSV load was 38 times lower compared to the TBS control group. RSV genomes were also detectable after three immunizations with MVA-mBN201B but the load was 158 times lower compared to the TBS control group. There was no major difference between mice immunized two or three times. Interestingly, the decrease in the RSV load observed with MVA-mBN201B was not observed after vaccination with MVA-mBN201B Δ M2 which was in absence of M2 equivalent to MVA-mBN199B.

[0157] Nearly complete protection comparable that obtained in the group treated with RSV was observed after i.n. immunization with MVA-mBN201B, although a few copies of the L gene were still detectable in one mouse out of five.

Intranasal immunization with MVA-mBN199B also induced a strong decrease in the RSV load, but the L gene was still detected at a low level in three mice out of four.

Discussion and Conclusions

[0158] Although MVA-mBN201B expresses truncated versions of RSV F and G proteins in addition to the full-length RSV F and G proteins also included in the MVA-mBN199B construct, MVA-mBN201B induced a humoral immune response of similar magnitude. Both constructs induced an antibody response directed mostly against the RSV F protein as judged by similarly good responses measured in the RSV F-only ELISA compared to the RSV F and G ELISA. The antibody level following two i.n. applications was higher than after two s.c. applications. A third s.c. application was required to reach the antibody response level induced by two i.n. applications. In contrast, no major differences were observed in the T-cell responses induced using the s.c. versus i.n. routes, or using 2 versus 3 s.c. applications. However, MVA-mBN199B induced a good RSV F-specific cellular response, whereas a strong M2-specific T-cell response with MVA-mBN201B was observed. The RSV G-specific response induced by MVA-mBN201B was also more pronounced compared to MVA-mBN199B. The pattern of T-cell response induced by MVA-mBN201B was similar to the T-cell response induced by RSV immunization, albeit much higher.

[0159] Independent of the routes or the number of applications, both constructs protected mice from challenge with RSV(A2), and no replicating virus could be recovered from the lungs. However, as previously observed, s.c. immunizations with MVA-mBN199B or MVA-mBN201B did not result in sterile immunity (i.e., immunity which persists even after the targeted infectious agent is cleared from the body). The genomic RSV load (measured by levels of the viral RNA polymerase (L) gene) in the lungs of mice immunized by s.c. application of MVA-mBN199B or MVA-mBN201B was significantly reduced but still detectable by quantitative RT-PCR, and a third s.c. immunization had no beneficial impact on viral load despite its increase in RSV-specific IgG levels. The reduction in RSV L protein expression was a little more pronounced after vaccination with MVA-mBN201B compared to MVA-mBN199B, which might be due to the increased M2-specific CD8⁺ T-cell response, as the RSV genomic load was higher in animals vaccinated with MVA-mBN201B Δ M2 than for animals vaccinated with MVA-mBN201B, like MVA-mBN199B.

[0160] Sterile immunity was almost obtained after two i.n. applications of MVA-mBN199B or MVA-mBN201B. This observation correlated with the induction and secretion of RSV-specific IgA at the mucosal infection site.

Example 3: Safety of Recombinant MVA Vaccines Expressing RSV F Protein, RSV G Protein, RSV N Protein, and RSV M2 Protein, compared to FI-RSV.

[0161] Vaccine candidate MVA-mBN199B encodes the glycoprotein (G) and the fusion (F) protein of RSV, while MVA-mBN201B express truncated versions of F and G in addition to full-length proteins, the nucleocapsid protein (N) and the matrix protein (M2) of RSV (see Figure 1). The objective of these experiments was to analyze the safety of MVA-mBN199B and MVA-mBN201 B compared to FI-RSV after two immunizations via the subcutaneous (s.c.) or intranasal (i.n.) routes of administration.

[0162] The safety of these constructs was tested using an RSV(A2) challenge model in BALB/c mice. Two immunizations with MVA-mBN199B or MVA-mBN201B did not induced increased IL4 and IL5 secretion in BAL following RSV(A2) challenge, compared to FI-RSV.

Study Design

[0163] Mice were treated twice three weeks apart subcutaneously (s.c.) or intranasally (i.n.) with 1×10^8 TCID₅₀ MVA-mBN199B (Groups 3 and 4), 1×10^8 TCID₅₀ MVA-mBN201B (Groups 5 and 6) according to Table x. The three control groups were treated (s.c.) twice with TBS (Group 1) or i.n. with RSV (Group 2) or i.m. with 30 μ g FI-RSV(Group 7), according to Table x. On Day 35, mice were challenged (i.n.) with 10^6 pfu RSV A2. Four days post challenge, mice were sacrificed by injection of an elevated dose of Ketamine-Xylazine and end-bled. After lung lavage, IL4 and IL5 level were analyzed in BAL by ELISA.

Table 4: Experimental Design

Group	Group Size	Administration of Test or Reference Items				Challenge (Day)%, #
		Injections	Schedule (Day)%	Route	Dose per Injection	
1	5	TBS	0 and 21	s.c.	n.a.	35
2	5	RSV		i.n.	10 ⁶ pfu	
3	5	MVA- mBN199B		s.c.	1×10 ⁸ TCID ₅₀	
4	5			i.n.	1×10 ⁸ TCID ₅₀	
5	5	MVA- mBN201B		s.c.	1×10 ⁸ TCID ₅₀	
6	5			i.n.	1×10 ⁸ TCID ₅₀	
7	5	FI-RSV		i.m.	30μg	
% Relative to the first immunization.						
# Mice were challenged by the intranasal route with 10 ⁶ pfu of RSV A2. Four days after challenge, mice were bled and sacrificed under anesthesia. BAL fluid were sampled.						

[0164] Study Schedule. The schedule of the in-life phase is summarized in Table y.

Table 5: Study schedule of the In-life Phase

Day**	Procedures
-9	Arrival and import in animal facility of BALB/c mice, cage card allocation and allocation of 5 mice per cage
-1	Ear clipping, inclusion/exclusion examination of all mice
0	1 st administration of mice
21	2 nd administration of mice
35	RSV(A2) Challenge
39	Final bleed, sacrifice & sampling of BAL
** Relative to the day of the 1 st immunization.	

Material and methods

[0165] Experimental Animals. female BALB/cJ Rj (H-2d) mice at the age of seven weeks were obtained from Janvier (Route des Chênes Secs, F-53940 Le Genest-Saint-Isle, France). All mice were specific pathogen free.

[0166] Housing. The study was performed in room 117 of the animal facility at Bavarian Nordic-Martinsreid. This unit was provided with filtered air at a temperature of 20-24°C and a relative humidity between 40% and 70%. The room was artificially illuminated on a cycle of 14 hours of light and 10 hours of darkness. The study acclimatization period was 15 days.. The animals were housed in transparent SealSafe™-cages (H Temp [polysulfon] cage Type II L - Euro standard), with a floor area of 530 cm². The cages were covered with an H-Temp SealSafe™ lid. The cages were placed in a TECNIPLAST-IVC SealSafe™ system with a SLIMLine™ circulation unit providing every single cage separately with HEPA-filtered air. Animal bedding was changed once a week.

[0167] Diet and water. Mice were provided with free access to irradiated maintenance diet (SSNIFF R/M-H, irradiated, V1534-727) and water (autoclaved at 121°C for 20 minutes).

[0168] Pre-Treatment Procedures: Identification of Animals. To individually mark animals within each cage, ear punching was done according to standard procedures.

[0169] Inclusion/Exclusion Examination. Inclusion/exclusion examination was done according to standard procedures.

[0170] Blood Sampling for Pre-bleed. Blood samples of approximately 150 µl were obtained by facial vein puncture according to standard procedures. Blood samples were transferred to the laboratory for further processing according to standard procedures.

[0171] Treatment Procedures: Preparation and administration of Test Items and Reference Item. Preparation and administration of test and reference items was performed in a class II microbiological safety cabinet (HERAsafe®/class

II type H, Kendro) according to standard procedures. Briefly, for s.c. administration, recombinant MVAs were diluted in TBS to obtain a working solution with a concentration of 2×10^8 TCID₅₀/ml. 1×10^8 TCID₅₀ in 500 µl was injected s.c. according to standard procedures. For i.n. administration, recombinant MVAs were diluted in TBS to obtain a working solution with a concentration of 2×10^9 TCID₅₀/ml. 50 µl of the diluted viruses was administered in one nostril of anesthetized (Xylazine/Ketamine) mice according to standard procedures. 500 µl TBS was administered s.c. according to standard procedures.

[0172] Preparation and Administration of RSV(A2) Virus. The RSV stock vial was thawed and used as quickly as possible due to virus instability (maximal 15 minutes on ice). Virus was kept on ice at all times and used immediately to challenge anaesthetized (Xylazine/Ketamine) mice with 100 µl of the neat virus solution by the intranasal route according to standard procedures.

[0173] Preparation and Administration of FI-RSV. 30 µg FI-RSV in 40 µl was injected intramuscularly.

[0174] Euthanasia. On Day 35, the remaining mice received a double dose of Ketamine-Xylazine by intra-peritoneal injection and euthanasia was done by cutting the aorta within the peritoneal cavity.

[0175] Lung Lavage. Bronchoalveolar lavage (BAL) fluid was collected by flushing the lungs 4 times with 1 ml of PBS.

Analysis

[0176] IL-4 and IL-5 levels were measured in bronchoalveolar lavage (BAL) supernatant using commercially available ELISA kits (mIL4 PLATINUM ELISA from eBioscience Cat N° BMS613 and READY-SET-GO MIL-5 ELISA from eBioscience Cat N° 88-7054-22).

[0177] Study Documentation. An in-life phase flow chart was prepared to collect all information during the individual steps of the in-life phase. In addition, mouse- or cage-specific information was recorded on the corresponding cage card. Cage cards are not considered as study raw data but a requirement from the Government of Upper Bavaria.

[0178] An analysis phase flow chart was prepared to collect all information during the individual steps of the analysis phase. Assays were documented in assay-specific test records or Laboratory Note Books; cross-references were documented in the analysis phase flow chart. All assay documentation including raw data was reviewed according to standard procedures. In addition, sample tracking sheets for serum samples were prepared according to standard procedures.

[0179] Data Processing. The raw data were transferred into the corresponding Excel files for further analysis according to standard procedures.

[0180] ELISA. Cytokine concentrations were determined from the standard curve of the respective ELISA kits.

Results

[0181] An increase of IL-4 (Figure 11) and IL-5 (Figure 12) production like that observed with FI-RSV was not observed for MVA-mBN199B or MVA-mBN201B. Both cytokines were below the detection level when mice were immunized i.n. with MVA-mBN199B or MVA-mBN201B.

Discussion and Conclusions

[0182] Both MVA-mBN199B and MVA-mBN201B do not induce enhanced disease compared to FI-RSV as assessed by TH2 response.

Example 4: Comparison of immunogenicity Efficacy and Safety of different Recombinant MVA Vaccines Expressing RSV F Protein, RSV G Protein, RSV N Protein, and RSV M2 Proteins.

[0183] Vaccine candidate MVA-mBN199B encodes the glycoprotein (G) and the fusion (F) protein of RSV, MVA-mBN201B expresses truncated versions of F and G in addition to full-length proteins, the nucleocapsid protein (N) and the matrix protein (M2) of RSV and MVA-mBN294B expresses one F and and 2 G full-length proteins, the nucleocapsid protein (N) and the matrix protein (M2) of RSV (see Figure 1). MVA-mBN294A is in an intermediate product in the cloning MVA-mBN294B which still has one cloning cassette in. This cloning cassette does not impact either transgene expression or the immunogenic properties of the transgenic proteins. The objective of this experiment was to analyze the immunogenicity, efficacy and safety of MVA-mBN294A compared to MVA-mBN199B and MVA-mBN201B after two immunizations via the subcutaneous (s.c.) route of administration.

[0184] The immunogenicity efficacy and safety of these constructs was tested using an RSV(A2) challenge model in BALB/c mice. We confirmed that despite the changes in MVA-mBN294A (equivalent to MVA-mBN294B) compared to MVA-mBN201B, it induced similar B- and T-cell responses and offered similar protection. This experiment showed that any constructs (MVA-mBN201B or MVA-mBN294A) expressing at least one antigenic determinant of an RSV membrane glycoprotein (F or G) and at least one antigenic determinant of an RSV nucleocapsid protein (N or M2) induces better

protection than a construct expressing only antigenic determinants of RSV membrane glycoproteins (MVA-mBN199B)

Study Design

[0185] Mice were vaccinated (s.c.) with 1×10^8 TCID₅₀ MVA-mBN294A, MVA-mBN199B or MVA-mBN201B in a prime-boost schedule (Day 0 and 21) according to Table 6. The control groups were treated twice subcutaneously with TBS or with RSV-A2 according to Table 6. Formalin Inactivated (FI)-RSV was injected intramuscularly (i.m.) either once or twice according to Table 6.

[0186] Blood was collected one day prior to each immunization and prior to challenge, as well as on the day of sacrifice. For 5 animals of groups 1 to 5 on Day 34, RSV-specific IgG titers and RSV-specific neutralizing antibody titers were determined by ELISA and PRNT respectively.

[0187] On Day 34, some mice (Table 6) were sacrificed by injection of a lethal dose of ketamine-xylazine and final bleed. Spleens were removed and prepared for the analysis of RSV-specific T cell responses by ELISPOT.

[0188] On Day 35, the remaining mice (Table 6) were challenged with 10^6 pfu RSV-A2. Four days post-challenge, mice were sacrificed by injection of a lethal dose of ketamine-xylazine and final bleed. After lung lavage, the lungs were removed and RSV load was analyzed by plaque assay and RT-qPCR. Cellular infiltration and cytokines level in Bronchoalveolar lavage (BAL) fluids were analyzed.

Table 6: Experimental Design

Group	Group Size	Administration of Test or Reference Items				Bleed (Day) ¹	Challenge (Day) ^{1,2}			
		Injections	Schedule for Injections (Day) ¹	Route	Dose per Injection					
1	10	TBS	0 and 21	s.c.	-	-1, 20, 34 and 39	35			
	5					-1, 20 and 34 ^{&}	-			
2	10	RSV		i.n.	10 ⁶ pfu	-1, 20, 34 and 39	35			
	5					-1, 20 and 34 ^{&}	-			
3	10	MVA-mBN199B		s.c.	1x10 ⁸ TCID ₅₀	-1, 20, 34 and 39	35			
	5					-1, 20 and 34 ^{&}	-			
4	10	MVA-mBN201B					-1, 20, 34 and 39	35		
	5						-1, 20 and 34 ^{&}	-		
5	10	MVA-mBN294A					-1, 20, 34 and 39	35		
	5						-1, 20 and 34 ^{&}	-		
6	10	FI-RSV					i.m.	50μl	-1, 20, 34 and 39	35
	5								-1, 20 and 34 ^{&}	-

EP 3 656 396 A1

(continued)

Group	Group Size	Administration of Test or Reference Items				Bleed (Day) ¹	Challenge (Day) ^{1,2}
		Injections	Schedule for Injections (Day) ¹	Route	Dose per Injection		
7	5	FI-RSV	0	i.m.	50µl	-1, 20, 34 and 39	35
¹ : relative to the first immunization ² : Mice will be challenged by the intranasal route with 10 ⁶ pfu of RSV-A2. Four days after challenge, mice will be bled, sacrificed under anesthesia and BAL and lungs will be sampled &: on Day 34, these mice will be sacrificed and spleens will be analyzed by ELISPOT							

[0189] Study Schedule. The schedule of the in-life phase is summarized in Table 7.

Table 7: Study schedule of the Part 1 of the In-life Phase

Day ¹	Procedures
-9	Arrival and import in animal facility of BALB/c mice, cage card allocation and allocation of 5 mice per cage
-1	Ear clipping, inclusion/exclusion examination of all mice
-1	Pre-bleed of all mice (facial vein puncture right side)
0	1 st administration
20	Bleed of all mice (facial vein puncture left side)
21	2 nd administration
34	Final bleed, sacrifice and sampling of spleen for cages B, D, F, H, K and M
34	Bleed of all remaining mice (retro-bulbar vein puncture right eye)
35	Challenge of all remaining mice
35 to 39	Appearance and body weight measurement daily
39	Final bleed, sacrifice and sampling of BAL and lung of mice
¹ : relative to the day of the 1 st immunization	

Material and methods

[0190] Experimental Animals. female BALB/cJ Rj (H-2d) mice at the age of seven weeks were obtained from Janvier (Route des Chênes Secs, F-53940 Le Genest-Saint-Isle, France). All mice were specific pathogen free.

[0191] Housing. The study was performed in room 117 of the animal facility at Bavarian Nordic-Martinsreid. This unit was provided with filtered air at a temperature of 20-24°C and a relative humidity between 40% and 70%. The room was artificially illuminated on a cycle of 14 hours of light and 10 hours of darkness. The study acclimatization period was 15 days.. The animals were housed in transparent SealSafe™-cages (H Temp [polysulfon] cage Type II L - Euro standard), with a floor area of 530 cm². The cages were covered with an H-Temp SealSafe™ lid. The cages were placed in a TECNIPLAST-IVC SealSafe™ system with a SLIMLine™ circulation unit providing every single cage separately with HEPA-filtered air. Animal bedding was changed once a week.

[0192] Diet and water. Mice were provided with free access to irradiated maintenance diet (SSNIFF R/M-H, irradiated, V1534-727) and water (autoclaved at 121°C for 20 minutes).

Pre-Treatment Procedures:

[0193] Identification of Animals. To individually mark animals within each cage, ear punching was done according to standard procedures.

[0194] Inclusion/Exclusion Examination. Inclusion/exclusion examination was done according to standard procedures.

[0195] Blood Sampling for Pre-bleed. Blood samples of approximately 150 µl were obtained by facial vein puncture

according to standard procedures. Blood samples were transferred to the laboratory for further processing according to standard procedures.

[0196] Treatment Procedures: Preparation and administration of Test Items and Reference Item. Preparation and administration of test and reference items was performed in a class II microbiological safety cabinet (HERAsafe®/class II type H, Kendro) according to standard procedures. Briefly, for s.c. administration, recombinant MVAs were diluted in TBS to obtain a working solution with a concentration of 2×10^8 TCID₅₀/ml. 1×10^8 TCID₅₀ in 500 µl was injected s.c. according to standard procedures. 500 µl TBS was administered s.c. according to standard procedures.

[0197] Preparation and Administration of RSV(A2) Virus. The RSV stock vial was thawed and used as quickly as possible due to virus instability (maximal 15 minutes on ice). Virus was kept on ice at all times and used immediately to challenge anaesthetized (Xylazine/Ketamine) mice with 100 µl of the neat virus solution by the intranasal route according to standard procedures.

[0198] Preparation and Administration of FI-RSV: 50 µl of FI-RSV was applied i.m..

Post-Treatment Procedures:

[0199] Blood Sampling. Blood samples (approximately 150 µl) were obtained by retro-bulbar or facial venous puncture (for details see Table 7) according to standard procedures. Blood samples were transferred to the laboratory for further processing according to standard procedures.

[0200] Euthanasia. Mice received a double dose of Ketamine-Xylazine by intra-peritoneal injection and euthanasia was done by cutting the aorta within the peritoneal cavity.

[0201] Spleen Removal. Spleens were removed aseptically. They were placed into tubes filled with medium according to standard procedures. These tubes had been imported into the animal facility and were then exported according to standard procedures.

[0202] Lung Lavage and Lung Removal. Bronchoalveolar lavage (BAL) fluid was collected by flushing the lungs 4 times with 1 ml of PBS. The lungs were then removed and snap-frozen in two halves in liquid nitrogen for subsequent plaque assay and RNA extraction.

Analysis:

[0203] Blood Sample Processing and Storage of Sera. Following transfer to the laboratory, the blood samples were processed to serum according to standard procedures. After preparation the sera were stored at -20°C ($\pm 5^\circ\text{C}$) until required for analysis.

[0204] Analysis of RSV-Specific Antibody Titres from Serum Samples. The total RSV-specific IgG ELISA titres were determined from all serum samples using a modified ELISA kit (Serion ELISA classic, Catalog No. ESR113G): Instead of the Alkaline Phosphatase-conjugated anti-human IgG antibody supplied with the kit, an Alkaline Phosphatase-conjugated goat anti-mouse IgG (Serotec cat: 103004) was used as the secondary antibody.

[0205] Analysis of RSV-Specific neutralizing Antibody Titres from Serum Samples. Briefly, 2-fold serial dilutions of the test sera were prepared and a defined number of RSV plaque forming units (pfu) were added to the serum dilution. After 185 min incubation at 36°C ($\pm 2^\circ\text{C}$) and 5% CO₂ ($\pm 1\%$), it was added to pre-seeded plates containing Vero cells. Two days later plates were fixed, immuno-stained with a mixture of RSV-specific antibodies and plaques were counted.

[0206] Analysis of RSV-Specific Cellular Immune Responses from Splenocytes. The RSV F- and RSV M2-specific cellular responses were determined two weeks after the last administration by re-stimulation of splenocytes with specific peptides as described elsewhere and detection of IFN γ release from the splenocytes by ELISPOT assay.

[0207] ELISPOT Assay Method. The Mouse IFN-Gamma-Kit (BD Biosciences, Catalog No. 551083) was used for the ELISPOT assay. The assay was performed according to the manufacturer's instructions. Briefly, plates were coated with the capture antibody the day prior to splenocyte isolation. After isolation, cells were transferred to the ELISPOT plates and stimulated with different peptides (see Table 3) for 20 hours at 37°C . IFN γ production was detected using the detection antibody. Plates were developed using the BD™ ELISPOT AEC Substrate Set (BD Biosciences, Catalog No. 551951) according to the manufacturer's instructions.

[0208] ELISPOT Stimulation Plan. All conditions were tested in duplicate. RSV-2 and RSV-5 peptides (see Table 8) were used at a final concentration of 5 µg/ml (1 µg/well) to stimulate 5×10^5 and 2.5×10^5 splenocytes per well. MVA (immunization control) was used at a Multiplicity of Infection (MOI) of 10 to stimulate 5×10^5 and 2.5×10^5 splenocytes per well and Concanavalin A (ConA [positive control]) was used at a final concentration of 0.5 µg/ml to stimulate 2.5×10^5 splenocytes. As a negative control, 5×10^5 splenocytes were cultured in medium only (RPMI-1640 supplemented with Glutamax, penicillin, streptomycin, 10% Fetal Calf Serum and 10^5 M β -mercaptoethanol).

Table 8: RSV-Specific Stimulation

Peptide Name	Specificity	Peptide Sequence
RSV-2	F	KYKNAVTEL (SEQ ID NO:20)
RSV-5	M2	SYIGSINNI (SEQ ID NO:27)

Analysis of BAL Fluid:

[0209] Two slides were prepared by cytospin centrifugation (800rpm, 5 minutes) of 100 µl of BAL fluid. Slides were dried overnight and then stained. Slides were analyzed by microscopy to determine the percentage of eosinophils and neutrophils. The rest of the BAL was then be centrifuged (12,000 rpm 5 minutes). After preparation, the BAL supernatants were stored at -20°C (± 5°C) until analysis. IL-4 and IL-5 levels were measured in bronchoalveolar lavage (BAL) supernatant using commercially available ELISA kits (mIL4 PLATINUM ELISA from eBIOSCIENCE Cat N° BMS613 and READY-SET-GO MIL-5 ELISA from eBIOSCIENCE Cat N° 88-7054-22).

Analysis of RSV load in the lung

[0210] The RSV load in the lung samples was determined by RSV plaque assay and by RT-qPCR.

[0211] RSV plaque assay. One half each of the snap-frozen lungs was homogenized in 1 ml cold medium using a French Press (Dulbecco's Modified Eagle Medium supplemented with 7% Fetal Calf Serum). After a brief centrifugation, two tubes of each supernatant were titrated in two-fold serial dilutions onto Vero cell monolayers grown in 48-well flat-bottomed plates. Six days later, the monolayers were washed and fixed with 1% Formaldehyde. After 24 hours, the monolayers were stained with 0.04% Neutral Red and plaques were counted.

[0212] RSV RT-qPCR. 100 µl of the homogenized lung tissue was removed immediately and RNA was isolated using the RNeasy® Mini Kit from Qiagen (Catalog No. 74104). The reverse transcription reaction was performed using the High Capacity RNA-to-cDNA Kit from Applied Biosystems (Catalog No. 4387406). PCR specific for the RSV L gene was performed with the following parameters in a thermal cycler: (1) 50°C for 2 minutes; (2) 95°C for 10 minutes; (3) 45 cycles of (15 seconds at 95°C, 1 minute at 60°C) using the Universal PCR Master Mix from Applied Biosystems (Catalog No. 4352042) and a mixture of three primers: (1) primer 1 (5'-GAA CTC AGT GTA GGT AGA ATG TTT GCA-3'; SEQ ID NO:36); (2) primer 2 (5'-TTC AGC TAT CAT TTT CTC TGC CAA T-3'; SEQ ID NO:37); and (3) probe 6 (5'-TTT GAA CCT GTC TGA ACA TTC CCG GTT-3'; (SEQ ID NO:38). Copy number was determined from a standard curve of pMISC202 plasmid vector containing a fragment of the RSV L gene. Similar reactions for murine beta-actin were used as internal controls for input cDNA using a VIC/MGB-labeled probe from Applied Biosystems (Catalog No. 4351315).

Study Documentation.

[0213] An in-life phase flow chart was prepared to collect all information during the individual steps of the in-life phase. In addition, mouse- or cage-specific information was recorded on the corresponding cage card. Cage cards are not considered as study raw data but a requirement from the Government of Upper Bavaria.

[0214] An analysis phase flow chart was prepared to collect all information during the individual steps of the analysis phase. Assays were documented in assay-specific test records or Laboratory Note Books; cross-references were documented in the analysis phase flow chart. All assay documentation including raw data was reviewed according to standard procedures. In addition, sample tracking sheets for serum samples were prepared according to standard procedures.

[0215] Data Processing. The raw data were transferred into the corresponding Excel files for further analysis according to standard procedures.

[0216] ELISA. Mean values of the OD and standard errors of the mean were calculated using Excel.

[0217] PRNT. Plaques were transfer to a macro to calculate a PRNT titer according to standard procedures.

[0218] ELISPOT. ELISPOT plates were read with a CTL reader according to the manufacturer's instructions. The number of spot forming cells (SFC) was determined for each well and transferred into an Excel file for further evaluation. From the incubation with 5×10^5 and 2.5×10^5 cells per well, the number of spots per 1×10^6 splenocytes was calculated for each well. The mean for the negative control was calculated and was subtracted from each individual value prior to the calculation of the mean value per mouse to obtain the Stimulation Index (SI) value (peptide-specific frequency of IFN-γ releasing splenocytes) per mouse.

[0219] For the peptide stimulations, SI was obtained from the wells with 5×10^5 and 2.5×10^5 cells, except when the spots were too numerous to count or for the RSV immunized animals. In those cases only the concentration 2.5×10^5 was used. For MVA-BN stimulation, SI was obtained from the wells with 5×10^5 , except when the spots were too numerous to count. In that case the concentration 2.5×10^5 was used. Following determination of the SI for individual animals, the

mean of SI (SFC per 1×10^6 splenocytes) and standard error of the mean (SEM) was calculated per group.

[0220] RSV plaque assay. The numbers of plaques were counted in the well with the three highest countable dilutions of virus. The average number of plaques adjusted by the dilution factor was then multiplied by 10 to obtain the titer of the solution in pfu/ml and finally multiplied by 2 to obtain the titer per lung.

[0221] RSV RT-qPCR. PCR amplifications were measured in real time using the ABI 7500 from Applied Biosystems (Catalog No. 4351107) and analyzed using the System Software supplied by Applied Biosystems. All values were compared to the L gene standard and were normalized to the murine beta-actin determination for each sample.

[0222] Cytokines ELISA. Cytokine concentrations were determined from the standard curve of the respective ELISA kits.

Results

Analysis of the Humoral Immune Response:

[0223] For both RSV-specific IgG (ELISA, Figure 13) and RSV-specific neutralizing antibody responses (PRNT, Figure 14) we did not observe any differences between the three constructs (MVA-mBN199B, MVA-mBN201B and MVA-mBN294A)

Analysis of the cellular Immune Response:

[0224] As expected, MVA-mBN294A had a similar T-cell response pattern than MVA-mBN201B (Figure 15), inducing both F and M2 specific responses dominated by the M2 T-cell response. In contrast, MVA-mBN199B only induced a F-specific response but at a higher level than MVA-mBN201B and MVA-mBN294A.

Analysis of the RSV load in the Lungs:

[0225] RSV Challenge with RSV A2 Strain. Mice were challenged intranasally with 10^6 pfu of RSV(A2) two weeks after the last immunization. Four days post-challenge, mice were sacrificed. After lung lavage with 1 ml PBS, lungs were removed and the RSV load in lung was determined by plaque assay and RT-qPCR conducted as described above.

[0226] RSV Load Measured by Plaque Assay. Four days post challenge an average of 29842 pfu per lung for the non-immunized mice was detected (Figure 16). As in the RSV-immunized control group, no RSV A2 plaques were detected in the lungs of animals immunized with MVA-mBN199B, MVA-mBN201B or MVA-mBN294A after 2 s.c. applications.

[0227] RSV Load Measured by Quantitative Real-Time PCR. The RSV load in lung was also analyzed by RT-qPCR (Figure 17). While RSV was not detected by plaque assay in any of the vaccinated mice, RSV genomes were still detectable in mice immunized s.c. twice with MVA-mBN199B, MVA-mBN201B or MVA-mBN294A. For MVA-mBN199B, the RSV load was 45 times lower compared to the TBS control group. RSV genomes were also detectable for MVA-mBN201 B and MVA-mBN294A but the load was strongly reduced compared to MVA-mBN199B, 416 times and 281 times lower compared to the TBS control group, respectively.

Analysis of the Enhanced Disease signs

[0228] In contrast to the batch of FI-RSV used in the experiments described in Example 3, the new batch used in this study did not show any increase of IL-4 or IL-5 production. However we were able with this batch to detect eosinophil and neutrophil infiltrations in the BAL fluid which is the main hallmark of enhanced diseases for FI-RSV. No signs of enhanced diseases were detectable for MVA-mBN199B, MVA-mBN201B, and MVA-mBN294A

Discussion and Conclusions

[0229] Despite the differences between MVA-mBN294A (equivalent to MVA-mBN294B) and MVA-mBN201B, both induced similar B- and T-cell responses and offer similar protection without inducing enhanced disease. Both constructs induced a better protection than MVA-mBN199B which expressed only antigenic determinants of membrane glycoproteins (F and G).

[0230] Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

[0231] The present invention furthermore includes the following aspects and embodiments:

1. A recombinant modified vaccinia virus Ankara (MVA) comprising a nucleotide sequence encoding an antigenic

determinant of at least one respiratory syncytial virus (RSV) membrane glycoprotein for treating or preventing an RSV infection by intranasal administration, wherein an intramuscular administration is excluded.

2. The recombinant MVA of item 1 comprising solely intranasal administration.

3. The recombinant MVA of item 1 or 2, wherein the recombinant MVA further comprises a nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein.

4. A recombinant modified vaccinia virus Ankara (MVA) comprising at least one nucleotide sequence encoding an antigenic determinant of a respiratory syncytial virus (RSV) membrane glycoprotein and at least one nucleotide sequence encoding an RSV nucleocapsid antigenic determinant.

5. The recombinant MVA of any one of items 1 to 4, wherein the nucleotide sequence encoding an antigenic determinant of the RSV membrane glycoprotein encodes an RSV F and/or an RSV G antigenic determinant.

6. The recombinant MVA of any one of items 3 to 5, wherein the nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein encodes an antigenic determinant of the RSV N nucleocapsid and/or of the RSV M2 matrix protein.

7. The recombinant MVA of any of items 1 to 6 comprising one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein, preferably of the RSV F or of the RSV G membrane glycoprotein, and one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein, preferably of the RSV N or of the RSV M2 protein.

8. The recombinant MVA of any one of items 1 to 6 comprising two nucleotide sequences encoding an antigenic determinant of an RSV membrane glycoprotein, preferably of the RSV F and/or of the RSV G membrane glycoproteins, and one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein, preferably of the RSV N nucleocapsid or of the RSV M2 matrix protein.

9. The recombinant MVA of any one of items 1 to 6 comprising two nucleotide sequences encoding antigenic determinants of an RSV membrane glycoprotein, preferably of an RSV F and/or of an RSV G membrane glycoprotein and two nucleotide sequences encoding antigenic determinants of an RSV nucleocapsid protein, preferably of an RSV N and/or of the RSV M2 protein.

10. The recombinant MVA of any one of items 1 to 6 comprising three nucleotide sequences encoding an antigenic determinant of an RSV membrane glycoprotein, preferably of two RSV F membrane glycoproteins and/or of one RSV G membrane glycoprotein or of two RSV G membrane glycoproteins and/or of one RSV F membrane glycoprotein, and two nucleotide sequences encoding antigenic determinants of an RSV nucleocapsid protein, preferably of the RSV N nucleocapsid and/or of the RSV M2 matrix proteins.

11. The recombinant MVA of any one of items 1 to 6 comprising four nucleotide sequences encoding antigenic determinants of RSV membrane glycoproteins, preferably of two RSV F membrane glycoproteins and/or of two RSV G membrane glycoproteins, and one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein, preferably of the RSV N nucleocapsid or of the RSV M2 matrix protein.

12. The recombinant MVA of any one of items 1 to 6 comprising four nucleotide sequences encoding antigenic determinants of RSV membrane glycoproteins, preferably of two RSV F membrane glycoproteins and/or of two RSV G membrane glycoproteins, and two nucleotide sequences encoding antigenic determinants of RSV nucleocapsid proteins, preferably of the RSV N and/or of the RSV M2 proteins.

13. A method for determining whether a subject is at risk of recurrent RSV infection, comprising determining by means of RT-qPCR whether in a sample obtained from the subject RSV is present, whereby the presence of RSV indicates the presence of a recurrent RSV infection.

14. A method for determining whether a subject has acquired sterile immunity against RSV, comprising determining by means of RT-qPCR whether in a sample obtained from the subject RSV is present, whereby the presence of RSV indicates that the subject has not acquired sterile immunity against RSV.

15. The recombinant MVA of any one of items 1 to 12 for use in a method of immunizing and/or of inducing sterile immunity in a subject diagnosed by the method of claim 14 to not have acquired sterile immunity against RSV, said method comprising intranasal administration of said recombinant MVA to the subject.

5

10

15

20

25

30

35

40

45

50

55

EP 3 656 396 A1

SEQUENCE LISTING

<110> Bavarian Nordic A/S

5 <120> RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) RESPIRATORY
SYNCYTIAL VIRUS (RSV) VACCINE

<130> BNI14747PCT

10 <140> Not yet assigned
<141> 2013-03-15

<150> US 61/678,367
<151> 2012-08-01

15 <150> EP 12005594.2
<151> 2012-08-01

<160> 43

20 <170> PatentIn version 3.5

<210> 1
<211> 897
<212> DNA
<213> Human Respiratory Syncytial Virus (hRSV), strain A2

25 <400> 1
atgagcaaga acaaggacca gcggaccgcc aagaccctgg aacggacctg ggacaccctg 60
aaccatctgc tgttcacacg tagctgcctg tacaagctga acctgaagtc cgtggcccag 120
30 atcacccctga gcatcctggc catgatcatc agcaccagcc tgatcattgc cgccatcatc 180
tttatcgcca gcgccaacca caaagtgacc cccaccacag ccatcatcca ggacgccacc 240
tcccagatca agaacaccac cccacacctac ctgaccacaga accctcagct gggcatcagc 300
35 cccagcaacc ccagcgagat caccagccag atcacaacca tcctggcctc caccacccct 360
ggcgtgaagt ccaccctgca gagcaccacc gtgaaaacca agaataccac caccacacag 420
40 acccagccca gcaagcccac caccaagcag agacagaaca agccccctc caagcccaac 480
aacgacttcc acttcgaggt gttcaacttc gtgccctgca gcatctgcag caacaacccc 540
acctgttggg ccatctgcaa gcggatcccc aacaagaagc ccggcaagaa aaccacaacc 600
45 aagcctacca agaagcctac cctgaaaacc accaagaagg accccaagcc ccagaccacc 660
aagagcaaag aggtgccaac caccaagccc accgaggaac ccaccatcaa caccaccaag 720
accaacatca tcaccaccct gctgacctcc aacaccaccg gcaaccccga gctgacaagc 780
50 cagatggaaa ccttccacag caccagcagc gagggcaacc ctagccctag ccaggtgtcc 840
accacctccg agtaccaccg ccagcctagc agccccccca acaccccag acagtga 897

55 <210> 2
<211> 298
<212> PRT

EP 3 656 396 A1

<213> hRSV strain A2

<400> 2

5	Met	Ser	Lys	Asn	Lys	Asp	Gln	Arg	Thr	Ala	Lys	Thr	Leu	Glu	Arg	Thr	1	5	10	15
10	Trp	Asp	Thr	Leu	Asn	His	Leu	Leu	Phe	Ile	Ser	Ser	Cys	Leu	Tyr	Lys	20	25	30	
15	Leu	Asn	Leu	Lys	Ser	Val	Ala	Gln	Ile	Thr	Leu	Ser	Ile	Leu	Ala	Met	35	40	45	
20	Ile	Ile	Ser	Thr	Ser	Leu	Ile	Ile	Ala	Ala	Ile	Ile	Phe	Ile	Ala	Ser	50	55	60	
25	Ala	Asn	His	Lys	Val	Thr	Pro	Thr	Thr	Ala	Ile	Ile	Gln	Asp	Ala	Thr	65	70	75	80
30	Ser	Gln	Ile	Lys	Asn	Thr	Thr	Pro	Thr	Tyr	Leu	Thr	Gln	Asn	Pro	Gln	85	90	95	
35	Leu	Gly	Ile	Ser	Pro	Ser	Asn	Pro	Ser	Glu	Ile	Thr	Ser	Gln	Ile	Thr	100	105	110	
40	Thr	Ile	Leu	Ala	Ser	Thr	Thr	Pro	Gly	Val	Lys	Ser	Thr	Leu	Gln	Ser	115	120	125	
45	Thr	Thr	Val	Lys	Thr	Lys	Asn	Thr	Thr	Thr	Thr	Gln	Thr	Gln	Pro	Ser	130	135	140	
50	Lys	Pro	Thr	Thr	Lys	Gln	Arg	Gln	Asn	Lys	Pro	Pro	Ser	Lys	Pro	Asn	145	150	155	160
55	Asn	Asp	Phe	His	Phe	Glu	Val	Phe	Asn	Phe	Val	Pro	Cys	Ser	Ile	Cys	165	170	175	
	Ser	Asn	Asn	Pro	Thr	Cys	Trp	Ala	Ile	Cys	Lys	Arg	Ile	Pro	Asn	Lys	180	185	190	
	Lys	Pro	Gly	Lys	Lys	Thr	Thr	Thr	Lys	Pro	Thr	Lys	Lys	Pro	Thr	Leu	195	200	205	
	Lys	Thr	Thr	Lys	Lys	Asp	Pro	Lys	Pro	Gln	Thr	Thr	Lys	Ser	Lys	Glu	210	215	220	
	Val	Pro	Thr	Thr	Lys	Pro	Thr	Glu	Glu	Pro	Thr	Ile	Asn	Thr	Thr	Lys	225	230	235	240

EP 3 656 396 A1

Thr Asn Ile Ile Thr Thr Leu Leu Thr Ser Asn Thr Thr Gly Asn Pro
245 250 255

5 Glu Leu Thr Ser Gln Met Glu Thr Phe His Ser Thr Ser Ser Glu Gly
260 265 270

10 Asn Pro Ser Pro Ser Gln Val Ser Thr Thr Ser Glu Tyr Pro Ser Gln
275 280 285

Pro Ser Ser Pro Pro Asn Thr Pro Arg Gln
290 295

15
<210> 3
<211> 1725
<212> DNA
<213> hRSV strain A2

20
<400> 3
atggaactgc tgatcctgaa ggccaacgcc atcaccacaa tcctgaccgc cgtgaccttc 60
tgcttcgcca gcggccagaa catcaccgag gaattctacc agagcacctg tagcgccgtg 120
25 agcaagggct acctgagcgc cctgagaacc ggctggtaca cctccgtgat caccatcgag 180
ctgtccaaca tcaaagaaaa caagtgcac gccaccgacg ccaaagtga gctgatcaag 240
caggaactgg acaagtacaa gaacgccgtg accgaactcc agctcctcat gcagtccacc 300
30 cctgccacca acaaccgggc cagaagagaa ctgccccggt ttatgaacta cacactgaac 360
aacgccaaaa agaccaatgt cactctgagc aagaagcggg agcggcggtt cctgggcttt 420
ctgctgggcg tgggcagcgc cattgccagc ggctggtggc tgtccaaggt gctgcacctg 480
35 gaaggcgaag tgaacaagat caagagtgcc ctgctctcca caaacaaggc cgtggtgtcc 540
ctgagcaacg gcgtgagcgt gctgaccagc aaggtcctgg atctgaagaa ctacatcgac 600
40 aagcagctcc tgcccatcgt gaacaagcag agctgcagca tcagcaacat cgagactgtc 660
atcgagttcc agcagaagaa caaccggctg ctggaaatca cccgggagtt cagcgtgaac 720
gcaggcgtga ccacccccgt gtccacctac atgctgacca acagcgagct gctgtccctg 780
45 atcaatgaca tgcccatcac caacgatcag aagaaactca tgagcaacaa cgtgcagatc 840
gtgcggcagc agagttacag tatcatgagc atcatcaaag aagaggtgct ggcctacgtg 900
gtgcagctgc ccctgtacgg cgtgatcgac accccctgct ggaagctgca caccagcccc 960
50 ctgtgcacca ccaacacaaa agagggcagt aacatctgcc tgaccgggac cgacagaggc 1020
tggtactgcg acaacgccgg cagcgtgtca ttctttccac aggcgagac atgcaaggtg 1080
cagagcaacc ggggtgttctg cgacaccatg aacagcctga ccctgccctc cgaagtcaac 1140
55 ctgtgcaacg tggacatctt caaccccaag tacgactgca agatcatgac ttccaagacc 1200

EP 3 656 396 A1

gacgtgtcca gcagcgtgat tacctccctg ggcgccatcg tgtcctgcta cggcaagacc 1260
aagtgcaccg ccagcaacaa gaatagagga atcatcaaga ccttcagcaa cggctgcgac 1320
5 tacgtgtcca ataagggcat ggacaccgtg tccgtgggca acacactgta ctacgtgaat 1380
aagcaggaag gcaagagcct gtacgtgaag ggcgagccca tcatcaactt ctacgacccc 1440
ctggtgttcc ccagcgacga gttcgacgcc agtatcagcc aggtcaacga gaagatcaac 1500
10 cagagcctgg ccttcatcag aaagagcgac gaactgctgc acaatgtgaa cgctggcaag 1560
agtaccacaa acatcatgat caccaccatc atcatcgtga tcattgtgat cctgctgagt 1620
ctgatcgccg tgggcctgct gctgtactgc aaggcccga gcacccctgt gaccctgtcc 1680
15 aaggatcagc tgtccggcat caacaatatc gccttctcca actga 1725

<210> 4
<211> 574
20 <212> PRT
<213> hRSV strain A2
<400> 4

Met Glu Leu Leu Ile Leu Lys Ala Asn Ala Ile Thr Thr Ile Leu Thr
25 1 5 10 15

Ala Val Thr Phe Cys Phe Ala Ser Gly Gln Asn Ile Thr Glu Glu Phe
30 20 25 30

Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu
35 35 40 45

Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile
40 50 55 60

Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Lys Val Lys Leu Ile Lys
45 65 70 75 80

Gln Glu Leu Asp Lys Tyr Lys Asn Ala Val Thr Glu Leu Gln Leu Leu
50 85 90 95

Met Gln Ser Thr Pro Ala Thr Asn Asn Arg Ala Arg Arg Glu Leu Pro
55 100 105 110

Arg Phe Met Asn Tyr Thr Leu Asn Asn Ala Lys Lys Thr Asn Val Thr
60 115 120 125

Leu Ser Lys Lys Arg Lys Arg Arg Phe Leu Gly Phe Leu Leu Gly Val
65 130 135 140

Gly Ser Ala Ile Ala Ser Gly Val Ala Val Ser Lys Val Leu His Leu

EP 3 656 396 A1

	145				150				155				160			
5	Glu	Gly	Glu	Val	Asn 165	Lys	Ile	Lys	Ser	Ala 170	Leu	Leu	Ser	Thr	Asn 175	Lys
10	Ala	Val	Val	Ser 180	Leu	Ser	Asn	Gly	Val 185	Ser	Val	Leu	Thr	Ser 190	Lys	Val
15	Leu	Asp	Leu	Lys 195	Asn	Tyr	Ile	Asp 200	Lys	Gln	Leu	Leu	Pro 205	Ile	Val	Asn
20	Lys	Gln 210	Ser	Cys	Ser	Ile	Ser 215	Asn	Ile	Glu	Thr	Val 220	Ile	Glu	Phe	Gln
25	Gln 225	Lys	Asn	Asn	Arg	Leu 230	Leu	Glu	Ile	Thr	Arg 235	Glu	Phe	Ser	Val	Asn 240
30	Ala	Gly	Val	Thr	Thr 245	Pro	Val	Ser	Thr	Tyr 250	Met	Leu	Thr	Asn	Ser 255	Glu
35	Leu	Leu	Ser	Leu 260	Ile	Asn	Asp	Met	Pro 265	Ile	Thr	Asn	Asp	Gln 270	Lys	Lys
40	Leu	Met	Ser 275	Asn	Asn	Val	Gln	Ile 280	Val	Arg	Gln	Gln	Ser 285	Tyr	Ser	Ile
45	Met	Ser 290	Ile	Ile	Lys	Glu	Glu 295	Val	Leu	Ala	Tyr	Val 300	Val	Gln	Leu	Pro
50	Leu	Tyr	Gly	Val	Ile	Asp 310	Thr	Pro	Cys	Trp	Lys 315	Leu	His	Thr	Ser	Pro 320
55	Leu	Cys	Thr	Thr	Asn 325	Thr	Lys	Glu	Gly	Ser 330	Asn	Ile	Cys	Leu	Thr 335	Arg
	Thr	Asp	Arg	Gly 340	Trp	Tyr	Cys	Asp 345	Asn	Ala	Gly	Ser	Val	Ser 350	Phe	Phe
	Pro	Gln	Ala 355	Glu	Thr	Cys	Lys	Val 360	Gln	Ser	Asn	Arg	Val 365	Phe	Cys	Asp
	Thr	Met 370	Asn	Ser	Leu	Thr	Leu 375	Pro	Ser	Glu	Val	Asn 380	Leu	Cys	Asn	Val
	Asp 385	Ile	Phe	Asn	Pro	Lys 390	Tyr	Asp	Cys	Lys	Ile 395	Met	Thr	Ser	Lys	Thr 400

EP 3 656 396 A1

Asp Val Ser Ser Ser Val Ile Thr Ser Leu Gly Ala Ile Val Ser Cys
 405 410 415
 5 Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly Ile Ile
 420 425 430
 10 Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly Met Asp
 435 440 445
 Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys Gln Glu Gly
 450 455 460
 15 Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn Phe Tyr Asp Pro
 465 470 475 480
 20 Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser Gln Val Asn
 485 490 495
 Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg Lys Ser Asp Glu Leu
 500 505 510
 25 Leu His Asn Val Asn Ala Gly Lys Ser Thr Thr Asn Ile Met Ile Thr
 515 520 525
 30 Thr Ile Ile Ile Val Ile Ile Val Ile Leu Leu Ser Leu Ile Ala Val
 530 535 540
 Gly Leu Leu Leu Tyr Cys Lys Ala Arg Ser Thr Pro Val Thr Leu Ser
 545 550 555 560
 35 Lys Asp Gln Leu Ser Gly Ile Asn Asn Ile Ala Phe Ser Asn
 565 570
 40 <210> 5
 <211> 1725
 <212> DNA
 <213> hRSV strain A-Long
 45 <400> 5
 atggaactgc ccatacctgaa ggccaacgcc atcaccacaa tcctggccgc cgtgaccttc 60
 tgcttcgcca gcagccagaa catcacccag gaattctacc agagcacctg tagcgccgtg 120
 agcaagggtt acctgagcgc cctgagaacc ggctggtaca cctccgtgat caccatcgag 180
 50 ctgtccaaca tcaaagaaaa caagtgaac ggcaccgacg ccaaagtga gctgatcaag 240
 caggaactgg acaagtacaa gaacgccgtg accgaactcc agctcctcat gcagtccacc 300
 cctgccgcca acaaccgggc cagaagagaa ctgccccggt ttatgaacta cactgaac 360
 55 aacaccaaaa agaccaatgt gaccctgagc aagaagcggg agcggcggtt cctgggcttt 420

EP 3 656 396 A1

ctgctgggcg tgggcagcgc cattgccagc ggcattgccg tgtccaaggt gctgcacctg 480
 gaaggcgaag tgaacaagat caagagcgcc ctgctgtcca ccaacaaggc cgtggtgtcc 540
 5 ctgagcaacg gcgtgagcgt gctgaccagc aagggtgctgg atctgaagaa ctacatcgac 600
 aagcagctcc tgcccatcgt gaacaagcag agctgccgga tcagcaacat cgagacagtg 660
 atcgagttcc agcagaagaa caaccggctg ctggaaatca cccgggagtt cagcgtgaac 720
 10 gtgggcgtga ccacccccgt gtccacctac atgctgacca acagcgagct gctgtccctg 780
 atcaatgaca tgcccatcac caacgaccag aagaaactga tgagcaacaa cgtgcagatc 840
 gtgcggcagc agagctacag catcatgagc atcatcaaag aagaggtgct ggcctacgtg 900
 15 gtgcagctgc ccctgtacgg cgtgatcgac accccctgct ggaagctgca caccagcccc 960
 ctgtgcacca ccaacacaaa agagggcagt aacatctgcc tgacccggac cgacagaggc 1020
 20 tgggtactgcg acaacgccgg cagcgtgtca ttctttccac aggccgagac atgcaagggtg 1080
 cagagcaacc ggggtgttctg cgacaccatg aacagcctga ccctgccctc cgaagtcaac 1140
 ctgtgcaacg tggacatctt caaccccaag tacgactgca agatcatgac ttccaagacc 1200
 25 gacgtgtcca gcagcgtgat tacctccctg ggcgccatcg tgtcctgcta cggcaagacc 1260
 aagtgcaccg ccagcaacaa gaatagagga atcatcaaga ccttcagcaa cggctgcgac 1320
 tacgtgtcca ataagggcgt ggacaccgtg tccgtgggca acacactgta ctacgtgaat 1380
 30 aagcaggaag gcaagagcct gtacgtgaag ggcgagccca tcatcaactt ctacgacccc 1440
 ctggtgttcc ccagcgacga gttcgacgcc agcatcagcc aggtcaacga gaagatcaac 1500
 cagagcctgg ccttcacag aaagagcgac gaactgctgc acaatgtgaa cgctggcaag 1560
 35 agtaccacaa acatcatgat caccaccatc atcatcgtga tcattgtgat cctgctgagt 1620
 ctgatcgccg tgggcctgct gctgtactgc aaggcccgca gcaccctgt gaccctgtcc 1680
 40 aaggatcagc tgtccggcat caacaatatc gccttctcca actga 1725

<210> 6

<211> 574

<212> PRT

<213> hRSV strain A-Long

<400> 6

Met Glu Leu Pro Ile Leu Lys Ala Asn Ala Ile Thr Thr Ile Leu Ala
 1 5 10 15

Ala Val Thr Phe Cys Phe Ala Ser Ser Gln Asn Ile Thr Glu Glu Phe
 20 25 30

Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu
 35 40 45

EP 3 656 396 A1

	Arg	Thr	Gly	Trp	Tyr	Thr	Ser	Val	Ile	Thr	Ile	Glu	Leu	Ser	Asn	Ile	
	50						55					60					
5	Lys	Glu	Asn	Lys	Cys	Asn	Gly	Thr	Asp	Ala	Lys	Val	Lys	Leu	Ile	Lys	
	65					70					75					80	
	Gln	Glu	Leu	Asp	Lys	Tyr	Lys	Asn	Ala	Val	Thr	Glu	Leu	Gln	Leu	Leu	
10					85					90					95		
	Met	Gln	Ser	Thr	Pro	Ala	Ala	Asn	Asn	Arg	Ala	Arg	Arg	Glu	Leu	Pro	
				100					105					110			
15	Arg	Phe	Met	Asn	Tyr	Thr	Leu	Asn	Asn	Thr	Lys	Lys	Thr	Asn	Val	Thr	
			115					120					125				
	Leu	Ser	Lys	Lys	Arg	Lys	Arg	Arg	Phe	Leu	Gly	Phe	Leu	Leu	Gly	Val	
20			130				135					140					
	Gly	Ser	Ala	Ile	Ala	Ser	Gly	Ile	Ala	Val	Ser	Lys	Val	Leu	His	Leu	
25						150					155					160	
	Glu	Gly	Glu	Val	Asn	Lys	Ile	Lys	Ser	Ala	Leu	Leu	Ser	Thr	Asn	Lys	
					165					170					175		
30	Ala	Val	Val	Ser	Leu	Ser	Asn	Gly	Val	Ser	Val	Leu	Thr	Ser	Lys	Val	
				180					185					190			
	Leu	Asp	Leu	Lys	Asn	Tyr	Ile	Asp	Lys	Gln	Leu	Leu	Pro	Ile	Val	Asn	
35			195					200					205				
	Lys	Gln	Ser	Cys	Arg	Ile	Ser	Asn	Ile	Glu	Thr	Val	Ile	Glu	Phe	Gln	
		210					215					220					
40	Gln	Lys	Asn	Asn	Arg	Leu	Leu	Glu	Ile	Thr	Arg	Glu	Phe	Ser	Val	Asn	
						230					235					240	
	Val	Gly	Val	Thr	Thr	Pro	Val	Ser	Thr	Tyr	Met	Leu	Thr	Asn	Ser	Glu	
					245					250					255		
	Leu	Leu	Ser	Leu	Ile	Asn	Asp	Met	Pro	Ile	Thr	Asn	Asp	Gln	Lys	Lys	
50				260					265					270			
	Leu	Met	Ser	Asn	Asn	Val	Gln	Ile	Val	Arg	Gln	Gln	Ser	Tyr	Ser	Ile	
			275					280					285				
55	Met	Ser	Ile	Ile	Lys	Glu	Glu	Val	Leu	Ala	Tyr	Val	Val	Gln	Leu	Pro	

EP 3 656 396 A1

	290		295		300											
5	Leu	Tyr	Gly	Val	Ile	Asp	Thr	Pro	Cys	Trp	Lys	Leu	His	Thr	Ser	Pro
	305					310					315					320
	Leu	Cys	Thr	Thr	Asn	Thr	Lys	Glu	Gly	Ser	Asn	Ile	Cys	Leu	Thr	Arg
10					325					330					335	
	Thr	Asp	Arg	Gly	Trp	Tyr	Cys	Asp	Asn	Ala	Gly	Ser	Val	Ser	Phe	Phe
				340					345					350		
15	Pro	Gln	Ala	Glu	Thr	Cys	Lys	Val	Gln	Ser	Asn	Arg	Val	Phe	Cys	Asp
			355					360					365			
	Thr	Met	Asn	Ser	Leu	Thr	Leu	Pro	Ser	Glu	Val	Asn	Leu	Cys	Asn	Val
20		370					375					380				
	Asp	Ile	Phe	Asn	Pro	Lys	Tyr	Asp	Cys	Lys	Ile	Met	Thr	Ser	Lys	Thr
	385					390					395					400
25	Asp	Val	Ser	Ser	Ser	Val	Ile	Thr	Ser	Leu	Gly	Ala	Ile	Val	Ser	Cys
					405					410					415	
	Tyr	Gly	Lys	Thr	Lys	Cys	Thr	Ala	Ser	Asn	Lys	Asn	Arg	Gly	Ile	Ile
30				420				425						430		
	Lys	Thr	Phe	Ser	Asn	Gly	Cys	Asp	Tyr	Val	Ser	Asn	Lys	Gly	Val	Asp
35			435					440					445			
	Thr	Val	Ser	Val	Gly	Asn	Thr	Leu	Tyr	Tyr	Val	Asn	Lys	Gln	Glu	Gly
	450					455						460				
40	Lys	Ser	Leu	Tyr	Val	Lys	Gly	Glu	Pro	Ile	Ile	Asn	Phe	Tyr	Asp	Pro
	465					470					475					480
	Leu	Val	Phe	Pro	Ser	Asp	Glu	Phe	Asp	Ala	Ser	Ile	Ser	Gln	Val	Asn
45					485					490					495	
	Glu	Lys	Ile	Asn	Gln	Ser	Leu	Ala	Phe	Ile	Arg	Lys	Ser	Asp	Glu	Leu
50				500					505					510		
	Leu	His	Asn	Val	Asn	Ala	Gly	Lys	Ser	Thr	Thr	Asn	Ile	Met	Ile	Thr
			515					520					525			
55	Thr	Ile	Ile	Ile	Val	Ile	Ile	Val	Ile	Leu	Leu	Ser	Leu	Ile	Ala	Val
	530						535					540				

EP 3 656 396 A1

Gly Leu Leu Leu Tyr Cys Lys Ala Arg Ser Thr Pro Val Thr Leu Ser
545 550 555 560

5 Lys Asp Gln Leu Ser Gly Ile Asn Asn Ile Ala Phe Ser Asn
565 570

<210> 7

<211> 738

<212> DNA

<213> hRSV strain B

<400> 7

atgattatatt ccactagtct cattatcgct gctattatct tcatcattag tgccaatcat 60

aaagtcacccc tcacaaccgt caccgtgcag accattaaaa accataccga gaagaatatt 120

tcaacatatc tgacacaggt cccccccgaa agagtgaact cttccaaaca gccacaacc 180

acctccccca ttcataccaa tagtgccaca atttctccca acacaaagtc tgaaacacac 240

cacactactg ctgagacaaa gggccgaatc accacctcta ctgagaccaa taagccatca 300

acaaaatccc gctccaaaaa cccacctaaa aaacctaaag atgactatca tttcgaagtc 360

tttaattttcg tcccatgttc catttgcgga aacaaccagc tctgtaaatc tatctgtaaa 420

accatcccct ctaacaagcc aaaaaagaaa cctactatta aaccaactaa taagcccacc 480

actaagacta ctaacaaacg cgatccaaaa acacccgcca aaatgcctaa aaaagagatc 540

attacaaacc cagccaagaa accaactctc aaaactaccg aacgggacac ctccatttct 600

cagtctaccg tgctcgatac catcactccc aaatacacta tccagcagca gtcactccac 660

tcaacaacct ccgagaacac cccctcctca acccagattc ctactgcttc cgaaccatcc 720

accctcaacc ccaattga 738

<210> 8

<211> 245

<212> PRT

<213> hRSV strain B

<400> 8

Met Ile Ile Ser Thr Ser Leu Ile Ile Ala Ala Ile Ile Phe Ile Ile
1 5 10 15

Ser Ala Asn His Lys Val Thr Leu Thr Thr Val Thr Val Gln Thr Ile
20 25 30

Lys Asn His Thr Glu Lys Asn Ile Ser Thr Tyr Leu Thr Gln Val Pro
35 40 45

Pro Glu Arg Val Asn Ser Ser Lys Gln Pro Thr Thr Thr Ser Pro Ile
50 55 60

EP 3 656 396 A1

	His	Thr	Asn	Ser	Ala	Thr	Ile	Ser	Pro	Asn	Thr	Lys	Ser	Glu	Thr	His	
	65					70					75					80	
5	His	Thr	Thr	Ala	Gln	Thr	Lys	Gly	Arg	Ile	Thr	Thr	Ser	Thr	Gln	Thr	
					85					90					95		
	Asn	Lys	Pro	Ser	Thr	Lys	Ser	Arg	Ser	Lys	Asn	Pro	Pro	Lys	Lys	Pro	
10				100					105					110			
	Lys	Asp	Asp	Tyr	His	Phe	Glu	Val	Phe	Asn	Phe	Val	Pro	Cys	Ser	Ile	
		115						120					125				
15	Cys	Gly	Asn	Asn	Gln	Leu	Cys	Lys	Ser	Ile	Cys	Lys	Thr	Ile	Pro	Ser	
	130						135					140					
	Asn	Lys	Pro	Lys	Lys	Lys	Pro	Thr	Ile	Lys	Pro	Thr	Asn	Lys	Pro	Thr	
20	145					150					155					160	
	Thr	Lys	Thr	Thr	Asn	Lys	Arg	Asp	Pro	Lys	Thr	Pro	Ala	Lys	Met	Pro	
25					165					170					175		
	Lys	Lys	Glu	Ile	Ile	Thr	Asn	Pro	Ala	Lys	Lys	Pro	Thr	Leu	Lys	Thr	
				180					185					190			
30	Thr	Glu	Arg	Asp	Thr	Ser	Ile	Ser	Gln	Ser	Thr	Val	Leu	Asp	Thr	Ile	
			195					200					205				
	Thr	Pro	Lys	Tyr	Thr	Ile	Gln	Gln	Gln	Ser	Leu	His	Ser	Thr	Thr	Ser	
35		210					215					220					
	Glu	Asn	Thr	Pro	Ser	Ser	Thr	Gln	Ile	Pro	Thr	Ala	Ser	Glu	Pro	Ser	
	225					230					235					240	
40																	
	Thr	Leu	Asn	Pro	Asn												
					245												
45	<210>	9															
	<211>	1176															
	<212>	DNA															
	<213>	hRSV strain A2															
50	<400>	9															
	atggccctga	gcaaagtgaa	gctgaacgac	accctgaaca	aggaccagct	gctgtccagc											60
	tccaagtaca	ccatccagag	aagcaccggc	gacagcatcg	acacccccaa	ctacgacgtg											120
	cagaagcaca	tcaataagct	gtgcggcatg	ctgctgatca	ccgaggacgc	caaccacaag											180
55	ttcaccggcc	tgatcgggat	gctgtacgcc	atgagccggc	tgggccggga	ggacaccatc											240

EP 3 656 396 A1

aagatcctgc gggacgccgg ctaccacgtg aaggccaacg gcgtggacgt gaccacccac 300
 cggcaggaca tcaacggcaa agaaatgaag ttcgaggtgc tgaccctggc cagcctgacc 360
 5 accgagatcc agatcaacat cgagatcgag agccggaagt cctacaagaa aatgctgaaa 420
 gaaatgggcg aggtggcccc cgagtacaga cagcagacgc ccgactgcgg catgatcatc 480
 ctgtgtatcg ccgccctggt catcacaaag ctggccgctg gcgacagatc tggcctgacc 540
 10 gccgtgatca gacggggcaa caacgtgctg aagaacgaga tgaagcggta caagggcctg 600
 ctgcccgaagg atatcgccaa cagcttctac gaggtgttcg aaaagcacc cacttcatc 660
 gacgtgttcg tgcacttcgg cattgcccag agcagcacca gaggcggcag cagagtggag 720
 15 ggcattcttcg ccggcctggt catgaacgcc tacggcgctg gccaggtcat gctgagatgg 780
 ggcgtgctgg ccaagagcgt gaagaacatc atgctgggcc acgccagcgt gcaggccgag 840
 atggaacagg tgggtggaggt gtacgagtac gcccagaagc tgggcggcga ggccggcttc 900
 20 taccacatcc tgaacaacc caaggcctcc ctgctgtccc tgaccagtt cccctacttt 960
 agcagcgtgg tgctcggaaa tgcagccgga ctgggcatca tgggcgagta ccgcggcacc 1020
 25 cccagaaaacc aggacctgta cgacgccgcc aaggcctacg ccgagcagct gaaagaaaac 1080
 ggcgtgatca actacagcgt gctggacctg acagccgagg aactggaagc cattaagcac 1140
 cagctgaacc ctaaggacaa cgacgtggag ctgtga 1176

30
 <210> 10
 <211> 391
 <212> PRT
 <213> hRSV strain A2

35
 <400> 10

Met Ala Leu Ser Lys Val Lys Leu Asn Asp Thr Leu Asn Lys Asp Gln
 1 5 10 15

40
 Leu Leu Ser Ser Ser Lys Tyr Thr Ile Gln Arg Ser Thr Gly Asp Ser
 20 25 30

45
 Ile Asp Thr Pro Asn Tyr Asp Val Gln Lys His Ile Asn Lys Leu Cys
 35 40 45

50
 Gly Met Leu Leu Ile Thr Glu Asp Ala Asn His Lys Phe Thr Gly Leu
 50 55 60

Ile Gly Met Leu Tyr Ala Met Ser Arg Leu Gly Arg Glu Asp Thr Ile
 65 70 75 80

55
 Lys Ile Leu Arg Asp Ala Gly Tyr His Val Lys Ala Asn Gly Val Asp
 85 90 95

EP 3 656 396 A1

	Val	Thr	Thr	His	Arg	Gln	Asp	Ile	Asn	Gly	Lys	Glu	Met	Lys	Phe	Glu	
				100					105					110			
5	Val	Leu	Thr	Leu	Ala	Ser	Leu	Thr	Thr	Glu	Ile	Gln	Ile	Asn	Ile	Glu	
				115				120					125				
	Ile	Glu	Ser	Arg	Lys	Ser	Tyr	Lys	Lys	Met	Leu	Lys	Glu	Met	Gly	Glu	
10		130					135					140					
	Val	Ala	Pro	Glu	Tyr	Arg	His	Asp	Ser	Pro	Asp	Cys	Gly	Met	Ile	Ile	
	145					150					155					160	
15																	
	Leu	Cys	Ile	Ala	Ala	Leu	Val	Ile	Thr	Lys	Leu	Ala	Ala	Gly	Asp	Arg	
					165					170					175		
	Ser	Gly	Leu	Thr	Ala	Val	Ile	Arg	Arg	Ala	Asn	Asn	Val	Leu	Lys	Asn	
20					180				185					190			
	Glu	Met	Lys	Arg	Tyr	Lys	Gly	Leu	Leu	Pro	Lys	Asp	Ile	Ala	Asn	Ser	
25			195					200					205				
	Phe	Tyr	Glu	Val	Phe	Glu	Lys	His	Pro	His	Phe	Ile	Asp	Val	Phe	Val	
		210					215					220					
30																	
	His	Phe	Gly	Ile	Ala	Gln	Ser	Ser	Thr	Arg	Gly	Gly	Ser	Arg	Val	Glu	
	225					230					235					240	
35	Gly	Ile	Phe	Ala	Gly	Leu	Phe	Met	Asn	Ala	Tyr	Gly	Ala	Gly	Gln	Val	
					245					250					255		
	Met	Leu	Arg	Trp	Gly	Val	Leu	Ala	Lys	Ser	Val	Lys	Asn	Ile	Met	Leu	
				260					265					270			
40																	
	Gly	His	Ala	Ser	Val	Gln	Ala	Glu	Met	Glu	Gln	Val	Val	Glu	Val	Tyr	
			275					280					285				
45	Glu	Tyr	Ala	Gln	Lys	Leu	Gly	Gly	Glu	Ala	Gly	Phe	Tyr	His	Ile	Leu	
		290					295					300					
	Asn	Asn	Pro	Lys	Ala	Ser	Leu	Leu	Ser	Leu	Thr	Gln	Phe	Pro	His	Phe	
50	305					310					315					320	
	Ser	Ser	Val	Val	Leu	Gly	Asn	Ala	Ala	Gly	Leu	Gly	Ile	Met	Gly	Glu	
					325					330					335		
55	Tyr	Arg	Gly	Thr	Pro	Arg	Asn	Gln	Asp	Leu	Tyr	Asp	Ala	Ala	Lys	Ala	
				340					345					350			

EP 3 656 396 A1

Tyr Ala Glu Gln Leu Lys Glu Asn Gly Val Ile Asn Tyr Ser Val Leu
355 360 365

5 Asp Leu Thr Ala Glu Glu Leu Glu Ala Ile Lys His Gln Leu Asn Pro
370 375 380

10 Lys Asp Asn Asp Val Glu Leu
385 390

<210> 11

<211> 54

<212> DNA

15 <213> Foot and Mouth Disease Virus (FMDV)

<400> 11

ctgaacttcg atctgctgaa actggccggc gacgtggaaa gcaaccctgg cccc

54

20 <210> 12

<211> 18

<212> PRT

<213> FMDV

25 <400> 12

Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro
1 5 10 15

30 Gly Pro

<210> 13

35 <211> 585

<212> DNA

<213> hRSV strain A2

<400> 13

40 atgagcagac ggaacccctg caagtctgag atccggggcc actgcctgaa cggcaagcgg 60

tgccaacttca gccacaacta ctctgagtggt cccctcatg ctctgctggt ccggcagaac 120

tttatgctga accggatcct gaagtccatg gacaagagca tcgataccct gagcgagatc 180

45 agcggagccg ccgaactgga tagaaccgag gaatacgccc tgggcgtggt cggagtgtgt 240

gaaagctaca tcggcagcat caacaacatc accaagcaga gcgcctgcgt ggccatgagc 300

aagctgtctga ccgagctgaa cagcgacgat atcaagaagc tgccgcgacaa cgaagaactg 360

50 aactccccca agatccgggt gtacaacaca gtgatcagct acattgagag caaccggaag 420

aacaacaagc agaccatcca tctgctgaag cggctgcccg ccgacgtgct gaaaaagacc 480

55 atcaagaaca ccctggacat ccacaagtcc atcaccatca ataaccctaa agaaagcacc 540

gtgtccgaca ccaacgacca cgccaagaac aacgacacca cctga 585

EP 3 656 396 A1

<210> 14
 <211> 194
 <212> PRT
 <213> hRSV strain A2

<400> 14

Met Ser Arg Arg Asn Pro Cys Lys Phe Glu Ile Arg Gly His Cys Leu
 1 5 10 15

Asn Gly Lys Arg Cys His Phe Ser His Asn Tyr Phe Glu Trp Pro Pro
 20 25 30

His Ala Leu Leu Val Arg Gln Asn Phe Met Leu Asn Arg Ile Leu Lys
 35 40 45

Ser Met Asp Lys Ser Ile Asp Thr Leu Ser Glu Ile Ser Gly Ala Ala
 50 55 60

Glu Leu Asp Arg Thr Glu Glu Tyr Ala Leu Gly Val Val Gly Val Leu
 65 70 75 80

Glu Ser Tyr Ile Gly Ser Ile Asn Asn Ile Thr Lys Gln Ser Ala Cys
 85 90 95

Val Ala Met Ser Lys Leu Leu Thr Glu Leu Asn Ser Asp Asp Ile Lys
 100 105 110

Lys Leu Arg Asp Asn Glu Glu Leu Asn Ser Pro Lys Ile Arg Val Tyr
 115 120 125

Asn Thr Val Ile Ser Tyr Ile Glu Ser Asn Arg Lys Asn Asn Lys Gln
 130 135 140

Thr Ile His Leu Leu Lys Arg Leu Pro Ala Asp Val Leu Lys Lys Thr
 145 150 155 160

Ile Lys Asn Thr Leu Asp Ile His Lys Ser Ile Thr Ile Asn Asn Pro
 165 170 175

Lys Glu Ser Thr Val Ser Asp Thr Asn Asp His Ala Lys Asn Asn Asp
 180 185 190

Thr Thr

<210> 15
 <211> 1575

EP 3 656 396 A1

<212> DNA
<213> hRSV strain A2

<400> 15

5	atggaactcc ctattctcaa agccaatgct attactacca ttctcgccgc tgtcaccttt	60
	tgttttcgcct cttcccagaa tattaccgaa gagttttacc agtctacctg ttccgcccgc	120
	agtaaaggat acctgtccgc cctccgcact ggttggtata ctagtgtcat tacaatcgaa	180
10	ctctcaaata taaaagaaaa taagtgtaat gggaccgatg ctaaagtcaa actcattaaa	240
	caagaactcg ataagtataa gaatgctgtc actgagctgc aactgctgat gcagtctaca	300
	cccgcagcca ataatcgagc cagacgcgag ctgcctcgct ttatgaatta tactctcaat	360
15	aataactaaaa agacaaacgt caccctcagt aaaaagcgaa aaagacggtt tctcggattc	420
	ctcctcggcg tgggctctgc tatcgctagc ggaattgctg tctccaaagt cctccatctg	480
	gaaggggagg tcaacaaaat taagtctgct ctcctctcta caaacaagc cgtcgtgtct	540
20	ctctccaatg gcgtgtctgt gtcacctct aaagtgtcg acctcaaaaa ttacattgat	600
	aaacagctgc tccctattgt gaacaaacag tcttgccgca ttagcaatat cgaaaccgtc	660
	attgaatttc aacaaaagaa taataggctc ctcgaaatta cccgcgaatt ctccgtgaat	720
25	gtgggagtca caacacctgt ctctacctat atgctcacta actccgaact cctctccctc	780
	attaacgata tgcccattac aaatgatcag aaaaaactca tgtctaataa cgtccagatt	840
	gtccgccagc agtcttatag cattatgtcc attatcaaag aggaagtcct cgcttacgtc	900
	gtccagctcc ctctgtatgg ggtcatcgat acaccttggt ggaaactcca tacctcccca	960
	ctgtgtacaa ccaataccaa agaagggtcc aatatttgcc tgacaagaac cgaccgcggg	1020
35	tggtagctgtg ataatgccgg ctctgtctcc tttttccccc aggccgaaac ctgtaaagtc	1080
	cagtctaata gagtcttttg cgatactatg aattccctca ccctcccttc agaagtgaat	1140
	ctctgtaacg tcgatatttt caaccctaaa tatgattgca aaattatgac cagtaaaaact	1200
40	gacgtgtcct cttccgtcat cacctccctc ggtgctattg tgtcttggtta cggaaaaact	1260
	aaatgcacgg ctagtaataa gaaccgaggc attattaaga ccttttccaa cggctgtgat	1320
	tatgtgtcta acaaaggcgt ggatactgtc agtgtcggaa atacactcta ctatgtcaac	1380
45	aaacaggaag ggaaaagtct ctacgtcaaa ggggagccga taatcaattt ttacgatccc	1440
	ctcgtctttc cctccgatga atttgatgcc agtatttccc aggtgaacga aaaaatcaat	1500
	cagtctctcg cttttattag aaaatctgat gaactcctgc ataacgtcaa tgcaggcaaa	1560
50	agcactacta attga	1575

<210> 16
<211> 524
<212> PRT
<213> hRSV strain A2

EP 3 656 396 A1

<400> 16

5	Met	Glu	Leu	Pro	Ile	Leu	Lys	Ala	Asn	Ala	Ile	Thr	Thr	Ile	Leu	Ala	1	5	10	15
10	Ala	Val	Thr	Phe	Cys	Phe	Ala	Ser	Ser	Gln	Asn	Ile	Thr	Glu	Glu	Phe	20	25	30	
15	Tyr	Gln	Ser	Thr	Cys	Ser	Ala	Val	Ser	Lys	Gly	Tyr	Leu	Ser	Ala	Leu	35	40	45	
20	Arg	Thr	Gly	Trp	Tyr	Thr	Ser	Val	Ile	Thr	Ile	Glu	Leu	Ser	Asn	Ile	50	55	60	
25	Lys	Glu	Asn	Lys	Cys	Asn	Gly	Thr	Asp	Ala	Lys	Val	Lys	Leu	Ile	Lys	65	70	75	80
30	Gln	Glu	Leu	Asp	Lys	Tyr	Lys	Asn	Ala	Val	Thr	Glu	Leu	Gln	Leu	Leu	85	90	95	
35	Met	Gln	Ser	Thr	Pro	Ala	Ala	Asn	Asn	Arg	Ala	Arg	Arg	Glu	Leu	Pro	100	105	110	
40	Arg	Phe	Met	Asn	Tyr	Thr	Leu	Asn	Asn	Thr	Lys	Lys	Thr	Asn	Val	Thr	115	120	125	
45	Leu	Ser	Lys	Lys	Arg	Lys	Arg	Arg	Phe	Leu	Gly	Phe	Leu	Leu	Gly	Val	130	135	140	
50	Gly	Ser	Ala	Ile	Ala	Ser	Gly	Ile	Ala	Val	Ser	Lys	Val	Leu	His	Leu	145	150	155	160
55	Glu	Gly	Glu	Val	Asn	Lys	Ile	Lys	Ser	Ala	Leu	Leu	Ser	Thr	Asn	Lys	165	170	175	
	Ala	Val	Val	Ser	Leu	Ser	Asn	Gly	Val	Ser	Val	Leu	Thr	Ser	Lys	Val	180	185	190	
	Leu	Asp	Leu	Lys	Asn	Tyr	Ile	Asp	Lys	Gln	Leu	Leu	Pro	Ile	Val	Asn	195	200	205	
	Lys	Gln	Ser	Cys	Arg	Ile	Ser	Asn	Ile	Glu	Thr	Val	Ile	Glu	Phe	Gln	210	215	220	
	Gln	Lys	Asn	Asn	Arg	Leu	Leu	Glu	Ile	Thr	Arg	Glu	Phe	Ser	Val	Asn	225	230	235	240

EP 3 656 396 A1

	Val	Gly	Val	Thr	Thr	Pro	Val	Ser	Thr	Tyr	Met	Leu	Thr	Asn	Ser	Glu	
					245					250					255		
5	Leu	Leu	Ser	Leu	Ile	Asn	Asp	Met	Pro	Ile	Thr	Asn	Asp	Gln	Lys	Lys	
				260					265					270			
10	Leu	Met	Ser	Asn	Asn	Val	Gln	Ile	Val	Arg	Gln	Gln	Ser	Tyr	Ser	Ile	
			275					280					285				
15	Met	Ser	Ile	Ile	Lys	Glu	Glu	Val	Leu	Ala	Tyr	Val	Val	Gln	Leu	Pro	
		290					295					300					
20	Leu	Tyr	Gly	Val	Ile	Asp	Thr	Pro	Cys	Trp	Lys	Leu	His	Thr	Ser	Pro	
	305					310					315					320	
25	Leu	Cys	Thr	Thr	Asn	Thr	Lys	Glu	Gly	Ser	Asn	Ile	Cys	Leu	Thr	Arg	
					325					330					335		
30	Thr	Asp	Arg	Gly	Trp	Tyr	Cys	Asp	Asn	Ala	Gly	Ser	Val	Ser	Phe	Phe	
				340					345					350			
35	Pro	Gln	Ala	Glu	Thr	Cys	Lys	Val	Gln	Ser	Asn	Arg	Val	Phe	Cys	Asp	
			355					360					365				
40	Thr	Met	Asn	Ser	Leu	Thr	Leu	Pro	Ser	Glu	Val	Asn	Leu	Cys	Asn	Val	
		370					375					380					
45	Asp	Ile	Phe	Asn	Pro	Lys	Tyr	Asp	Cys	Lys	Ile	Met	Thr	Ser	Lys	Thr	
	385					390					395					400	
50	Asp	Val	Ser	Ser	Ser	Val	Ile	Thr	Ser	Leu	Gly	Ala	Ile	Val	Ser	Cys	
				405						410					415		
55	Tyr	Gly	Lys	Thr	Lys	Cys	Thr	Ala	Ser	Asn	Lys	Asn	Arg	Gly	Ile	Ile	
				420				425						430			
60	Lys	Thr	Phe	Ser	Asn	Gly	Cys	Asp	Tyr	Val	Ser	Asn	Lys	Gly	Val	Asp	
			435					440					445				
65	Thr	Val	Ser	Val	Gly	Asn	Thr	Leu	Tyr	Tyr	Val	Asn	Lys	Gln	Glu	Gly	
		450					455					460					
70	Lys	Ser	Leu	Tyr	Val	Lys	Gly	Glu	Pro	Ile	Ile	Asn	Phe	Tyr	Asp	Pro	
	465					470					475					480	
75	Leu	Val	Phe	Pro	Ser	Asp	Glu	Phe	Asp	Ala	Ser	Ile	Ser	Gln	Val	Asn	
				485						490					495		

EP 3 656 396 A1

Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg Lys Ser Asp Glu Leu
500 505 510

5 Leu His Asn Val Asn Ala Gly Lys Ser Thr Thr Asn
515 520

<210> 17
<211> 1809
10 <212> DNA
<213> Artificial

<220>
15 <223> cDNA encoding fusion protein comprising full-length N protein
from hRSV strain A2 fused to the protease 2A fragment from FMDV
fused to full-length M2 protein from hRSV strain A2.

<400> 17
atggccctga gcaaagtga gctgaacgac accctgaaca aggaccagct gctgtccagc 60
20 tccaagtaca ccatccagag aagcaccggc gacagcatcg acacccccaa ctacgacgtg 120
cagaagcaca tcaataagct gtgcggcatg ctgctgatca ccgaggacgc caaccacaag 180
ttcaccggcc tgatcgggat gctgtacgcc atgagccggc tgggccggga ggacaccatc 240
25 aagatcctgc gggacgccg ctaccacgtg aaggccaacg gcgtggacgt gaccaccac 300
cggcaggaca tcaacggcaa agaaatgaag ttcgaggtgc tgaccctggc cagcctgacc 360
accgagatcc agatcaacat cgagatcgag agccggaagt cctacaagaa aatgctgaaa 420
30 gaaatgggcg aggtggcccc cgagtacaga cagcagacgc ccgactgagg catgatcatc 480
ctgtgtatcg ccgccctggt catcaciaag ctggccgctg gcgacagatc tggcctgacc 540
35 gccgtgatca gacgggcca caacgtgctg aagaacgaga tgaagcggta caagggcctg 600
ctgccaagg atatcgcaa cagcttctac gaggtgttcg aaaagcacc ccacttcatc 660
gacgtgttcg tgcacttcg cattgcccag agcagcacca gaggcggcag cagagtggag 720
40 ggcattcttc ccggcctgtt catgaacgcc tacggcgctg gccagggtcat gctgagatgg 780
ggcgtgctgg ccaagagcgt gaagaacatc atgctgggcc acgccagcgt gcaggccgag 840
atggaacagg tgggtggaggt gtacgagtac gcccagaagc tgggcggcga ggccggcttc 900
45 taccacatcc tgaacaaccc caaggcctcc ctgctgtccc tgaccagtt cccccacttt 960
agcagcgtgg tgctcgaaa tgcagccgga ctgggcatca tgggcgagta ccgcggcacc 1020
cccagaaacc aggacctgta cgacgccgcc aaggcctacg ccgagcagct gaaagaaaac 1080
50 ggcgtgatca actacagcgt gctggacctg acagccgagg aactggaagc cattaagcac 1140
cagctgaacc ctaaggacaa cgacgtggag ctgctgaact tcgatctgct gaaactggcc 1200
ggcgacgtgg aaagcaaccc tggccccagc agacggaacc cctgcaagtt cgagatccgg 1260
55 ggccactgcc tgaacggcaa gcggtgccac ttcagccaca actacttcga gtggccccct 1320

EP 3 656 396 A1

catgctctgc tgggtccggca gaactttatg ctgaaccgga tcctgaagtc catggacaag 1380

agcatcgata ccctgagcga gatcagcggga gccgccgaac tggatagaac cgaggaatac 1440

5 gccctgggcg tgggtcggagt gctggaaagc tacatcggca gcatcaacaa catcaccaag 1500

cagagcgcct gcgtggccat gagcaagctg ctgaccgagc tgaacagcga cgatatcaag 1560

aagctgcgcg acaacgaaga actgaactcc cccaagatcc ggggtgtacaa cacagtgatc 1620

10 agctacattg agagcaaccg gaagaacaac aagcagacca tccatctgct gaagcggctg 1680

cccgccgacg tgctgaaaaa gaccatcaag aacaccctgg acatccacaa gtccatcacc 1740

atcaataacc ccaaagaaag caccgtgtcc gacaccaacg accacgcca gaacaacgac 1800

15 accacctga 1809

<210> 18

20 <211> 602

<212> PRT

<213> Artificial

<220>

25 <223> Fusion protein comprising full-length N protein from hRSV strain A2 fused to the protease 2A fragment from FMDV fused to full-length M2 protein from hRSV strain A2.

<400> 18

30 Met Ala Leu Ser Lys Val Lys Leu Asn Asp Thr Leu Asn Lys Asp Gln

1 5 10 15

Leu Leu Ser Ser Ser Lys Tyr Thr Ile Gln Arg Ser Thr Gly Asp Ser

20 25 30

35 Ile Asp Thr Pro Asn Tyr Asp Val Gln Lys His Ile Asn Lys Leu Cys

35 40 45

40 Gly Met Leu Leu Ile Thr Glu Asp Ala Asn His Lys Phe Thr Gly Leu

50 55 60

45 Ile Gly Met Leu Tyr Ala Met Ser Arg Leu Gly Arg Glu Asp Thr Ile

65 70 75 80

Lys Ile Leu Arg Asp Ala Gly Tyr His Val Lys Ala Asn Gly Val Asp

85 90 95

50 Val Thr Thr His Arg Gln Asp Ile Asn Gly Lys Glu Met Lys Phe Glu

100 105 110

55 Val Leu Thr Leu Ala Ser Leu Thr Thr Glu Ile Gln Ile Asn Ile Glu

115 120 125

EP 3 656 396 A1

	Ile	Glu	Ser	Arg	Lys	Ser	Tyr	Lys	Lys	Met	Leu	Lys	Glu	Met	Gly	Glu	
	130						135					140					
5	Val	Ala	Pro	Glu	Tyr	Arg	His	Asp	Ser	Pro	Asp	Cys	Gly	Met	Ile	Ile	
	145					150					155					160	
	Leu	Cys	Ile	Ala	Ala	Leu	Val	Ile	Thr	Lys	Leu	Ala	Ala	Gly	Asp	Arg	
10					165					170					175		
	Ser	Gly	Leu	Thr	Ala	Val	Ile	Arg	Arg	Ala	Asn	Asn	Val	Leu	Lys	Asn	
				180					185					190			
15	Glu	Met	Lys	Arg	Tyr	Lys	Gly	Leu	Leu	Pro	Lys	Asp	Ile	Ala	Asn	Ser	
			195					200					205				
	Phe	Tyr	Glu	Val	Phe	Glu	Lys	His	Pro	His	Phe	Ile	Asp	Val	Phe	Val	
20		210					215					220					
	His	Phe	Gly	Ile	Ala	Gln	Ser	Ser	Thr	Arg	Gly	Gly	Ser	Arg	Val	Glu	
25	225					230					235					240	
	Gly	Ile	Phe	Ala	Gly	Leu	Phe	Met	Asn	Ala	Tyr	Gly	Ala	Gly	Gln	Val	
					245					250					255		
30	Met	Leu	Arg	Trp	Gly	Val	Leu	Ala	Lys	Ser	Val	Lys	Asn	Ile	Met	Leu	
				260					265					270			
	Gly	His	Ala	Ser	Val	Gln	Ala	Glu	Met	Glu	Gln	Val	Val	Glu	Val	Tyr	
35			275					280					285				
	Glu	Tyr	Ala	Gln	Lys	Leu	Gly	Gly	Glu	Ala	Gly	Phe	Tyr	His	Ile	Leu	
		290					295					300					
40	Asn	Asn	Pro	Lys	Ala	Ser	Leu	Leu	Ser	Leu	Thr	Gln	Phe	Pro	His	Phe	
	305					310					315					320	
	Ser	Ser	Val	Val	Leu	Gly	Asn	Ala	Ala	Gly	Leu	Gly	Ile	Met	Gly	Glu	
45					325					330					335		
	Tyr	Arg	Gly	Thr	Pro	Arg	Asn	Gln	Asp	Leu	Tyr	Asp	Ala	Ala	Lys	Ala	
50				340					345					350			
	Tyr	Ala	Glu	Gln	Leu	Lys	Glu	Asn	Gly	Val	Ile	Asn	Tyr	Ser	Val	Leu	
			355					360					365				
55	Asp	Leu	Thr	Ala	Glu	Glu	Leu	Glu	Ala	Ile	Lys	His	Gln	Leu	Asn	Pro	
		370					375					380					

EP 3 656 396 A1

	Lys	Asp	Asn	Asp	Val	Glu	Leu	Leu	Asn	Phe	Asp	Leu	Leu	Lys	Leu	Ala	
	385					390					395					400	
5	Gly	Asp	Val	Glu	Ser	Asn	Pro	Gly	Pro	Ser	Arg	Arg	Asn	Pro	Cys	Lys	
					405					410					415		
10	Phe	Glu	Ile	Arg	Gly	His	Cys	Leu	Asn	Gly	Lys	Arg	Cys	His	Phe	Ser	
				420					425					430			
15	His	Asn	Tyr	Phe	Glu	Trp	Pro	Pro	His	Ala	Leu	Leu	Val	Arg	Gln	Asn	
			435					440					445				
20	Phe	Met	Leu	Asn	Arg	Ile	Leu	Lys	Ser	Met	Asp	Lys	Ser	Ile	Asp	Thr	
	450						455					460					
25	Leu	Ser	Glu	Ile	Ser	Gly	Ala	Ala	Glu	Leu	Asp	Arg	Thr	Glu	Glu	Tyr	
	465					470					475					480	
30	Ala	Leu	Gly	Val	Val	Gly	Val	Leu	Glu	Ser	Tyr	Ile	Gly	Ser	Ile	Asn	
					485					490					495		
35	Asn	Ile	Thr	Lys	Gln	Ser	Ala	Cys	Val	Ala	Met	Ser	Lys	Leu	Leu	Thr	
				500					505					510			
40	Glu	Leu	Asn	Ser	Asp	Asp	Ile	Lys	Lys	Leu	Arg	Asp	Asn	Glu	Glu	Leu	
			515					520					525				
45	Asn	Ser	Pro	Lys	Ile	Arg	Val	Tyr	Asn	Thr	Val	Ile	Ser	Tyr	Ile	Glu	
		530					535					540					
50	Ser	Asn	Arg	Lys	Asn	Asn	Lys	Gln	Thr	Ile	His	Leu	Leu	Lys	Arg	Leu	
	545					550					555					560	
55	Pro	Ala	Asp	Val	Leu	Lys	Lys	Thr	Ile	Lys	Asn	Thr	Leu	Asp	Ile	His	
					565					570					575		
60	Lys	Ser	Ile	Thr	Ile	Asn	Asn	Pro	Lys	Glu	Ser	Thr	Val	Ser	Asp	Thr	
				580					585					590			
65	Asn	Asp	His	Ala	Lys	Asn	Asn	Asp	Thr	Thr							
			595					600									
70	<210>	19															
75	<211>	10															
80	<212>	PRT															
85	<213>	Artificial															

EP 3 656 396 A1

<220>

<223> Synthetic peptide.

<400> 19

Thr Tyr Met Leu Thr Asn Ser Glu Leu Leu
1 5 10

<210> 20

<211> 9

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide.

<400> 20

Lys Tyr Lys Asn Ala Val Thr Glu Leu
1 5

<210> 21

<211> 15

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide.

<400> 21

Glu Leu Gln Leu Leu Met Gln Ser Thr Pro Ala Ala Asn Asn Arg
1 5 10 15

<210> 22

<211> 13

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide.

<400> 22

Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly
1 5 10

<210> 23

<211> 9

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide.

<400> 23

Lys Tyr Thr Ile Gln Arg Ser Thr Gly
1 5

EP 3 656 396 A1

5
 <210> 24
 <211> 9
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic peptide.
 <400> 24
 10
 Leu Ser Leu Thr Gln Phe Pro Asn Phe
 1 5
 <210> 25
 <211> 9
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic peptide.
 <400> 25
 20
 Ser Arg Leu Gly Arg Glu Asp Thr Ile
 1 5
 <210> 26
 <211> 9
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic peptide.
 <400> 26
 30
 Ile Pro Lys Asp Ile Ala Asn Ser Phe
 1 5
 <210> 27
 <211> 9
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic peptide.
 <400> 27
 40
 Ser Tyr Ile Gly Ser Ile Asn Asn Ile
 1 5
 <210> 28
 <211> 1725
 <212> DNA
 <213> hRSV strain A2
 55

EP 3 656 396 A1

	<400> 28	
	atggagttgc taatcctcaa agcaaatgca attaccacaa tcctcactgc agtcacat	60
5	ttgttttgctt ctggtcaaaa catcactgaa gaattttatc aatcaacatg cagtgcagtt	120
	agcaaaggct atcttagtgc tctgagaact ggttgggtata ccagtgttat aactatagaa	180
	ttaagtaata tcaaggaaaa taagtgtaat ggaacagatg ctaaggtaaa attgataaaa	240
10	caagaattag ataaatataa aaatgctgta acagaattgc agttgctcat gcaaagcaca	300
	ccaccaacaa acaatcgagc cagaagagaa ctaccaaggt ttatgaatta taaactcaac	360
	aatgccaaaa aaaccaatgt aacattaagc aagaaaagga aaagaagatt tcttggtttt	420
15	ttgttaggtg ttggatctgc aatcgccagt ggcgttgctg tatctaaggt cctgcaccta	480
	gaaggggaag tgaacaagat caaaagtgct ctactatcca caaacaaggc tgtagtcagc	540
	ttatcaaagc gagttagtgt cttaaccagc aaagtgttag acctcaaaaa ctatatagat	600
20	aaacaattgt tacctattgt gaacaagcaa agctgcagca tatcaaata agaaactgtg	660
	atagagttcc aacaaaagaa caacagacta ctagagatta ccagggaatt tagtgtaaat	720
	gcaggtgtaa ctacacctgt aagcacttac atgttaacta atagtgaatt attgtcatta	780
25	atcaatgata tgcctataac aaatgatcag aaaaagttaa tgcctaaca tgttcaaata	840
	gtagacagc aaagttactc tatcatgtcc ataataaaag aggaagtctt agcatatgta	900
	gtacaattac cactatatgg tggtatagat acaccctgtt ggaaactaca cacatcccct	960
30	ctatgtacaa ccaacacaaa agaagggtcc aacatctgtt taacaagaac tgacagagga	1020
	tggtactgtg acaatgcagg atcagtatct ttcttccac aagctgaaac atgtaaagtt	1080
35	caatcaaatac gagtatcttg tgacacaatg aacagtttaa cattaccaag tgaaataaat	1140
	ctctgcaatg ttgacatatt caaccccaaa tatgattgta aaattatgac ttcaaaaaca	1200
	gatgtaagca gctccgttat cacatctcta ggagccattg tgtcatgcta tggcaaaact	1260
40	aaatgtacag catccaataa aaatcgtgga atcataaaga catttttctaa cgggtgcgat	1320
	tatgtatcaa ataaagggat ggacactgtg tctgtaggta acacattata ttatgtaaat	1380
	aagcaagaag gtaaaagtct ctatgtaaaa ggtgaaccaa taataaattt ctatgaccca	1440
45	ttagtattcc cctctgatga atttgatgca tcaatatctc aagtcaacga gaagattaac	1500
	cagagcctag cattttattcg taaatccgat gaattattac ataattgtaa tgctggtaaa	1560
	tccaccacaa atatcatgat aactactata attatagtga ttatagtaat attgttatca	1620
50	ttaattgctg ttggactgct cttatactgt aaggccagaa gcacaccagt cacactaagc	1680
	aaagatcaac tgagtgggtat aaataatatt gcatttagta actaa	1725
55	<210> 29	
	<211> 574	
	<212> PRT	

EP 3 656 396 A1

<213> hRSV strain A2

<400> 29

5	Met	Glu	Leu	Leu	Ile	Leu	Lys	Ala	Asn	Ala	Ile	Thr	Thr	Ile	Leu	Thr	1	5	10	15
10	Ala	Val	Thr	Phe	Cys	Phe	Ala	Ser	Gly	Gln	Asn	Ile	Thr	Glu	Glu	Phe	20	25	30	
15	Tyr	Gln	Ser	Thr	Cys	Ser	Ala	Val	Ser	Lys	Gly	Tyr	Leu	Ser	Ala	Leu	35	40	45	
20	Arg	Thr	Gly	Trp	Tyr	Thr	Ser	Val	Ile	Thr	Ile	Glu	Leu	Ser	Asn	Ile	50	55	60	
25	Lys	Glu	Asn	Lys	Cys	Asn	Gly	Thr	Asp	Ala	Lys	Val	Lys	Leu	Ile	Lys	65	70	75	80
30	Gln	Glu	Leu	Asp	Lys	Tyr	Lys	Asn	Ala	Val	Thr	Glu	Leu	Gln	Leu	Leu	85	90	95	
35	Met	Gln	Ser	Thr	Pro	Pro	Thr	Asn	Asn	Arg	Ala	Arg	Arg	Glu	Leu	Pro	100	105	110	
40	Arg	Phe	Met	Asn	Tyr	Thr	Leu	Asn	Asn	Ala	Lys	Lys	Thr	Asn	Val	Thr	115	120	125	
45	Leu	Ser	Lys	Lys	Arg	Lys	Arg	Arg	Phe	Leu	Gly	Phe	Leu	Leu	Gly	Val	130	135	140	
50	Gly	Ser	Ala	Ile	Ala	Ser	Gly	Val	Ala	Val	Ser	Lys	Val	Leu	His	Leu	145	150	155	160
55	Glu	Gly	Glu	Val	Asn	Lys	Ile	Lys	Ser	Ala	Leu	Leu	Ser	Thr	Asn	Lys	165	170	175	
	Ala	Val	Val	Ser	Leu	Ser	Asn	Gly	Val	Ser	Val	Leu	Thr	Ser	Lys	Val	180	185	190	
	Leu	Asp	Leu	Lys	Asn	Tyr	Ile	Asp	Lys	Gln	Leu	Leu	Pro	Ile	Val	Asn	195	200	205	
	Lys	Gln	Ser	Cys	Ser	Ile	Ser	Asn	Ile	Glu	Thr	Val	Ile	Glu	Phe	Gln	210	215	220	
	Gln	Lys	Asn	Asn	Arg	Leu	Leu	Glu	Ile	Thr	Arg	Glu	Phe	Ser	Val	Asn	225	230	235	240

EP 3 656 396 A1

	Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Met Leu Thr Asn Ser Glu	245	250	255
5	Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp Gln Lys Lys	260	265	270
10	Leu Met Ser Asn Asn Val Gln Ile Val Arg Gln Gln Ser Tyr Ser Ile	275	280	285
15	Met Ser Ile Ile Lys Glu Glu Val Leu Ala Tyr Val Val Gln Leu Pro	290	295	300
20	Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His Thr Ser Pro	305	310	315
25	Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys Leu Thr Arg	325	330	335
30	Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val Ser Phe Phe	340	345	350
35	Pro Gln Ala Glu Thr Cys Lys Val Gln Ser Asn Arg Val Phe Cys Asp	355	360	365
40	Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Ile Asn Leu Cys Asn Val	370	375	380
45	Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr Ser Lys Thr	385	390	395
50	Asp Val Ser Ser Ser Val Ile Thr Ser Leu Gly Ala Ile Val Ser Cys	405	410	415
55	Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly Ile Ile	420	425	430
60	Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly Met Asp	435	440	445
65	Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys Gln Glu Gly	450	455	460
70	Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn Phe Tyr Asp Pro	465	470	475
75	Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser Gln Val Asn	485	490	495

EP 3 656 396 A1

Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg Lys Ser Asp Glu Leu
500 505 510

5 Leu His Asn Val Asn Ala Gly Lys Ser Thr Thr Asn Ile Met Ile Thr
515 520 525

10 Thr Ile Ile Ile Val Ile Ile Val Ile Leu Leu Ser Leu Ile Ala Val
530 535 540

Gly Leu Leu Leu Tyr Cys Lys Ala Arg Ser Thr Pro Val Thr Leu Ser
545 550 555 560

15 Lys Asp Gln Leu Ser Gly Ile Asn Asn Ile Ala Phe Ser Asn
565 570

20 <210> 30
<211> 897
<212> DNA
<213> hRSV strain A2

25 <400> 30
atgagcaaga acaaggacca gcggaccgcc aagaccctgg aacggacctg ggacaccctg 60
aaccatctgc tgttcatcag tagctgcctg tacaagctga acctgaagtc cgtggcccag 120
atcacccctga gcatcctggc catgatcatc agcaccagcc tgatcattgc cgccatcatc 180
30 tttatcgcca gcgccaacca caaagtgacc cccaccacag ccatcatcca ggacgccacc 240
tcccagatca agaacaccac cccacacctac ctgaccacaga accctcagct gggcatcagc 300
cccagcaacc ccagcgagat caccagccag atcacaacca tcctggcctc caccaccctt 360
35 ggcgtgaagt ccaccctgca gagcaccacc gtgaaaacca agaataccac caccacacag 420
accagcccca gcaagcccac caccaagcag agacagaaca agccccctc caagcccaac 480
aacgacttcc acttcgaggt gttcaacttc gtgccctgca gcatctgcag caacaacccc 540
acctgttggg ccatctgcaa gcggatcccc aacaagaagc ccggcaagaa aaccacaacc 600
aagcctacca agaagcctac cctgaaaacc accaagaagg accccaagcc ccagaccacc 660
45 aagagcaaag aggtgccaac caccaagccc accgaggaac ccaccatcaa caccaccaag 720
accaacatca tcaccacct gctgacctcc aacaccaccg gcaaccccga gctgacaagc 780
cagatggaaa ccttccacag caccagcagc gagggcaacc ctagccctag ccaggtgtcc 840
50 accacctccg agtaccaccag ccagcctagc agccccccca acaccccag acagtga 897

55 <210> 31
<211> 298
<212> PRT
<213> hRSV strain A2

EP 3 656 396 A1

<400> 31

5	Met	Ser	Lys	Asn	Lys	Asp	Gln	Arg	Thr	Ala	Lys	Thr	Leu	Glu	Arg	Thr	1	5	10	15
10	Trp	Asp	Thr	Leu	Asn	His	Leu	Leu	Phe	Ile	Ser	Ser	Cys	Leu	Tyr	Lys	20	25	30	
15	Leu	Asn	Leu	Lys	Ser	Val	Ala	Gln	Ile	Thr	Leu	Ser	Ile	Leu	Ala	Met	35	40	45	
20	Ile	Ile	Ser	Thr	Ser	Leu	Ile	Ile	Ala	Ala	Ile	Ile	Phe	Ile	Ala	Ser	50	55	60	
25	Ala	Asn	His	Lys	Val	Thr	Pro	Thr	Thr	Ala	Ile	Ile	Gln	Asp	Ala	Thr	65	70	75	80
30	Ser	Gln	Ile	Lys	Asn	Thr	Thr	Pro	Thr	Tyr	Leu	Thr	Gln	Asn	Pro	Gln	85	90	95	
35	Leu	Gly	Ile	Ser	Pro	Ser	Asn	Pro	Ser	Glu	Ile	Thr	Ser	Gln	Ile	Thr	100	105	110	
40	Thr	Ile	Leu	Ala	Ser	Thr	Thr	Pro	Gly	Val	Lys	Ser	Thr	Leu	Gln	Ser	115	120	125	
45	Thr	Thr	Val	Lys	Thr	Lys	Asn	Thr	Thr	Thr	Thr	Gln	Thr	Gln	Pro	Ser	130	135	140	
50	Lys	Pro	Thr	Thr	Lys	Gln	Arg	Gln	Asn	Lys	Pro	Pro	Ser	Lys	Pro	Asn	145	150	155	160
55	Asn	Asp	Phe	His	Phe	Glu	Val	Phe	Asn	Phe	Val	Pro	Cys	Ser	Ile	Cys	165	170	175	
60	Ser	Asn	Asn	Pro	Thr	Cys	Trp	Ala	Ile	Cys	Lys	Arg	Ile	Pro	Asn	Lys	180	185	190	
65	Lys	Pro	Gly	Lys	Lys	Thr	Thr	Thr	Lys	Pro	Thr	Lys	Lys	Pro	Thr	Leu	195	200	205	
70	Lys	Thr	Thr	Lys	Lys	Asp	Pro	Lys	Pro	Gln	Thr	Thr	Lys	Ser	Lys	Glu	210	215	220	
75	Val	Pro	Thr	Thr	Lys	Pro	Thr	Glu	Glu	Pro	Thr	Ile	Asn	Thr	Thr	Lys	225	230	235	240

EP 3 656 396 A1

Thr Asn Ile Ile Thr Thr Leu Leu Thr Ser Asn Thr Thr Gly Asn Pro
245 250 255

5 Glu Leu Thr Ser Gln Met Glu Thr Phe His Ser Thr Ser Ser Glu Gly
260 265 270

10 Asn Pro Ser Pro Ser Gln Val Ser Thr Thr Ser Glu Tyr Pro Ser Gln
275 280 285

Pro Ser Ser Pro Pro Asn Thr Pro Arg Gln
290 295

15 <210> 32
<211> 585
<212> DNA
<213> hRSV strain A2

20 <400> 32
atgtcacgaa ggaatccttg caaatttgaa attcgaggtc attgcttaaa tggtaaagagg 60
tgtcattttta gtcataatta ttttgaatgg ccaccccatg cactgcttgt aagacaaaac 120
tttatgttaa acagaatact taagtctatg gataaaagta tagatacctt atcagaaata 180
25 agtggagctg cagagttgga cagaacagaa gagtatgctc ttggtgtagt tggagtgcta 240
gagagttata taggatcaat aaacaatata actaaacaat cagcatgtgt tgccatgagc 300
aaactcctca ctgaactcaa tagtgatgat atcaaaaagc tgagggacaa tgaagagcta 360
aattcaccca agataagagt gtacaatact gtcatatcat atattgaaag caacaggaaa 420
aacaataaac aaactatcca tctgttaaaa agattgccag cagacgtatt gaagaaaacc 480
35 atcaaaaaca cattggatat ccataagagc ataaccatca acaaccctaaa agaatacaact 540
gttagtgata caaatgacca tgccaaaaat aatgatacta cctga 585

40 <210> 33
<211> 194
<212> PRT
<213> hRSV strain A2

45 <400> 33

Met Ser Arg Arg Asn Pro Cys Lys Phe Glu Ile Arg Gly His Cys Leu
1 5 10 15

50 Asn Gly Lys Arg Cys His Phe Ser His Asn Tyr Phe Glu Trp Pro Pro
20 25 30

His Ala Leu Leu Val Arg Gln Asn Phe Met Leu Asn Arg Ile Leu Lys
35 40 45

55 Ser Met Asp Lys Ser Ile Asp Thr Leu Ser Glu Ile Ser Gly Ala Ala

EP 3 656 396 A1

	50	55	60	
5	Glu Leu Asp Arg Thr	Glu Glu Tyr Ala Leu	Gly Val Val Gly Val Leu	65 70 75 80
10	Glu Ser Tyr Ile	Gly Ser Ile Asn Asn Ile Thr Lys Gln Ser Ala Cys		85 90 95
15	Val Ala Met Ser Lys Leu Leu Thr	Glu Leu Asn Ser Asp Asp Ile Lys		100 105 110
20	Lys Leu Arg Asp Asn Glu Glu Leu Asn Ser Pro Lys Ile Arg Val Tyr			115 120 125
25	Asn Thr Val Ile Ser Tyr Ile Glu Ser Asn Arg Lys Asn Asn Lys Gln			130 135 140
30	Thr Ile His Leu Leu Lys Arg Leu Pro Ala Asp Val Leu Lys Lys Thr			145 150 155 160
35	Ile Lys Asn Thr Leu Asp Ile His Lys Ser Ile Thr Ile Asn Asn Pro			165 170 175
40	Lys Glu Ser Thr Val Ser Asp Thr Asn Asp His Ala Lys Asn Asn Asp			180 185 190
45	Thr Thr			
50	<210> 34			
55	<211> 1176			
	<212> DNA			
	<213> hRSV strain A2			
60	<400> 34			
65	atggctctta gcaaagtcaa gttgaatgat acactcaaca aagatcaact tctgtcatcc			60
70	agcaaataca ccatccaacg gagcacagga gatagtattg atactcctaa ttatgatgtg			120
75	cagaaacaca tcaataagtt atgtggcatg ttattaatca cagaagatgc taatcataaa			180
80	ttcactgggt taataggtat gttatatgcg atgtctaggt taggaagaga agacaccata			240
85	aaaataactca gagatgcggg atatcatgta aaagcaaagt gagtagatgt aacaacacat			300
90	cgtcaagaca ttaatggaaa agaaatgaaa tttgaagtgt taacattggc aagcttaaca			360
95	actgaaattc aaatcaacat tgagatagaa tctagaaaat cctacaaaaa aatgctaaaa			420
100	gaaatgggag aggtagctcc agaatacagg catgactctc ctgattgtgg gatgataata			480
105	ttatgtatag cagcattagt aataactaaa ttagcagcag gggacagatc tggtcttaca			540

EP 3 656 396 A1

gccgtgatta ggagagctaa taatgtccta aaaaatgaaa tgaaacgtta caaaggctta 600
ctaccaagga acatagccaa cagcttctat gaagtgtttg aaaaacatcc ccactttata 660
5 gatgtttttg ttcatttttg tatagcacia tcttctacca gaggtggcag tagagttgaa 720
gggatttttg caggattgtt tatgaatgcc tatggtgcag ggcaagtgat gttacggtgg 780
ggagtcttag caaaatcagt taaaaatatt atgttaggac atgctagtgt gcaagcagaa 840
10 atggaacaag ttgttgaggt ttatgaatat gcccaaaaat tgggtggtga agcaggattc 900
taccatatat tgaacaaccc aaaagcatca ttattatctt tgactcaatt tcctcacttc 960
tccagtgtag tattaggcaa tgctgctggc ctaggcataa tgggagagta cagaggtaca 1020
15 ccgaggaatc aagatctata tgatgcagca aaggcatatg ctgaacaact caaagaaaat 1080
ggtgtgatta actacagtgt actagacttg acagcagaag aactagaggc tatcaaacat 1140
cagcttaatc caaaagataa tgatgtagag ctttga 1176

20

<210> 35
<211> 391
<212> PRT
<213> hRSV strain A2

25

<400> 35

Met Ala Leu Ser Lys Val Lys Leu Asn Asp Thr Leu Asn Lys Asp Gln
1 5 10 15

30

Leu Leu Ser Ser Ser Lys Tyr Thr Ile Gln Arg Ser Thr Gly Asp Ser
20 25 30

35

Ile Asp Thr Pro Asn Tyr Asp Val Gln Lys His Ile Asn Lys Leu Cys
35 40 45

40

Gly Met Leu Leu Ile Thr Glu Asp Ala Asn His Lys Phe Thr Gly Leu
50 55 60

Ile Gly Met Leu Tyr Ala Met Ser Arg Leu Gly Arg Glu Asp Thr Ile
65 70 75 80

45

Lys Ile Leu Arg Asp Ala Gly Tyr His Val Lys Ala Asn Gly Val Asp
85 90 95

50

Val Thr Thr His Arg Gln Asp Ile Asn Gly Lys Glu Met Lys Phe Glu
100 105 110

Val Leu Thr Leu Ala Ser Leu Thr Thr Glu Ile Gln Ile Asn Ile Glu
115 120 125

55

Ile Glu Ser Arg Lys Ser Tyr Lys Lys Met Leu Lys Glu Met Gly Glu

EP 3 656 396 A1

	130		135		140											
5	Val	Ala	Pro	Glu	Tyr	Arg	His	Asp	Ser	Pro	Asp	Cys	Gly	Met	Ile	Ile
	145					150					155					160
	Leu	Cys	Ile	Ala	Ala	Leu	Val	Ile	Thr	Lys	Leu	Ala	Ala	Gly	Asp	Arg
10				165						170					175	
	Ser	Gly	Leu	Thr	Ala	Val	Ile	Arg	Arg	Ala	Asn	Asn	Val	Leu	Lys	Asn
				180					185					190		
15	Glu	Met	Lys	Arg	Tyr	Lys	Gly	Leu	Leu	Pro	Lys	Asp	Ile	Ala	Asn	Ser
			195					200					205			
	Phe	Tyr	Glu	Val	Phe	Glu	Lys	His	Pro	His	Phe	Ile	Asp	Val	Phe	Val
20		210					215					220				
	His	Phe	Gly	Ile	Ala	Gln	Ser	Ser	Thr	Arg	Gly	Gly	Ser	Arg	Val	Glu
	225					230					235					240
25	Gly	Ile	Phe	Ala	Gly	Leu	Phe	Met	Asn	Ala	Tyr	Gly	Ala	Gly	Gln	Val
				245						250					255	
30	Met	Leu	Arg	Trp	Gly	Val	Leu	Ala	Lys	Ser	Val	Lys	Asn	Ile	Met	Leu
				260					265					270		
	Gly	His	Ala	Ser	Val	Gln	Ala	Glu	Met	Glu	Gln	Val	Val	Glu	Val	Tyr
35			275					280					285			
	Glu	Tyr	Ala	Gln	Lys	Leu	Gly	Gly	Glu	Ala	Gly	Phe	Tyr	His	Ile	Leu
	290						295					300				
40	Asn	Asn	Pro	Lys	Ala	Ser	Leu	Leu	Ser	Leu	Thr	Gln	Phe	Pro	His	Phe
	305					310					315					320
	Ser	Ser	Val	Val	Leu	Gly	Asn	Ala	Ala	Gly	Leu	Gly	Ile	Met	Gly	Glu
45					325					330					335	
	Tyr	Arg	Gly	Thr	Pro	Arg	Asn	Gln	Asp	Leu	Tyr	Asp	Ala	Ala	Lys	Ala
50				340					345					350		
	Tyr	Ala	Glu	Gln	Leu	Lys	Glu	Asn	Gly	Val	Ile	Asn	Tyr	Ser	Val	Leu
		355						360					365			
55	Asp	Leu	Thr	Ala	Glu	Glu	Leu	Glu	Ala	Ile	Lys	His	Gln	Leu	Asn	Pro
	370						375					380				

EP 3 656 396 A1

Lys Asp Asn Asp Val Glu Leu
385 390

5 <210> 36
<211> 27
<212> DNA
<213> Artificial

10 <220>
<223> RT-PCR primer.

<400> 36
gaactcagtg taggtagaat gtttgca 27

15 <210> 37
<211> 25
<212> DNA
<213> Artificial

20 <220>
<223> RT-PCR primer.

<400> 37
ttcagctatc attttctctg ccaat 25

25 <210> 38
<211> 27
<212> DNA
<213> Artificial

30 <220>
<223> RT-PCR probe.

<400> 38
tttgaacctg tctgaacatt cccggtt 27

35 <210> 39
<211> 40
<212> DNA
<213> Artificial

40 <220>
<223> Synthetic promoter.

45 <400> 39
aaaaattgaa attttatattt ttttttttgg aatataaata 40

50 <210> 40
<211> 104
<212> DNA
<213> Artificial

<220>
<223> Synthetic promoter.

55 <400> 40
tccaaaccga cccgcttttt atagtaagtt tttcacccat aaataataaa tacaataatt 60

aatttctcgt aaaagtagaa aatatattct aatttattgc acgg 104

5 <210> 41
 <211> 73
 <212> DNA
 <213> Artificial

10 <220>
 <223> Synthetic promoter.

<400> 41
 taaaaattga aaaaatattc taatttatag gacggttttg attttctttt tttctattct 60
 15 ataaataata aat 73

20 <210> 42
 <211> 227
 <212> DNA
 <213> Artificial

<220>
 <223> Synthetic promoter.

25 <400> 42
 gttttgaaaa tttttttata ataaatatcc ggtaaaaatt gaaaaactat tctaatttat 60
 tgcacgggtcc ggtaaaaatt gaaaaactat tctaatttat tgcacgggtcc ggtaaaaatt 120
 30 gaaaaactat tctaatttat tgcacgggtcc ggtaaaaatt gaaaaactat tctaatttat 180
 tgcacgggtcc ggtaaaaatt gaaaaactat tctaatttat tgcacgg 227

35 <210> 43
 <211> 112
 <212> DNA
 <213> Artificial

40 <220>
 <223> Synthetic promoter.

<400> 43
 tacttaaaaa ttgaaaataa atacaaaggt tcttgagggt tgtgttaaat tgaaagcgag 60
 45 aaataatcat aaataatttc attatcgoga tatccgttaa gtttgtatcg ta 112

Claims

- 50 1. A recombinant modified vaccinia virus Ankara (MVA) comprising:
- (a) at least one nucleotide sequence encoding an antigenic determinant of a respiratory syncytial virus (RSV) membrane glycoprotein, wherein
 the nucleotide sequence encodes an RSV F antigenic determinant;
- 55 (b) at least one nucleotide sequence encoding an RSV nucleocapsid antigenic determinant, wherein
 the nucleotide sequence encodes an antigenic determinant of an RSV N nucleocapsid protein;
- (c) at least one nucleotide sequence encoding an RSV nucleocapsid antigenic determinant, wherein
 the nucleotide sequence encodes an antigenic determinant of an RSV M2 matrix protein;

and further comprising:

(d) at least one nucleotide sequence encoding an antigenic determinant of an RSV G membrane glycoprotein.

2. The recombinant MVA of claim 1, wherein the nucleotide sequence in (a) encodes a full-length RSV F membrane glycoprotein.
3. The recombinant MVA of claim 1 or 2, wherein the nucleotide in (a) is from RSV strain A, preferably from A2, and/or A_{long}.
4. The recombinant MVA of anyone of claims 1 to 3, wherein the nucleotide sequence in (a) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 6 or comprises the nucleotide sequence of SEQ ID NO: 5.
5. The recombinant MVA of anyone of claims 1 to 4, wherein the nucleotide sequence in (b) and the nucleotides sequence in (c) encodes a full-length protein.
6. The recombinant MVA of anyone of claims 1 to 5, wherein the nucleotides sequence in (b) is from strain A, preferably strain A2.
7. The recombinant MVA of anyone of claims 1 to 6, wherein the nucleotide sequence in (b) comprises a nucleotides sequence encoding the amino acid sequence of SEQ ID NO: 35 or comprises the nucleotide sequence of SEQ ID NO: 34.
8. The recombinant MVA of anyone of claims 1 to 6, wherein the nucleotide sequence in (b) comprises a nucleotides sequence encoding the amino acid sequence of SEQ ID NO: 10 or comprises the nucleotide sequence of SEQ ID NO: 9.
9. The recombinant MVA of anyone of claims 1 to 8, wherein the nucleotide sequence in (c) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 33 or comprises the nucleotide sequence of SEQ ID NO: 32.
10. The recombinant MVA of anyone of claims 1 to 8, wherein the nucleotide sequence in (c) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 14 or comprises the nucleotide sequence of SEQ ID NO: 13.
11. The recombinant MVA of anyone of claims 1 to 10, wherein both the antigenic determinants of the RSV N nucleocapsid and the RSV M2 matrix proteins are encoded by one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein and are both encoded by a single open reading frame.
12. The recombinant MVA of claim 11, wherein the antigenic determinants of the RSV N nucleocapsid and the RSV M2 matrix proteins are separated by a self-cleaving protease domain, preferably wherein the self-cleaving protease domain sequence is derived from foot and mouth disease virus, more preferably wherein the self-cleaving protease domain sequence is the protease 2A fragment sequence.
13. The recombinant MVA of any one claims 1 to 12, wherein the nucleotide sequence in (d) encodes a full-length RSV G membrane glycoprotein.
14. The recombinant MVA of any one of claims 1 to 13, wherein the nucleotide sequence in (d) is from RSV strain A, preferably from strain A2, and/or B.
15. The recombinant MVA of any one of claims 1 to 14, wherein the nucleotide sequence in (d) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2 or comprises the nucleotide sequence of SEQ ID NO: 1.
16. The recombinant MVA of any one of claims 1 to 15, wherein the MVA used for generating the recombinant MVA is MVA-BN deposited at the European Collection of Cell Cultures (ECACC) under number V00083008.
17. A recombinant MVA of any one of claims 1 to 16 for use in preventing an RSV infection.
18. The recombinant MVA for use of claim 17, wherein the recombinant MVA is administered intranasally and/or sub-

cutaneously, preferably intranasally.

5

10

15

20

25

30

35

40

45

50

55

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17





FIGURE 18





EUROPEAN SEARCH REPORT

 Application Number
EP 19 21 1547

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 2012/085936 A2 (PANACEA BIOTECH LTD [IN]; JAIN RAJESH [IN]; VINAYAK VIRENDER KUMAR [IN] 28 June 2012 (2012-06-28)	1-3,5,6, 11-14, 16-18	INV. A61K39/155
Y	* page 8, line 26 * * page 15, line 1 - line 11; claims 14, 21,28-32; examples *	4,7-10, 15	
Y	* page 17, line 19 - page 18, line 15 *		
Y	US 2012/009254 A1 (POWELL THOMAS J [US] ET AL) 12 January 2012 (2012-01-12)	15	
A	* sequence 1 *	1-14, 16-18	
Y	WO 2008/114149 A2 (ID BIOMEDICAL CORP QUEBEC [CA]; BLAIS NORMAND [CA] ET AL.) 25 September 2008 (2008-09-25)	4	
A	* figure 4A *	1-3,5-18	
Y	WO 2010/077717 A1 (NOVAVAX INC [US]; PUSHKO PETER [US] ET AL.) 8 July 2010 (2010-07-08)	15	
A	* sequence 26 *	1-14, 16-18	TECHNICAL FIELDS SEARCHED (IPC) A61K
Y	WO 2008/133663 A2 (US GOV HEALTH & HUMAN SERV [US]; GRAHAM BARNEY S [US] ET AL.) 6 November 2008 (2008-11-06)	7-10,15	
A	* sequences 1,5,9 *	1-6, 11-14, 16-18	
----- -/--			
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 17 April 2020	Examiner Loubradou, Gabriel
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

 Application Number
EP 19 21 1547

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	WYATT LINDA S ET AL: "Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA", VACCINE, ELSEVIER LTD, GB, vol. 18, no. 5-6, 1 October 1999 (1999-10-01), pages 392-397, XP002316543, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(99)00257-1 * abstract * * page 394, left-hand column, paragraph 2 * * page 395, left-hand column, paragraph 1 - paragraph 2 *	1-18	
A	DE WAAL L ET AL: "Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology", VACCINE, ELSEVIER LTD, GB, vol. 22, no. 8, 25 February 2004 (2004-02-25), pages 923-926, XP004489102, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2003.10.010 * abstract * * page 924, left-hand column, paragraph 1 * * page 925, right-hand column, paragraph 3 - paragraph 4 *	1-18	TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 17 April 2020	Examiner Loubradou, Gabriel
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 19 21 1547

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	GHERARDI M MAGDALENA ET AL: "Recombinant poxviruses as mucosal vaccine vectors", JOURNAL OF GENERAL VIROLOGY, vol. 86, no. Part 11, November 2005 (2005-11), pages 2925-2936, XP002685593, ISSN: 0022-1317 * abstract; table 1 *	1-18	
A	S. HALLE ET AL: "Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 206, no. 12, 23 November 2009 (2009-11-23), pages 2593-2601, XP055041459, ISSN: 0022-1007, DOI: 10.1084/jem.20091472 * abstract * * page 2600, left-hand column, paragraph 2 - paragraph 3 *	1-18	
A	FU Y ET AL: "Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 381, no. 4, 17 April 2009 (2009-04-17), pages 528-532, XP026045583, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2009.02.075 [retrieved on 2009-02-20] * abstract *	1-18	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search Munich		Date of completion of the search 17 April 2020	Examiner Loubradou, Gabriel
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 19 21 1547

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	WO 2009/038270 A1 (UNIV EWHA IND COLLABORATION [KR]; CHANG JUN [KR]; YU JAE-RANG [KR]; KI) 26 March 2009 (2009-03-26) * examples *	1-18	
A	WO 02/28422 A2 (SMITHKLINE BEECHAM BIOLOG [BE]; COLAU BRIGITTE DESIREE ALBERTE [BE]; D) 11 April 2002 (2002-04-11) * example 2 *	1-18	
A	HURWITZ J L: "Respiratory syncytial virus vaccine development", EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB, vol. 10, no. 10, 1 October 2011 (2011-10-01), pages 1415-1433, XP009163825, ISSN: 1476-0584, DOI: 10.1586/ERV.11.120 * the whole document *	1-18	
A	ANDREW FRETZAYAS ET AL: "The Challenges of RSV Vaccines. Where do we Stand?", RECENT PATENTS ON ANTI-INFECTIVE DRUG DISCOVERY, vol. 5, no. 2, 1 June 2010 (2010-06-01), pages 99-108, XP055008503, ISSN: 1574-891X, DOI: 10.2174/157489110791233504 * the whole document *	1-18	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search Munich		Date of completion of the search 17 April 2020	Examiner Loubradou, Gabriel
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 19 21 1547

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	ANTONIS ET AL: "Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge", VACCINE, ELSEVIER LTD, GB, vol. 25, no. 25, 30 May 2007 (2007-05-30), pages 4818-4827, XP022098626, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2007.04.002 * abstract * -----	1-18	
			TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 17 April 2020	Examiner Loubradou, Gabriel
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 19 21 1547

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

17-04-2020

10

15

20

25

30

35

40

45

50

55

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2012085936 A2	28-06-2012	AR 084439 A1	15-05-2013
		WO 2012085936 A2	28-06-2012

US 2012009254 A1	12-01-2012	AU 2011276251 A1	08-11-2012
		BR 112013000345 A2	31-05-2016
		CA 2799934 A1	12-01-2012
		CN 103037898 A	10-04-2013
		CN 106008716 A	12-10-2016
		DK 2590675 T3	29-10-2018
		EP 2590675 A1	15-05-2013
		ES 2688993 T3	07-11-2018
		JP 5890407 B2	22-03-2016
		JP 2013535428 A	12-09-2013
		MX 340796 B	27-07-2016
		RU 2013101972 A	20-08-2014
		US 2012009254 A1	12-01-2012
		WO 2012006395 A1	12-01-2012

WO 2008114149 A2	25-09-2008	CA 2684578 A1	25-09-2008
		EP 2181121 A2	05-05-2010
		JP 2010522540 A	08-07-2010
		US 2010203071 A1	12-08-2010
		WO 2008114149 A2	25-09-2008

WO 2010077717 A1	08-07-2010	AU 2009333484 A1	21-07-2011
		BR P10922867 A2	27-09-2016
		CA 2746228 A1	08-07-2010
		CN 102307591 A	04-01-2012
		CN 106146671 A	23-11-2016
		CY 1117757 T1	17-05-2017
		DK 2370099 T3	01-08-2016
		EP 2370099 A1	05-10-2011
		EP 3067064 A1	14-09-2016
		ES 2582005 T3	08-09-2016
		HK 1161690 A1	02-06-2017
		HR P20160859 T1	23-09-2016
		HU E029037 T2	30-01-2017
		IL 213450 A	28-02-2018
		IL 247341 A	30-04-2018
		JP 5813513 B2	17-11-2015
		JP 6162751 B2	12-07-2017
		JP 6462048 B2	30-01-2019
		JP 2012511579 A	24-05-2012
		JP 2015171378 A	01-10-2015
		JP 2018007655 A	18-01-2018
		JP 2019069982 A	09-05-2019

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 19 21 1547

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

17-04-2020

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		KR 20110112328 A	12-10-2011
		KR 20160148720 A	26-12-2016
		MX 337932 B	28-03-2016
		MX 345700 B	10-02-2017
		MX 358836 B	05-09-2018
		PL 2370099 T3	31-10-2016
		PT 2370099 T	14-07-2016
		RU 2011128371 A	20-01-2013
		SG 172022 A1	28-07-2011
		SG 10201500161X A	30-03-2015
		US 2010239617 A1	23-09-2010
		US 2014294879 A1	02-10-2014
		US 2015265698 A1	24-09-2015
		US 2015266930 A1	24-09-2015
		US 2015359872 A1	17-12-2015
		US 2019134187 A1	09-05-2019
		US 2020030436 A1	30-01-2020
		WO 2010077717 A1	08-07-2010

WO 2008133663 A2	06-11-2008	EP 2099486 A2	16-09-2009
		US 2010247621 A1	30-09-2010
		WO 2008133663 A2	06-11-2008

WO 2009038270 A1	26-03-2009	KR 20090031053 A	25-03-2009
		WO 2009038270 A1	26-03-2009

WO 0228422 A2	11-04-2002	AU 1398402 A	15-04-2002
		BR 0114393 A	26-08-2003
		CA 2427842 A1	11-04-2002
		CN 1477971 A	25-02-2004
		EP 1324769 A2	09-07-2003
		HU 0302643 A2	28-11-2003
		JP 2004510744 A	08-04-2004
		KR 20030031200 A	18-04-2003
		PL 362705 A1	02-11-2004
		US 2004022808 A1	05-02-2004
		WO 0228422 A2	11-04-2002
		ZA 200302522 B	30-06-2004

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 84929986, B. Moss [0014]
- US 5185146 A [0026]
- WO 0242480 A [0029] [0031]
- US 20030206926 A [0029]
- WO 03048184 A [0029]
- US 20060159699 A [0029]
- WO 2011092029 A [0033]
- WO 03097845 A [0104]

Non-patent literature cited in the description

- **A.M. ALIYU et al.** *Bayero J. PureAppl. Sci.*, 2010, vol. 3 (1), 147-155 [0002]
- **W.P. GLEZEN.** *Ped. Virol.*, 1987, vol. 2, 1-4 [0002]
- **Y. MURATA.** *Clin. Lab. Med.*, 2009, vol. 29 (4), 725-739 [0002]
- **M. SATO et al.** *J. Clin. Microbiol.*, 2005, vol. 43 (1), 36-40 [0007]
- **A.F.G. ANTONIS et al.** *Vaccine*, 2007, vol. 25, 4818-4827 [0010]
- **M.R. OLSON ; S.M. VARGA.** *J. Immunol.*, 2007, vol. 179, 5415-5424 [0013]
- **BLANCO JC et al.** *Hum Vaccin.*, 2010, vol. 6, 482-92 [0013]
- **W. OLSZEWSKA et al.** *Vaccine*, 2004, vol. 23, 215-221 [0014]
- **G. TAYLOR et al.** *J. Gen. Virol.*, 1997, vol. 78, 3195-3206 [0014]
- **L.S. WYATT et al.** *Vaccine*, 2000, vol. 18, 392-397 [0014]
- **L. DE WAAL et al.** *Vaccine*, 2004, vol. 22, 923-926 [0014]
- **MAYR et al.** *Infection*, 1975, vol. 3, 6-14 [0023]
- **MAYR, A. ; DANNER, K.** *Dev. Biol. Stand.*, 1978, vol. 41, 225-234 [0024]
- **STICKL.** *Prev. Med.*, 1974, vol. 3, 97-101 [0024]
- **STICKL ; HOCHSTEIN-MINTZEL.** *Munich Med. Wochenschr.*, 1971, vol. 113, 1149-1153 [0024]
- **MAYR et al.** *Zentralbl. Bacteriol. (B)*, 1978, vol. 167, 375-390 [0024]
- **BLANCHARD et al.** *J Gen Virol*, 1998, vol. 79, 1159-1167 [0026]
- **CARROLL ; MOSS.** *Virology*, 1997, vol. 238, 198-211 [0026]
- **AMBROSINI et al.** *J Neurosci Res*, 1999, vol. 55, 569 [0026]
- **E. HARRER et al.** *Antivir. Ther.*, 2005, vol. 10 (2), 285-300 [0028]
- **A. COSMA et al.** *Vaccine*, 2003, vol. 22 (1), 21-9 [0028]
- **M. DI NICOLA et al.** *Hum. Gene Ther.*, 2003, vol. 14 (14), 1347-1360 [0028]
- **M. DI NICOLA et al.** *Clin. Cancer Res.*, 2004, vol. 10 (16), 5381-5390 [0028]
- **BOUKAMP et al.** *J Cell Biol*, 1988, vol. 106, 761-771 [0029]
- **SMITH ; WATERMAN.** *Advances in Applied Mathematics*, 1981, vol. 2, 482-489 [0039]
- **DAYHOFF.** *Atlas of Protein Sequences and Structure.* National Biomedical Research Foundation, vol. 5, 353-358 [0039]
- **GRIBSKOV.** *Nucl. Acids Res.*, 1986, vol. 14 (6), 6745-6763 [0039]
- **J. SAMBROOK et al.** *Molecular Cloning, A laboratory Manual.* Cold Spring Harbor Laboratory Press, 1989 [0072]
- *Virology Methods Manual.* Academic Press, 1996 [0072]
- *Molecular Virology: A Practical Approach.* The Practical Approach Series. IRL Press at Oxford University Press, 1993 [0072]
- *Expression of genes by Vaccinia virus vectors* [0072]
- *Current Protocols in Molecular Biology.* John Wiley & Son, Inc, 1998 [0072]
- **L.S. WYATT et al.** *Vaccine*, 1996, vol. 14 (15), 1451-1458 [0076]
- **H. STICKL et al.** *Dtsch. med. Wschr.*, 1974, vol. 99, 2386-2392 [0083]
- **M.D. RYAN et al.** *J. Gen. Virol.*, 1991, vol. 72, 2727-2732 [0107]
- **R.P. DU et al.** *Biotechnology*, 1994, vol. 12 (8), 813-818 [0107]
- **A.B. KULKARNI et al.** *J. Virol.*, 1993, vol. 67 (7), 4086-4092 [0131]
- **OLSZEWSKA et al.** *Vaccine*, 2004, vol. 23, 215 [0154]